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Abstract 
Prostate and breast cancer are high rated in the numbers of cancer cases worldwide. The 
serious consequence of this disease is the metastatic spread of the cancer into the bones. It is 
associated with severe bone pain, spinal cord compression, skeletal fractures and a metabolic 
hypercalceamie. Finally, the symptoms reduce the patients quality of life dramatically. 
Radiopharmaceuticals play a key role in the assessment and therapy of this disease. 
Conjugates of macrocyclic chelates and bone affine bisphosphonates are an appropriate 
means, as so called theranostics, to unite diagnosis and therapy in one molecule. In this 
connection the generator based PET-nuclide 
68
Ga(III)
 
and the therapy nuclide 
177
Lu(III) 
showed promising first results with BPAMD in initial patient studies. For both trivalent 
radiometals, new derivatives were successful synthesized deduced by further developments 
of the BPAMD lead structure with enhanced pharmacological properties. These novel 
compounds, based on the modern osteoporosis drugs pamidronate and zoledronate, 
distinguished by an increased bone affinity and a superior target to background ratio. In 
addition it was also succeeded to develop a derivative of longer blood retention, which 
finally resulted in an enhanced bioavailability of the tracer. This class of bisphosphonate 
enables an increased tumor to healthy bone ratio, which might end up in an improved 
therapeutic success. One of these novel macrocyclic bisphosphonates, [
68
Ga]NO2AP
BP
 
showed superior results in the animal testing and was therefore chosen for an initial clinical 
phase 0 and I trials. Within this study the compound was able to underline its high diagnostic 
efficiency in combination with 
68
Ga-PET. The first series of tests in 12 patients revealed a 
similar compliance in the detection capability of skeletal metastases as the gold standard 
18
F-
fluoride. Moreover in selected metastatic foci a higher uptake of the bisphosphonate could be 
obtained.  
The promising results indicate that in future the macrocyclic bisphosphonate concept may 
play a key role in the management of skeletal metastases in nuclear medicine. 
 
   
Kurzzusammenfassung 
Die Fallzahlen von Prostata- und Brustkrebs nehmen aktuell die Spitzenplätze bei 
Krebserkrankungen weltweit ein. Eine schwerwiegende Folge dieser Erkrankung stellen 
Metastasierungen in das Knochengewebe dar, welche zu einer dramatischen 
Verschlechterung des Allgemeinzustandes und der Lebensqualität des Patienten führen. Die 
Symptome sind gekennzeichnet durch enorme Schmerzen in Kombination mit 
osteoblastischen und osteolytischen Knochenveränderungen, bis hin zu Frakturen und 
spinalen Kompressionssyndromen, sowie einer metabolischen Hypercalcaemie. 
Bei der Diagnose und Therapie nehmen verschiedene Radiopharmaka eine Schlüsselrolle ein. 
Konjugate aus makrozyklischen Chelatoren und knochenaffinen Bisphosphonaten stellen ein 
geeignetes Mittel dar als so genannte Theranostika, die Diagnose und Therapie in einem 
Molekül vereinen. Hierbei konnten mit dem Generator basierenden PET-Nuklid 
68
Ga(III) 
und dem Therapienuklid 
177
Lu(III) erste Erfolge mit der Verbindung BPAMD am Patienten 
erzielt werden. Im Rahmen der vorliegenden Arbeit ist es gelungen, die pharmakologischen 
Eigenschaften der BPAMD-Leitstruktur weiter zu optimieren und neue Derivate erfolgreich 
zu synthetisieren. Diese zeichneten sich durch eine erhöhte Knochenaffinität und eines 
besseren ´target to background´ Verhältnisses aus. Im Zuge der Derivatisierung ist es 
außerdem gelungen, erfolgreich eine Substanz darzustellen, welche über eine gesteigerte 
Blutretention verfügt und die letztendlich die Bioverfügbarkeit des Tracers erhöhte. 
Verbindungen solchen Typs können zu einem besseren Tumor zu gesundem Knochen 
Verhältnis beitragen und eventuell einen höheren Therapieerfolg erzielen. Eines dieser neuen 
vielversprechenden Bisphosphonate, [
68
Ga]NO2AP
BP
 konnte innerhalb einer klinischen 
Phase 0 bzw. I sein großes Potential als Diagnostikum zur Erfassung von Skelettmetastasen 
unter Beweis stellen. Innerhalb einer Testreihe mit 12 Patienten wurde eine hohe 
diagnostische Übereinstimmung mit dem Goldstandard 
18
F-Fluorid erreicht. In ausgesuchten 
Metastasen konnte sogar eine höhere Tracer-Aufnahme erzielt werden. 
In Zukunft können makrozyklische Bisphosphonate eine wichtige Rolle bei der palliativen 
Schmerztherapie von Knochenmetastasen einnehmen.  
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1. Introduction 
Cancer is one of the leading causes of death, beside diseases of the heart and the vascular 
system [1]. Actually more than 32.6 million people worldwide suffering from that diseases 
and it must be assumed that the rate of cancer cases increases in the next decades, based on 
the further aging population [1,2]. Particularly in the industrialized and developing countries 
spreading cases of malignant diseases will be a challenging burden for their societies [2].  
The type of human cancer is various and more than 100 different forms are known today [3]. 
In Germany, the most cases are attributed to only some major types of malignant tumors 
inflicting selected tissues, such as the lung and the intestine [4], and gender characteristic 
diseases, like prostate and breast cancer, are the leading group with around 25-30 % of all 
new cancer cases [4]. The World Health Organization expects that close to the half of all 
cancer cases could have been prevented by a better lifestyle, healthier environmental 
influences and a better medical care [2]. The consumption of tobacco and an unhealthy diet is 
one of the main risk factors to become a malignant disease in the developed countries. The 
second cause is based on environmental pollution, whereas air contamination is the major 
threat. Additionally, infections such as hepatitis viruses or human papilloma viruses are 
important factors [5,6,7]. On the other hand, the origin of most cancer cases is not definable 
or unavoidable, like the genetical preferences for the development of tumorous tissue [4].  
Besides the avoiding of the risk factors, the fight against the acute tumor diseases is an urgent 
challenge in medicine. The therapy of cancer differs in the type of the malignant tissue and 
includes the removal of neoplasms by surgery, chemotherapy and external beam radiation 
[8]. Recently, new methods come into clinical practice, like the targeted cancer therapies 
utilizing ´matching bullets´, such as antibodies and the peptide receptor radionuclide therapy 
(PRRT), as well as new pharmaceutical and radiation concepts [8,9,10]. Today, in the 
developed countries the mean 5-year survival rate is between 50 to 60 %, whereby large 
distinctions in the morbidity of different tumor types exist, which varies from a 5-year 
survival rate of less than 10 % for pancreatic cancer to more than 90 % for the melanoma of 
the skin [2,4]. The main factor which influences the success of the cancer treatment is the 
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diagnosis in an early stage of diseases. Regular cancer check-ups, an informed population 
and the overall resources of the public health system show here an important criterion for the 
clinical prediction of cancer patients. In contrary, the mean 5-year survival rate in the rest of 
the world is only between 30 to 40 % and many patients in the developing countries 
diagnosed in late stages of their diseases without no prospect of any cure of their suffering 
[1,2]. 
The consequences for patients living with and dying from cancer are severe and reduce the 
quality of life drastically. These consequences include mostly serious pain and physical and 
psychological suffering. Palliative care, which comes more and more into the focus of 
medical welfare, is an urgent humanitarian need to relief patients and their families from 
these sufferings. On the contrary, patients with an improved quality of life show longer 
survival tendencies [2,11]. Malignant tumors inflict in their late stages several tissues and 
lead to various symptoms.  
One major complication is the spread of cancer from the primary tumor tissue to other organs 
[12]. By penetrating the walls of blood and lymphatic vessels, single tumor cells are able to 
circulate in the body and can thus invade healthy tissues to generate new tumor lesions. The 
organ preferences of metastases depend on the type of the primary tumor, but statistically 
lymphnotes, the lungs, the liver and the brain are frequently affected [13,14]. Another organ, 
where tumor cell invasion occurs at a high percentage, with severe complications inflicting 
the patients quality of life, are the bones [14]. 
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1.1. Bone Metastases 
In the year 1889, Stephen Paget summarized the results of the necropsies of breast cancer 
victims in The Lancet [13]. He reported that the bones are most frequently inflicted by breast 
tumor metastases, furthermore he postulated his seed and soil theory of secondary cancer 
growths. Since other primary tumors did not show these statistical high preference for the 
skeleton, Paget concluded that circulating cancer cells originating from a certain tissue (the 
seed) only colonize in specific organs of the body (the soil), where the microenvironment is 
convenient for the type of tumor. Additional autopsy studies revealed that not only breast 
cancer enhances the risk of developing secondary tumor growths in the bone, but rather 
prostate and lung cancer are likewise the main causes. It was found, that close to 85 % of 
patients dying on breast, prostate or lung cancer suffering from osseous metastases [15]. The 
results showed further that the cancer does not spread randomly over the skeleton, quite the 
opposite is the case and the metastases are located predominantly in the spine, pelvis and the 
ribs at an early stage. Later on the skull, the scapula, the femur and the sternum are involved. 
Usually patients develop not only one metastatic site, but rather multiple lesions [15]. 
The growths of secondary cancer in bone have fatal consequences and it is associated with a 
higher morbidity and mortality. The most harmful effect is the severe multiple pain 
syndrome, which decreases the patients quality of life dramatically. The further progress of 
the diseases is characterized by bone fractions and spinal cord, as well as nerve root 
compressions [16]. A common metabolic complication is the hypercalcemia, which induces 
acute renal failures and cardiac arrhythmias leading to death at last [17].  
The genesis of these symptoms has its origin in the disorder of the well balanced bone 
remodelling, mediated by the tumor cell invasion. The healthy bone underlies a continuous 
degradation and reconstruction of the mature mineral compartment and the rate of bone 
replacement averages 10 % of the skeleton per year. The bone turnover is executed by two 
types of cells associated on the bone matrix, which are known as the osteoblasts and the 
osteoclasts. 
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The osteoblasts mineralizing the bone with hydroxyl apatite (HAP), which is a hard inorganic 
salt of the chemical formula Ca10(PO4)5(OH)2, attributing the skeleton its solid strength. 
About 50-60 % of the human bone consists of this material, embedded with few amounts of 
different counter ions like Mg
2+
 and Cl
-
, while the remaining proteins, mainly collagen, 
preserve the elasticity to prevent an easy splintering of the bone [18]. The bones function 
further as the hugest reservoir of Ca
2+
 and phosphate in the human body. A sketch of the cells 
and the mechanism involved in the bone remodelling is depicted in figure 1. The osteoblasts 
originate from mesenchymal stem cells (MSC) and are located usually on the bone surface. 
During the formation of new bone tissue some osteoblasts were implanted inside the bone 
and develop further to osteocytes, which are known to have a very long lifespan and are 
rather sparsely active, but sensitive to the mechanical bone stress. The remaining osteoblasts 
develop in their inactive state to so called lining cells, which cover the bone surface and 
protect it with a cell layer [19]. Recruitment of the osteoblasts takes place by signaling 
pathways including high serum Ca
2+
 levels, growth factors and cytokines [20].  
 
Figure 1. Overview of cells and signaling pathways involved in the bone remodelling. Osteoblasts develop 
from mesenchymal stem cells (MSC), osteoclasts from haematopoietic stem cells (HSC). The osteoblasts 
synthesize the bone proteins, mostly collagen and depose calcium and phosphate minerals in the bone matrix. 
Implemented osteoblasts develop to osteocytes, remained surface osteoblast to lining cells. Osteoclast 
recruitment is mediated by RANK/L and M-CSF (K. N. Weilbaecher et al. [19]).  
The counterpart of the osteoblasts are the osteoclasts, which degrade the bone by the 
secretion of acids and collagenases. Osteoclasts are large multinucleated cells and can have 
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huge dimensions especially around tumor lesions. The bone remodeling is complexely 
organized and several organs like the kidneys and the parathyroid glands are involved as well 
as a feedback mechanism between the osteoblasts and the osteoclasts, controlling their 
activity. The recruitment of the osteoclasts is mediated by RANK/L (receptor activator of 
nuclear factor κβ ligand), which is expressed on the surface of osteoblasts and M-CSF 
(macrophage-colony stimulating factor), secreted also by osteoblasts. The release of growth 
factors embedded in the bone matrix and the increase of Ca
2+
 levels by bone degradation of 
the osteoclasts, stimulates the osteoblast activity again to form new bone material. Finally, 
high osteoblast activity stimulates the osteoclast formation and vice versa [19,20]. This fine-
tuned balance is manipulated in the one or the other direction, as required. The factors 
influencing the osteoblast and osteoclast balance are signaling pathways by mechanical 
stimulation, by hormones of the kidneys (calcitriol) and the parathyroid (PTH, parathyroid 
hormone) as well as by local inflammatory occurrences [20,21].  
 
Figure 2. Steps in the tumor cell invasion to the bone. Tumor cell penetration of blood vessels releases 
malignant cells in the circulation, which get trapped in the bone marrow. Extravasation of the tumor cells trough 
the endothelium is followed by tumor growth in response to the favorable bone microenvironment [17]. 
The formation of secondary cancer growths in the bone can be described in six steps (see 
figure 2), starting with the penetration of blood and lymphatic vessels by tumor cells. In the 
second step tumor cells are released in the circulatory system and only a minority of less than 
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0.01 % of them are able to form metastases in general [22]. It is yet in the discussion if the 
tumor cells adhere in the bone preferably by a vascular niche which is permeable for tumor 
cells or if the tumor cells allocate randomly over the body and only the special bone 
microenvironment allows a tumor cell survival [15]. In the next step the bone placed tumor 
cells secret growth factors, cytokines and chemokines, which finally interrupt the 
RANK/RANKL communication between the osteoblasts and osteoclasts [23]. This 
interruption can be attributed to the secretion of the parathyroid hormone-related peptide 
(PTHrP) and interleukins (IL-8, IL-11) by the tumor cells, which increases the osteoclast 
activity. In turn the enhanced osteoclast activity, releases Ca
2+
 and matrix-embedded growth 
factors like TGF-β (tumor growth factor) and IGF (insulin like growth factor), stimulating the 
tumor growth. This feed-back mechanism of tumor growth and bone response is depicted in 
figure 3 and is so called as the vicious circle [23]. 
Despite an overall enhanced activity of osteoblasts and osteoclasts, the disturbance of the 
bone cell balance in the lesions caused by metastases can have preferentially an osteolytic or 
osteoblastic character. It could be the case, that the stimulation of one of these two bone 
modelling cells is more intense affected and the tumor lesion tends more or less to the one or 
the other trend. It is also known, that breast cancer metastases cause predominantly osteolytic 
lesions, while prostate cancer derived lesions tend to form osteoblastic metastases. However, 
in the most cases the lesions have a mixed character of osteolytic and osteoblastic sites or 
both types can be found in affected patients [17].  
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Figure 3. Illustration of the biochemical pathways and cells involved in the vicious circle of bone metastases. 
The tumor secrets signaling molecules like PTHrP (parathyroid hormone-related peptide) and IL-8/11 
(interleukin-8/11) which recruits osteoclast activity. Furthermore the secretory molecules inhibit the OPG 
(Osteoprotegerin) receptor of osteobolasts, which prevent in its natural state the activation pathways of 
osteoclasts by osteoblasts within RANK/L. The enhanced osteoclast activity further releases growth factors and 
Ca
2+
 from the bone matrix, which again increases tumor cell proliferation (M. Ignatiadis et al. [24]). 
Thus, the increased uncontrolled metabolic activity of bone cells on the metastatic lesion 
benefits the tumor to proliferate and supports the tumor growth deeper in the bone tissue, 
causing severe bone pain. In the later stage, the bone structure gets fragile and fractures can 
occur on the lesion sites. Furthermore, the tumor can invade the bone marrow itself and can 
cause a bone marrow carcinosis. The metabolic effects of bone metastasis are severe and the 
release of Ca
2+
 can further emerge a hypercalcaemia, which could finally lead to death. 
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1.2. Diagnosis 
Several methods are available for clinicians to diagnose bone metastases. One part are 
clinical markers related to enhanced bone metabolism. These specific markers can give an 
access to the rate of bone resorption or formation. Two serum parameters are recently in the 
discussion, one is the bone specific isoenzyme of the alkaline phosphatase (ALP), released 
by osteoblasts during the formation of new bone. The other one is the degradation product of 
type I collagen, which is a cross-linked telopeptide named NTx and CTx and is associated 
with the bone resorption by the osteoclasts [25]. Especially for prostate cancer related bone 
metastases, PSA (prostate specific antigen) serum levels are also an important factor. Clinical 
markers are easy to acquire and relatively cheap in practice, but in case of bone metastases 
they lack of their ability to localize the metastatic foci. For this reason imaging modalities are 
common to detect osseous tumor lesions and several techniques are suitable, but with 
differences in detection specifity, sensitivity and costs. The used techniques are XR (X-ray 
examination), CT (computed tomography), MRI (magnetic resonance imaging), the so called 
skeletal scintigraphy (SS) and the SPECT (single photon emission computed tomography) as 
well as the PET (positron emission tomography) and summarized in table 1, respectively 
[26].  
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Table 1. Characteristics of different imaging modalities for the detection of osseous metastases. 
imaging 
modality 
anatomic 
detail 
metabolism extent of image 
diagnostic 
sensitivity 
diagnostic 
specificity 
XR
a
 yes no 
regional / whole 
body 
low 
(44-50%) 
n.d. 
CT
a
 yes no regional 
high 
(71-100%) 
n.d. 
MRI
a
 yes no regional 
high 
(82-100%) 
high 
(73-100%) 
SS
a
 no yes whole body 
varies 
(62-100%) 
varies 
(78-100%) 
SPECT
a
 no yes whole body 
high 
(87-92%) 
high 
(91-93%) 
PET
b
 no yes whole body 
very high 
(94-99%) 
very high 
(97-100%) 
a
Data from Hamaoka et al. [26]. 
b
Data for [
18
F]NaF from Tateishi et al. [27]. 
XR: X-ray examinations are quite cheap to acquire but a whole body roentgenographic bone 
survey shows only low performance in specification and sensitivity for the detection of 
metastatic lesions. The XR exposes differences in bone density, and usually a change in 30 % 
to 75 % of the bone density according to the initial status has to be triggered by the tumor to 
ascertain an accurate result. This deduces that tumor lesions can only be detected by XR in a 
late state of diseases, when distinct pain syndromes are already present. Thus, XR appears to 
be as an additional method in the diagnosis of bone metastases to obtain some morphological 
information in addition to other better suited imaging techniques [26]. 
CT: The computed tomography offers a more detailed anatomic view on the skeletal 
structure in comparison to the XR and thus enhances the diagnostic sensitivity. It also shows 
superior results in the examination of the spine, but the technique is limited according to its 
long time frame to scan different parts of the body, and whole body images are quite not 
implemented. Despite the high radiation dose delivered to the patient, the CT reveals to be an 
efficient technique in addition with metabolic imaging modalities like SPECT or PET and 
combinations of PET and CT devices are recently introduced into clinical practice [26]. 
MRI: Magnetic resonance images are usually done to visualize soft tissue by the proton 
relaxation of water molecules. Nevertheless it is suitable to gain worthy anatomic 
information about the bone and the bone marrow, in particular. The recently developed 
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diffusion-weighted MRI (DIW) mode shows excellent results in the detection of boney 
metastases especially in the spinal cord and bones. The drawbacks are the time consuming 
imaging procedures, assoiated with the problems of obtaining a whole body scan [28].  
Skeletal scintigraphy and SPECT: From the above mentioned imaging techniques the skeletal 
scintigraphy, as well as the single photon emission computed tomography differ basically, 
not only in their imaging acquisition, but also in their imaging object. While XR, CT and 
MRI obtain morphological information, the SS and SPECT rather reveal biochemical and 
metabolic information, respectively. The source of the SS/SPECT imaging is of tracing the γ-
emission of radionuclides, which distribute in the human body. The concept of using 
radioactive indicators to monitor biochemical processes was introduced first by de Hevesy 
and offered revolutionary insights in chemistry and life [29]. Since metastases tend to 
increase bone resorption and formation, bone targeting radionuclides respectively radioactive 
labelled compounds, preferentially accumulate in tumor lesions. First applications of this 
concept localizing skeletal metastases were published in the late 1950´s. They followed the 
skeletal distribution of 
85
Sr
 
and 
47
Ca by simple external counting [30]. The techniques 
develop further and scinitigraphic images obtained from 
87m
Sr and 
85
Sr are widely used in the 
late 1960´s to visualize tumor lesions (Figure 4) [31]. By detecting the γ-emission of the 
radioactive decay, the origin of the radionuclide conversation can be calculated back and 
high metabolic areas are depicted as so-called hot spots.  
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Figure 4. Scinitgraphic images from the pelvis and the femurs, obtained in 1966 by 
85
Sr to detect skeletal 
metastases by enhanced bone turnover (G. L. DeNardo et al. [31]). 
The evolution of the γ-cameras offered more and more detailed images of the metabolic 
progress in the bone and the developing technique necessitates better fitted nuclides in terms 
of half-life and γ-emission yield. The most promising candidate was found to be 99mTc, which 
is still today the most commonly used radionuclide in nuclear medicine. 
99m
Tc has a half-life 
of 6.01 h combined with a very high γ-emission yield of 86 %. The energy of the γ-rays is 
140.5 keV and thus well suited for NaI-scintillators [32]. Technetium-99m is the decay 
product of 
99
Mo (EC, t1/2 = 66 h) and can be conveniently obtained from a 
99
Mo/
99m
Tc 
generator system. Molybdenum-99 is commonly produced by nuclear fission of 
235
U in 
nuclear reactors [32]. Techentium isotopes do not accumulate in the bone, like the isotopes of 
87m/85
Sr and 
47
Ca and therefore they have to be delivered in a complex with a targeting agent 
to the skeleton [33].  The complexing agents generally used to deliver the 
99m
Tc to the bone 
are MDP (methylene diphosphonate), HMDP (hydroxyl methylene diphosphonate) and 
EHDP (ethyl hydroxyl diphosphonate). These agents are depicted in figure 5 [34].  
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Figure 5. Common 
99m
Tc-complexing agents for bone scintigraphy. 
Images obtained by 
99m
Tc-phosphonates have been a giant leap in the diagnosis of skeletal 
related diseases, but first applications were only orientated in planar acquisitions, giving less 
detailed information about metabolic events compared to 3-dimensional techniques. 
Nevertheless, the plain skeletal scintigraphy with 
99m
Tc-phosphonates became the work horse 
in the detection of osseous metastases. Today, the 3-dimensional whole body SPECT is the 
most commonly used imaging technique in nuclear medical practice, since it has a high 
sensitivity and specificity for visualizing areas of high bone turnover. Hence, it is not only 
indicated to reveal metastatic lesions, but also offers the opportunity for examinations of 
other skeletal related issues. Compared to the planar skeletal scintigraphy, the 3-dimensional 
multi-field of view SPECT results in a better image quality, which is clearly visible in figure 
6. 
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Figure 6. Examples of 
99m
Tc-diphosphonate images, obtained by different imaging methods. A: 
99m
Tc-
polyphosphate image of a metastatic patient developed with a γ-camera in the mid 1970´s by Malmud et al. 
[35]. B: Current anterior planar SS developed with [
99m
Tc]MDP with metastatic foci in the shoulder, sternum, 
ribs and the skull. C: SPECT image of patient (B) reveals a more detailed finding, with additional lesions 
countable (E. Even-Sapir et al. [36]). 
PET and PET/CT: Similar to SS and SPECT the PET scanner detects the emission of γ-rays 
and a mainframe calculates back the origin of the radioactive conversation to generate a 3-
dimensional image of the tracer concentration in the body. In contrast to the SPECT 
technique, the PET uses the photons emitted by the electron-positron annihilation. The 
positron (β+) is the antiparticle of the electron, it has the same mass and spin but an opposing 
charge. It was first postulated by Dirac in 1928 until it was discovered by Anderson in 1933 
[37,38]. The annihilation can occur in a direct way when a positron hits an electron from the 
surrounding matter. The electron-positron annihilation results in two photons with a distinct 
energy of 511 keV, which are emitted in a 180° angle. Instead of direct annihilation, the 
positron can form an exotic pseudo-atom of short half-life with an electron and annihilation 
can also occur out of this so called positronium [39]. The PET technique is superior in 
resolution compared to SPECT, because of the detector system, surrounding the patient, that 
registers only collinear photons of 511 keV, cf. figure 7. Due to that, single photon events as 
well as non-linear photon detections are withdrawn from the image calculation. 
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A B  
Figure 7. Principles of the photon detection of the PET techniques. A: Emission of the 511 keV annihilation 
photons in a 180° angle. The distance between the origin of decay and the annihilation event depends on the 
positron energy, emitted by a proton rich nuclide. B: Sketch of the scintillation detectors surrounding a positron 
source [39]. 
The source of the positrons are proton rich nuclides of low atomic number and the nuclear 
conversion can be described as following: 
Positron conversion: p → n + β+ + νe  
A proton in the nucleus is converted to a neutron under the emission of a positron and an 
electron neutrino. The competitive mechanism is the electron capture (EC) conversation and 
it occurs statistically higher with the increasing atomic number of the mother nuclide. 
EC: p + e
-
 → n + νe 
Optimal nuclides for PET imaging are thus characterized by having a high β+ yield and low 
β+ energies. Typical PET nuclides are 11C, 13N, 15O, 18F, 68Ga and 64Cu. The cyclotron 
produced isotope 
18
F is most widely used. Because of its moderate half-life of 110 min, it 
could be introduced in several biological active molecules called as tracers, such as [
18
F]FDG 
(2-deoxy-2-(
18
F)fluoro-D-glucose), [
18
F]F-choline, [
18
F]FET (O-(2-[
18
F]fluoroethyl)-L-
tyrosine) and [
18
F]NaF [32]. 
PET scans of the bone revealing metastatic lesions can be performed with three different 
18
F-
tracers, and thus targeting different biochemical processes. [
18
F]FDG is the most common 
used PET radiopharmaceutical in clinical practice and several studies revealed the potential 
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of [
18
F]FDG-PET in the assessment of osseous metastases. The accumulation principle of 
[
18
F]FDG is based on its structural relationship to natural glucose and thus it is incorporated 
in high quantities by high metabolic cancer cells. Due to that fact [
18
F]FDG is a more or less 
unspecific tracer, it is also used to reveal several types of malignancies including the bone 
[26,32]. [
18
F]F-choline shows affinity to prostate cancer cells and was introduced to detect 
bone metastases derived from prostate carcinoma. However, [
18
F]F-choline showed 
insufficient target to background ratios, since other organs tend to accumulate large 
quantities of choline. Moreover, the application is limited to prostate cancer patients.  
A   B  
Figure 8. Comparison of PET images of a bone metastatic patient, implemented with [
18
F]FDG (A) and 
[
18
F]NaF [40]. 
Fluoride ions have a natural affinity to the bone based on their strong binding to hydroxyl 
apatite. Within the apatite structure (Ca10(PO4)5(OH)2), the F
-
 ions replace with OH
-
 by anion 
exchange to form the very stable fluoroapatit Ca5(PO4)3F. The use of [
18
F]NaF for bone 
scanning was first introduced by Monte Blau in the early 1960´s, but short after approval it 
was replaced by 
99m
Tc-bisphosphonates according to its lack of nuclide properties in relation 
with the SPECT technique [41]. Since the quality of the PET technology overtakes the 
SPECT in the last decades, [
18
F]NaF-PET scans offer now the best specificity and sensitivity 
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to detect skeletal metastases [42]. [
18
F]NaF-PET shows a superior quality against [
18
F]FDG 
and [
99m
Tc]MDP-SPECT as depicted in figure 8 and figure 9, respectively. Recently, new 
multimodality imaging techniques combine PET with CT and MRI and thus offer to gain 
hybrid images of anatomical and metabolical information. The accurate physiological 
localization of the PET-tracers enrichment in the human body, strengthen the diagnostic 
impact of the single imaging technique. Recently, the best results in the detection of bone 
metastases are provided by PET/CT [43,44].   
 
Figure 9. Comparison of images of a bone metastatic patient, obtained from [
99m
Tc]MDP SPECT (A) and 
[
18
F]NaF PET. The PET scan offers a more detailed view on the skeletal related metastases [36]. 
Recently developed compounds like 
68
Ga-HBED-CC-PSMA and BPAMD ((4-{[bis-
(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraaza-
cyclododec-1-yl) acetic acid)  provide new opportunities in the assessment of bone 
metastases. BPAMD offers not only a high qualitative imaging, but also a therapy option 
[45]. BPAMD is a conjugate of a chelator moiety to a specific bone targeting molecule and 
hence it can be labelled with the metal PET nuclide 
68
Ga(III). 
68
Ga(III) has a half-life of 
67.7 min and it provides β+-particles of a maximum energy of 1.9 MeV with a β+-branching 
of 89 %. 
68
Ga(III) can be obtained conveniently by a generator system from a 
68
Ge source 
[46]. The chelator-based concept of radiopharmaceuticals offers the chance of using various 
nuclides, which includes SPECT, PET and therapy applications. Instead of PSMA, BPAMD 
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can be used to detect bone lesions indifferently, whether it is from prostate, breast or any 
other type of cancer origin and it can be truly function as a carrier of therapeutic nuclides, 
such as 
177
Lu(III). Therefore BPAMD can be used for diagnostic imaging and therapy and it 
can be thus called as a theranostic agent [47]. 
 
1.3. Therapy 
Tumor metastases are generally difficult to treat and once spread to the bones, they are close 
to be incurable. The most treatments aim at the reduction of the follow up effects, like the 
hyper calcaemia, or the prevention of pathological fractures. Pain relief by analgetics needs 
the most attention, since this symptom is vigorously dominant and it reduces the patients 
quality of life dramatically [48]. 
Nevertheless, there are several treatment possibilities dealing with skeletal metastases. Single 
lesions might be removed surgically or treated by external radiation. Unfortunately, most 
patients suffer from metastases inflicting multiple sites in the skeleton and therefore a more 
systemic treatment is necessary. The application of the new cytostatic agent docetaxel 
showed promising results, but seemed not to influence the emerge of skeletal related events 
[49]. In case of bone metastases derived from prostate or breast cancer origin, androgen 
receptor targeting drugs or tumor specific antibodies like trastuzumab may delay the progress 
of the disease [49, 50]. Other drugs aim on the interruption of the vicious circle of the tumor 
cells and the bone micro environment. For this reason they reduce the onset of skeletal 
related events and bone pain and they also may increase the overall survival rate. This 
interruption can be initiated at different steps of the complicate way of tumor and bone cell 
interaction. The monoclonal antibody denosumab is an inhibitor of RANK and thus prevents 
the recruitment of osteoclasts, which is an important factor in the bone metastases formation. 
Denosumab reduces the occurrences of skeletal related events but showed not to enhance the 
overall survival rate [51]. There are several other new compounds and concepts in preclinical 
and clinical trials targeting different mechanistic parts of tumor cell invasion to the bone. 
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Some may become an important role in the treatment in future, but nevertheless the strongest 
focus in the management of bone metastases are of palliative care. Today, the common 
treatment of bone metastases are based on bisphosphonates and of targeted radionuclide 
therapy. 
Bisphosphonates (BPs): In the management of bone metastases the administration of BPs is 
an integral part of the treatment today. BPs have effects on the bone turnover and therefore in 
different ways on bone metastases. Their chemical structure is derived from natural 
pyrophosphate. Important derivatives are shown in chart 1.  
 
Chart 1. Overview of therapeutic bisphosphonates derived from pyrophosphate (box). In the BP structure the 
P-O-P  bond is replaced by a P-C-P bond, which is considerable stable against hydrolysis in contrast to the 
phosphate ester of pyrophosphate. The evolution of BPs started with the chloro-compound clodronate and the 
hydroxy-BP etidronate. Further developments leaded to the more powerful N-hydroxy-BPs pamidronate, 
alendronate and ibandronate. The recently most effective compounds are the nitrogen containing hetero aromats 
risedronate and zoledronate [52]. 
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BPs have a unique affinity to apatite, due to the high complexation ability of calcium, and 
thus they exlusively accumulate on the bone. The common indication for a BP treatment is 
osteoporosis, but also other bone related diseases are predestinated [53]. Their mechanism of 
action is the inhibition of the bone resorption induced by osteoclasts, which can be described 
as following. During the bone resorption process the osteoclasts incorporate the BPs, that are 
concentrated in the mineralic bone compartment. Once the BPs are in the osteoclast, they 
induce the apoptosis, which leads to a decreased osteoclast activity on the bone. In turn, the 
decreased bone resorption reduces the release of growth factors embedded in the bone matrix 
and thus have antiproliferating effects on the tumor. In addition, the tumor is not able to 
growth deeper in the solid bone, without the assistance of the bone remodelling cells. 
The apoptosis can be introduced in two ways. Since BPs function as pyrophosphate 
mimetics, it can be taken by enzyms as a substrate for phosphorylation reactions. 
Phosphorylation is an important mechanism for energy transfer and activation of biochemical 
compound, intermediates and proteins in the organism. Usually the step of energy release to 
initiate a chemical reaction at biochemical levels can be obtained by pyrophosphate 
hydrolysis. As a result of the very stabel P-C-P bond of bisphosphonates, the hydrolysis 
cannot occurre and the phosphorylated intermediate will be the endpoint of an initial reaction 
cascade. As a consequence, the apoptosis is initiated in the cell. The second mechanism is the 
function as an inhibtior of the farnesyl pyrophophosphate synthase (FPPS). The enzym is 
involved in the mevalonate pathway. It represents the main biochemical route for the 
production of farnesylated and geranyl-geranylated membrane proteins in the cell. A 
decrease in these proteins leads strongly to apoptosis [55,56].  
The therapeutic efficencies of BPs depend on two factors. The first one is the tendency of 
bone binding and depence on the complexation abilities to calcium within apatite. This 
affinity increases from simple α-H-BP to α-OH-BP. The OH-group between the 
bisphosphonate moiety function as an additional donor. It is arranged similar like the OH
-
 is 
placed in apatite. Nitrogen-containing BPs are not only stronger in binding to the bone 
surface by a hydrogen bridge, but also by their enhanced capability to inhibit the FPPS. 
Within these criteria, zoledronic acid shows the best FPPS inhibition and the best affinity to 
hydroxyl apatite as well, and it is therefore the most potent BP of all [56,57]. BP treatment is 
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now a common part in the treatment of bone metastases, they delay the occurrence of skeletal 
related events and thus showed improvements of the analgesia score [57,58]. 
Bone targeted radiotherapy: The usage of radioisotopes for bone pain palliation shows 
excellent results in terms of pain relief and thus enhances the patients quality of life. 
Moreover, endoradiotherapy (ERT) treatment of bone metastases indicates a decrease in bone 
and tumor markers and seems to enhance the overall longer survival rate. The therapeutic 
effect is based on a synergy of an increased skeletal accumulation of bone targeting agents on 
the metastatic foci and the nearby energy deposit of β-- or α-particle irradiation [59]. 
According to the natural bone accumulation of earth alkaline metals and phosphates, the 
radioisotopes of strontium and phosphorus were first included in clinical applications [60].  
32
P-labelled phosphate was used in the early 1950´s to treat bone related diseases, but it 
showed to have a poor tumor to healthy bone ratio and an intolerable high bone marrow 
uptake [61,62]. Additionally, 
32
P has a relatively long half-life of 14.3 d and a high β- range, 
based on the high energetic β--particle emission of Emax = 1.7 MeV, which inflicts the radio-
sensitive bone marrow with a high fraction of radiation energy [61].  
More effective was the calcium mimetic strontium isotope 
89
Sr in the management of bone 
pain in the last decades. Many studies were published, which revealed a pain reduction by the 
administration of 140 MBq 
89
SrCl2 per patient and the compound was finally approved for 
treatment [59].
 
The half-life of 
89
Sr is quite long with 50.5 days. Additionally, the energy of 
the β--particles emitted is as high as that of 32P (Emax = 1.5 MeV), and thus a palliative 
89
SrCl2 
therapy induces similar site effects, which are mainly myelosuppression, and anemia [59, 
60]. As a consequence, new therapeutic concepts, based on better fitted radionuclides, came 
into clinical practice. The development of new tracers focused on isotopes, which reduced 
the bone marrow toxicity and thus decreased the unpleasant side effects of an ERP for bone 
pain relief. However, most of these new isotopes like 
188/186
Rh or 
117m
Sn remained only in an 
preclinical experimental state [63].  
Today the most common radionuclide for bone palliation is the lanthanide 
153
Sm. It has a 
half-life of 1.9 d and emits β--particles of a low maximum energy of 0.8 MeV. The nuclide 
properties of 
153
Sm offer an effective pain relief combined with a low bone marrow toxicity 
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and 
153
Sm is thus now widely used in clinical practice. Despite all the advantages, no 
indications of a positive effect on the overall survival rate exist [59,64]. The administration 
of lanthanides like Sm is not that easy like the usage of calcium mimetics. Hence, they do not 
naturally accumulate on the bone like the earth alkaline isotopes 
89
Sr and [
32
P]PO4
3-
, a carrier 
complex is necessary to guide the radio nuclide to the bone. 
153
Sm is commonly used with 
the complexing agent EDTMP (ethylenediamine tetra(methylene phosphonic acid)), cf. chart 
2. EDTMP delegates the lanthanides to the bone by keeping the uptake low in critical organs 
like the liver [65]. It is further an open chain chelator, which is able to form complexes with 
various nuclides including the low energetic β--emitter 177Lu and the α-particle emitter 225Ac. 
Unfortunately, EDTMP complexes show the character of having a low kinetical inertness in 
vivo and thus have the tendencies at low EDTMP blood level to dissociate [66,67]. 
 
Chart 2. Structure of the open chain chelator EDTMP. 
Dissociation of the [
*
Me]EDTMP complex is characterized by the release of the therapy 
nuclide in the blood stream and its consequent liver accumulation, which is to avoid, due to 
the resulting high toxicity. The problem is bypassed by coinjection of a large EDTMP excess, 
thus keeping the complex stable in vivo [67]. The production route of 
153
Sm starts with a 
neutron capture reaction of enriched 
152
Sm targets in a nuclear reactor as described with the 
following formula [68]. 
152Sm(n,γ)153Sm 
It is apparent that the separation of the target nuclide of Sm and the desired therapy nuclide 
are not able to separate. As a consequence the 
153
Sm therapy compounds are carrier added 
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with a high rate of the non-functional ´cold´ 
152
Sm, thus could lower the therapeutic 
efficiency. Nevertheless, the results of [
153
Sm]EDTMP reveal a significant pain relief in 
metastatic patients in combination with a low toxicity and in line with this [
153
Sm]EDTMP is 
actually the most common administered bone targeting agent for palliative care. 
Recently new compounds were developed with improved characteristics. One of these 
compounds is [
177
Lu]EDTMP. The exchange of the therapy nuclide form 
153
Sm to 
177
Lu 
offers mainly two benefits. The first one is the lower β--energy of 177Lu compared to 153Sm 
and therefore 
177
Lu showed to be more bone marrow protective. It has a half-life of 6.7 d and 
provides β--particles of a maximum energy of 0.5 MeV. The second reason concerns to the 
production route of 
177
Lu, which could be done in two ways. The standard way is similar to 
that of 
153
Sm by neutron capture of enriched 
176
Lu targets [68]. 
176Lu(n,γ)177/177mLu 
Although the reaction is used worldwide and a new non-carrier added route is preferable, 
which starts by neutron irradiation of enriched 
176
Yb targets. The conversation of 
177
Yb 
yields 
177
Lu, free of the metastable 
177m
Lu. 
177
Lu is separated by ion exchange methods from 
the target [69].  
176Yb(n,γ)177Yb → 177Lu 
[
177
Lu]EDTMP is under clinical trials in phase II and shows promising results in terms of 
pain relief and bone marrow toxicity [70,71]. Nevertheless, the exchange of the therapy 
nuclide does not solve the problem of the low kinetic stability of EDTMP complexes with 
rare earth elements. 
The recently approved α-particle emitter 223Ra is actually the only ERT for bone metastases, 
which offers a significant longer overall survival rate. 
223
Ra is administered as the 
223
Ra-
chloride salt in six separate injections over a period of two month. In clinical trial it reveals a 
significant pain relief, which occurs usually after the second or third therapy cycle. It also 
shows a mean longer survival rate of 2.8 month against placebo [72]. Radium naturally 
accumulates in the skeleton based on its chemical analogy to calcium and for that reason it is 
strongly taken up by bone tumor lesions. The α-particle emission has the character of a very 
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short range combined with a high linear energy transfer and the energy deposit in the 
surrounding tissue by α-emission is obviously higher compared to β-emissions in a 
magnitude. Despite all the benefits the new 
223
Ra therapy offers, it shows still some 
disadvantages, among them are significant toxic side effects on the bone marrow and the guts 
and unsolved problems deduced from the decay chain [73]. 
Consequently, bone metastases remain a challenging disease to manage. A method for curing 
patients, who suffer from that plague, is still a claim of medical sciences. New concepts are 
needed to develop, with properties of improved pharmacokinetics and lower side effects. 
Multimodal compounds suitable for imaging and therapy, which are so called theranostics, 
offer a great potential in the management of skeletal metastases. Subsequent treatment with a 
personalized calculated dose in relation to the previously determined patients specific uptake 
profile provide an evidently improvement and clinicians as well as patients would strongly 
benefit. 
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2. Objectives and Outlines 
The management of bone metastases is a demanding multidisciplinary field, which 
physicians and patients have to deal with. Despite the medical progress in the last decades, 
the status of skeletal metastases is still a problematic burden. Imaging modalities are the 
backbone of metastases diagnosis and the endo-radiotherapy of disseminated bone lesions is 
well-established in the palliative care. While these keystones have been considered 
independently from each other in the past, a new concept was successfully developed in the 
previous work. It is based on a macrocyclic chelate which is combined with a bisphosphonate 
entity and depicted in figure 2.1 [1]. The new compound can be labelled both with the 
generator derived metallic PET nuclide 
68
Ga and the therapy nuclide 
177
Lu. It thus combines 
high quality imaging with an adequate therapy option. This theranostic concept opens up 
new possibilities in the treatment and assessment of bone metastases and thus qualifies 
macrocyclic bisphosphonates as a leap towards personalized medicine. First successful 
patient studies exhibited the potential of this approach using the proof of principle compound 
[
68
Ga/
177
Lu]BPAMD, cf. figure 2.2 [3,4].  
 
Figure 2.1. Structure of BPAMD  (4-{[bis-(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-
1,4,7,10-tetraazacyclododec-1-yl)acetic acid). The macroyclic bisphosphonate was successfully evaluated by 
Fellner et al. with the PET nuclide 
68
Ga(III) and the therapy nuclide 
177
Lu(III) [4]. 
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Figure 2.2. First study of [
68
Ga]BPAMD in a prostate cancer patient. From left to right: Coronal slice, sagittal 
slice and a coronal [
18
F]NaF scan for comparison (Fellner et al. [3]). 
Despite all achieved success, lots of questions remain unsolved and further improvements are 
open. The concept has to be proven in clinical practice and hence a routine GMP (good medical 
practice) application of [
177
Lu]BPAMD is installed, clinical trials can reveal the treatment 
potential in cancer patients, suffering from bone metastases. Nevertheless, BPAMD 
represents one compound of the first generation of macrocyclic bisphosphonates. New 
derivatives with improved structures concerning the chelate as well as the targeting moiety 
may enhance the theranostic power of this novel concept. The concept can be further 
developed by modification of the BPAMD lead structure and the used nuclides in five 
subitems and is illustrated in figure 2.3. 
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Figure. 2.3. Schematic overview of the BPAMD modification sites based on the bifunctional chelator concept 
of radiopharmaceutical. 
① The bifunctional chelator is the starting point in the evolution of macrocyclic 
bisphosphonates. New bifunctional chelates were recently developed for a fast and stable 
complexation of various radionuclides and new tracer designs should take account of that, 
consequently. The usage of NOTA (1,4,7-triazacyclononane-triacetic acid ) and NOTA-
derivatives instead of DOTA may enable a convenient Kit-type labelling approach for 
68
Ga-
PET imaging, since this chelator is ideal fitted for Ga-complexation. The chelator DO2A 
(1,4,7,10-tetraazacyclododecane-1,7-diacetic acid) offer the possibility of further 
modifications, since it provides an additional functional entity. The DOTA derivative 
DOTAGA (2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetracyclododecan-1-yl]pentanedioic 
acid) contains an auxiliary donor group, which may facilitates the radiometal complexation, 
with therapeutic lanthanides or actinides. 
 
2. Objectives and Outlines 
47 
 
② The common link between the macrocycle and the targeting moiety is an amide bond. 
The conjugation is relatively stable in vivo and easy to obtain. However, the formation 
occupies one of the carboxylic acid groups and thus reduces the number of donors of the 
macrocyclic chelate. Recently developed phosphinic acid based linkers enable a very stable 
connection between the chelator and the targeting vector, but the phosphinic acid acts as an 
additional complexation group and finally preserves the numbers of donors of the macrocycle 
in spite of conjugation. 
 
③ During the last decades novel highly potent bone targeting pharmaceuticals like 
pamidronic and zoledronic acid were developed and became keystones in the management of 
skeletal related diseases. Structural improvements of bone targeting macrocyclic ligands 
should thus orientate on the binding motif of these compounds. The substitution of α-H-BP 
of BPAMD with novel α-OH-BPs and heteroaromatic nitrogen containing α-OH-BPs may 
increase the affinity of the resulting radiopharmaceutical to the target. 
 
The pamidronate structure contains a primary amine and offers therefore a functional group 
for a convinient amide coupling to the bifunctional chelate. Contrary to that, the zoledronic 
acid structure has to be midified first for a subsequent conjugation, since it is missing a 
coupling site in the original molecule. 
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④ The additional conjugation site of the DO2A chelator makes it possible to add a further 
functional group. This could be the identical targeting vector leading to dimerizations, which 
may enhance the binding characteristics and may result in favorable target to background 
ratios [5]. Functional groups, which influence the pharmacokinetics of the tracer, such as an 
ablumin binding motif, can also be added. It is reported that small lipophilic molecules (e.g. 
428-D-Lys-OH) suitable for chemical derivatisation of imaging agents have a high binding 
affinity to serum albumin [6].  
 
Beside novel innovative nuclide and targeting vector applications, the focusing on an 
enhancement of the pharmacokinetics of the macrocyclic bisphosphonates is also a key note. 
Since bisphosphonates show a fast blood and body clearance, the most of the injected activity 
is not able to bind on the targeted tissue, thus a modified bisphosphonates with an albumin 
binding entity may influence the pharmacokinetics in terms of blood and skeletal retention. 
⑤ However, improvements of the quantitative structure-activity relationship are only one 
side of the medal. The bifunctional chelator concept of radiopharmaceuticals, offer the 
opportunity of choosing various radionuclides, which are suitable fitted for different issues 
and needs. Beside 
68
Ga (t1/2 = 67.6 min) other positron emitters like 
64
Cu (t1/2 = 12.7 h) or 
44
Sc (t1/2 = 3.9 h) have a promising potential as clinical PET nuclides. A wide range of 
therapeutic nuclides are available, including α and β--particle emitters. Indeed the targeted α-
particle therapy showed remarkable results in the past and the usage of macoryclic 
bisphosphonates in combination with the α-particle emitter 225Ac(III) might be pioneering for 
the future of the theranostic bone metastases treatment.  
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Within this present work novel macrocyclic bisphosphonates are described, representing the 
next generation of bone theranostics, and evaluated in in vitro and in vivo studies, including 
first clinical applications. The results are summarized in chapter 3 in individual manuscripts 
concerning the above outlined aspects and complemented with additional findings.
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Abstract  
Bone metastases are a class of cancerous metastases that result from the invasion of a tumor 
into bone. The solid mass which forms inside the bone is often associated with a constant 
dull ache and severe spikes in pain, which greatly reduce the quality of life of the patient. 
Numerous 
99m
Tc-labeled bisphosphonate functionalised complexes are well established 
tracers for bone metastases imaging. The objective of this research was to evaluate the 
pharmacokinetics and behaviour of three DOTA based bisphosphonate functionalised ligands 
(BPAMD, BPAPD and BPPED), using both 
68
Ga µ-PET in vivo imaging and ex vivo 
biodistribution studies in healthy Wistar rats. The compounds were labelled with 
68
Ga in high 
yields using an ammonium acetate buffer, and subsequently purified using a cation exchange 
resin. High bone uptake values were observed for all 
68
Ga-labelled bisphosphonates at 60 
minutes p.i. The highest uptake was observed for [
68
Ga]BPPED (2.6±0.3 % ID/g) which 
compares favourably with that of [
99m
Tc]MDP (2.7±0.1 ID/g) and [
18
F]fluoride (2.4±0.2 % 
ID/g). The 
68
Ga-labelled DOTA-bisphosphonates showed rapid clearance from the blood and 
renal system, as well as low binding to soft tissue, resulting in a high bone to blood ratio (9.9 
at 60 minutes p.i. for [
68
Ga]BPPED, for example). Although further studies are required to 
assess their performance in tumor models, the results obtained suggest that these ligands 
could be useful both in imaging (
68
Ga) and therapeutic treatment (
177
Lu) of bone metastases.  
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1. Introduction 
Together with the lungs and liver, the bones are most frequently affected by metastases. A 
significant portion (60-80 %) of bone metastases are caused by breast or prostate carcinoma. 
The formation usually occurs at the early stages of tumour development, however their 
symptoms are only recognized at later stages [1, 2]. For this reason the none-invasive 
diagnosis of bone metastases in a premature state, which allows for a profound and timely 
decision on subsequent therapy, is of great importance to improving the quality of life of the 
patients. 
99m
Tc-labelled bisphosphonate functionalised ligands are well established for 
SPECT/CT imaging of osteoblastic metastases [3]. The resolution and sensitivity of 
metastases imaging would be significantly enhanced if a positron emitter was to be used 
instead, of which there are only a few examples. The inherent advantages of PET/CT, over 
the SPECT/CT, is clearly demonstrated by using [
18
F]fluoride ([
18
F]Fˉ) [4]. The images 
obtained with [
18
F]Fˉ are far superior to those obtained using 99mTc-radiopharmaceuticals. 
There is considerable interest in 
68
Ga-labelled complexes as an alternatives to [
18
F]F
ˉ
. 
Bisphosphonates are known to show high and fast binding to apatite (bone) structures [5]. 
Commonly used 
99m
Tc-labelled phosphonates include methylene diphosphonate (MDP), 
dicarboxypropane diphosphonate (DPD) and hydroxymethylene diphosphonate (HDP). 
Chemically attaching these bisphosphonates to a positron emitter is of great interest and 
potential for the in vivo imaging of bone metastases using PET/C. Combining the 
bisphosphonate targeting moieties with the macrocyclic ligand DOTA, an established ligand 
for use in 
68
Ga-PET, led to a new generation of radiolabelled bisphosphonates. In addition to 
the benefits associated with the application of the PET radionuclide, in particular 
68
Ga, the 
DOTA-bisphonsphates also have the potential to be used in therapeutic applications. DOTA 
is known to form complexes, which are stable in vivo, with a range of metal cations, and 
therefore DOTA-bisphosphonates could also be labelled with therapeutic nuclides (such as 
177
Lu for example). In this way a single DOTA-bisphosphonate structure may have the 
potential to be used for both imaging and therapy of bone metastases simply by changing the 
radionuclide incorporated. This is a significant advantage over the [
18
F]F
ˉ
, [
153
Sm]EDMTP 
and [
99m
Tc]MDP/[
153
Sm]EDMTP systems. In general terms, this 2-in-1 "theranostic" 
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approach has a number of significant advantages (commercially and in practice) and is of 
considerable commercial interest.  
One of the more promising DOTA conjugated bisphosphonates, (4-{[bis-(phosphonomethyl) 
carbamoyl] methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclo-dodec-1-yl) acetic acid 
(BPAMD), has already been labelled using 
68
Ga, to give the PET tracer [
68
Ga]BPAMD [6]. 
Very promising initial human studies have been reported for this tracer following evaluation 
in a patient with extensive bone metastases arising from prostate cancer [7]. In this 
evaluation [
68
Ga]BPAMD provided excellent imaging of bone metastases with very high 
bone to soft tissue ratios and fast clearance (no detectable blood pool and very faint renal 
activity). PET/CT depicted multiple, intense osteoblastic metastases in the entire skeleton, 
with a maximum standardised uptake value (SUVmax) of 77.1 in the 10
th
 thoracic vertebra and 
an SUV of 62.1 for vertebra L2. These values are superior to those quantified for the same 
vertebra, 39.1 and 39.2 respectively, when the PET/CT was performed in the same patient 
using [
18
F]F
-
. 
Following the very favourable and promising results obtained with [
68
Ga]BPAMD, two 
further DOTA-bisphonates derivatives have been described recently in the search for even 
better structures [8]. How these derivatives compare to [
68
Ga]BPAMD has not yet been 
addressed, and is the subject of the present study. In vivo PET/CT studies and systematic 
biodistribution experiments have been carried out for each of these three 
68
Ga-labelled 
DOTA-bisphosphonates. The results obtained for these 
68
Ga-labelled compounds have been 
compared with [
18
F]F
-
 and [
99m
Tc]MDP. 
 
2. Materials and Methods 
2.1. Generator 
Decay of Germanium-68 (t1/2 = 270.8 d) provides an easily available source of the PET 
nuclide Gallium-68 (t1/2 = 67.71 min). Germanium-68 is fixed on a solid phase of modified 
titanium dioxide, and Gallium-68 eluted from the generator with 10 mL 0.1 M HCl. This is 
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followed by immobilisation of the 
68
Ga on an acidic cation exchanger. Impurities such as 
zinc, iron and titanium as well as 
68
Ge generator breakthrough are removed using a mixture 
of acetone and hydrochloric acid. Subsequently, 
68
Ga is quantitatively eluted with 1 M HCl 
(300 µL) from the cation exchanger. This eluate serves as an ideal low–volume and 
chemically highly pure source of 
68
Ga for subsequent labelling [9, 10]. 
 
2.2. DOTA-bisphosphonates 
The following macrocyclic DOTA based bisphosphonate chelators have been used (see Fig. 
1 for their chemical structures): BPAMD (4–{[(bis-phosphonomethyl) carbomoyl]methyl}–
7,10–bis–(carboxymethyl)–1,4,7,10-tetraazacyclododec–1–yl)–acetic acid, BPAPD (4–
{[(bis–phosphonopropyl)carbomoyl]methyl}–7,10–bis–(carboxymethyl)–1,4,7,10-
tetraazacyclododec–1–yl)–acetic acid and BPPED tetraethyl-10-{[(2,2-bis-
phosphonoethyl)hydroxyphosphoryl]methyl}-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic 
acid. According to a different terminology, these ligands are also denoted as DOTAM
BP
, 
DOTAP
BP
 and DO3AP
BP
. The ligands were synthesized following literature procedures [6, 
8]. 
 
Figure. 1. Structures of the DOTA functionalised bisphosphonate derivatives. 
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2.3. Labeling 
68
Ga labeling was performed in an ammonium acetate solution (2 M, 200 μL) by adding 300 
μL of processed 68Ga, giving a labeling pH of 3.75. The ligand (30 nmol) was added and the 
solution shaken in a heating block for 10 min at 100°C. After cooling, the labeled 
bisphosphonate was separated from un-complexed 
68
Ga by passing the solution over a strong 
cation exchange resin (STRATA X-C, Phenomenex). The pH was adjusted to pH = 7 by 
adding small amounts of a 1 M NaOH solution. The radiochemical yield was determined by 
radio-TLC (solid phase: SiO2, 60 F254, Merck) using a mixture of 2 parts A (conc. HCl, 
acetone, water) and 1 part B (acetylacetone) as the mobile phase. The radioactivity 
distribution on the TLC plates was determined on a Canberra Packard Instant Imager. The 
reaction was also monitored via radio-HPLC (SCX-column, solvent: 1 M phosphate buffer, 
pH=3). The labeled bisphosphonates were obtained in radiochemical purities greater than 
95%, after resin purification [11]. No-carrier-added aqueous [
18
F]F
-
 was obtained from an 
IBA CYCLONE 18/9 cyclotron (IBA, Louvain-la-Neuve, Belgium) by irradiation of 
[
18
O]H2O via the
18
O(p,n)
18
F nuclear reaction. [
18
F]F
-
 was dissolved in electrolyte injection 
solution E-153 (Serumwerk Bernburg AG). [
99m
Tc]NaTcO4 was obtained from a commercial 
99
Mo/
99m
Tc-generator (Covidien) and [
99m
Tc]MDP was produced according to the 
manufacturer procedure (ROTOP Pharmaka AG). 
 
2.4. Animals, Feeding, Husbandry, and Animal Preparation 
The local animal research committee at the Landesdirektion Dresden approved the animal 
facilities and the experiments according to institutional guidelines and the German animal 
welfare regulations. The experimental procedure used conforms to the European Convention 
for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes 
(ETS No. 123), to the Deutsches Tierschutzgesetz, and to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health [DHEW Publication 
No. (NIH) 82-23, revised 1996, Office of Science and Health Reports, DRR/NIH, Bethesda, 
MD 20205]. Wistar rats (Wistar Unilever, HsdCpb:WU, Harlan Winkelmann, Borchen, 
Germany) were housed under standard conditions with free access to food (2016 Teklad 
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Global 16% Protein Rodent Diet, Harlan Laboratories, Inc., Germany) and tap water. Rats 
were housed (5 rats per cage) in Uni Protect airflow cabinet (Ehret GmbH Labor- und 
Pharmatechnik, Schönwalde, Germany) in polysulfone cages (380 x 200 x 590 mm; floor 
area, 1815 cm
2
). The caging had a solid bottom and stainless steel wire lid, andthe cage floor 
was covered with chipped wood. The cages were changed weekly. Tap water was provided in 
polycarbonate bottles, changed twice weekly, and refilled once between the cage changes. 
The room temperature was 22±1°C and relative humidity was 53±6%, but the temperature 
was 1 to 4°C higher in the airflow cabinets. Artificial lighting was in 12 h light and dark 
cycles with fluorescent tubes (light color, warm white). 
Surgery: Male Wistar-Unilever rats weighing 183±56g (mean ± SD, n=19) were anesthetized 
using desflurane. The guide value for breathing frequency was 65 breaths/min. Animals were 
put in the supine position and placed on a heating pad to maintain body temperature. The rats 
were treated with 100 units/kg heparin (Heparin-Sodium 25.000-ratiopharm, Ratiopharm, 
Germany) by subcutaneous injection to prevent blood clotting on intravascular catheters. 
After local anesthesia by injection of Lignocaine 1% (Xylocitin loc, Mibe, Jena, Germany) 
into the right groin, catheter was introduced into the right femoral artery (0.8 mm Umbilical 
Vessel Catheter, Tyco Healthcare, Tullamore, Ireland) for blood samples for metabolite 
analysis, for gas analysis, and arterial blood pressure measurements. A second needle (35 G) 
catheter in one tail vein was used for administration of the tracers. 
 
2.5. Metabolite analysis  
The metabolism of [
68
Ga]BPAPD, [
68
Ga]BPAMD, [
68
Ga]BPPED in vivo was analyzed in 
arterial blood plasma samples. The radiotracer was injected intravenously into anesthetized 
male Wistar rats. Blood samples from the right femoral artery were taken using the catheter 
at various time points up to 120 min post injection (p.i.). Plasma was separated by 
centrifugation (3 min, 11'000 g) followed by precipitation of the plasma proteins with ice-
cold methanol (1.5 parts per 1 part plasma) and centrifugation (3 min, 11'000 g). The 
supernatants were analyzed by TLC on cellulose (Merck KGaA, Darmstadt, Germany) with a 
mixture of 2 volume parts solution A) H2O (9 mL), 12 M HCl (0.6 mL), acetone (88 mL), 
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and one volume part B) acetylacetone. A second TLC system was used to determine free 
68
Ga with silica TLC-plates (Nano-Sil-20, Macherey-Nagel, Germany) with citrate buffer 
(0.24 M, pH 4). The metabolite fraction of the arterial blood plasma activity was calculated 
using the fraction of parent compound by the equation metfrac = 1 - parent fraction. The 
chemical nature of the radioactive metabolites was not evaluated. 
 
2.6. Biodistribution studies 
Biodistribution studies were performed in male Wistar rats.  The rats were injected 
intravenously, each with ~ 10 MBq of the 
68
Ga-labeled compound in 0.5 mL saline. Specific 
details are as follows. [
68
Ga]BPAPD: 63±13 MBq/kg, 123±16 body-weight (BW, g), n=16; 
[
68
Ga]BPAMD: 67±7 MBq/kg, 146±14 BW (g), n=16; [
68
Ga]BPPED: 82±28 MBq/kg, 
148±12 BW (g), n=16; [
99m
Tc]MDP: 1 MBq/kg, 204±5 (g), n=6; [
18
F]F
ˉ
: 7.0±0.5 MBq/kg, 
183±12 BW (g), n=8. Animals were sacrificed at 5 and 60 min p.i for [
18
F]F
ˉ
 and the 
68
Ga-
labeled tracers, and 5 and 120 min for [
99m
Tc]MDP. Organs and tissues of interest were 
excised rapidly, weighed, and the radioactivity determined using a Wallac WIZARD 
automatic gamma counter (PerkinElmer, Germany). The activity of the tissue samples was 
decay-corrected and calibrated by comparing the counts in the tissue with the counts in 
aliquots of the injected tracer. Counts of the sample and calibration aliquots were measured 
in the gamma counter at the same time. The amount of activity in the selected tissues and 
organs is expressed as a percent of the injected dose per organ (% ID) or activity 
concentration normalized to the BW as the SUV [(activity per g tissue)/(injected activity) × 
BW]. Values are quoted as the mean ID % ± standard deviation (SD) of the eight rats per 
group. The activity associated with the skeleton was calculated using the activity 
concentration in the femur and the total skeleton weight, calculated using: skeleton weight = 
9.66 + 0.0355 × BW [12]. 
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2.7. Small animal PET 
In vivo small animal PET imaging in male Wistar rats was carried out under general 
anesthesia of the rats (induced with 10% and maintained with inhalation of 6.5% desflurane 
in 30% oxygen/air), with a scan time of 120 min. Rats were immobilized in the supine 
position, with their medial axis parallel to the axial axis of the scanner (microPET® P4, 
Siemens Medical Solutions, Knoxville, TN, USA). In the PET experiments 0.5 mL of the 
tracers ([
68
Ga]BPAPD: n=2, 341±21 MBq/kg; [
68
Ga]BPAMD: n=3, 265±30 MBq/kg; 
[
68
Ga]BPPED: n=2, 232±75 MBq/kg; [
18
F]F
‾
: n=1, 77.8 MBq/kg) was administered via a tail 
vein as an infusion (0.5 mL/min) using a syringe pump (Harvard Apparatus, Holliston, MA, 
USA) and a needle catheter. Transmission scans and PET acquisition followed, details of 
which have been published elsewhere [13]. No correction for partial volume effects was 
applied. The image volume data were converted to Siemens ECAT7 format for further 
processing, and the image files processed using ROVER software (ABX GmbH, Radeberg, 
Germany). Masks for defining three-dimensional regions of interest were set and the regions 
of interest (ROI’s) defined by thresholding. ROI time activity curves (TAC) were derived for 
the subsequent data analysis. The ROI data and TAC were further analyzed using R (R is 
available as Free Software under the terms of the Free Software Foundation’s GNU General 
Public License in source code form) and specifically developed program packages [14]. 
SUV’s (mL/g) were calculated for the ROI’s using the equation: SUV = (activity/mL tissue)/ 
(injected activity/body weight). 
 
2.8. Small animal SPECT  
In vivo small animal SPECT imaging in a male Wistar rat was carried out under general 
anesthesia (induced with 10% and maintained with inhalation of 6.5% desflurane in 30% 
oxygen/air) with a scan time of 120 min. The rat was immobilized in the prone position with 
the medial axis parallel to the axial axis of the SPECT scanner (NanoSPECT, Bioscan Inc., 
Washington, D.C., USA).The camera was fitted with four nine-pin-hole apertures. The 
pinhole diameters were 2.5 mm and allow a resolution of ~ 1.6 mm in rat-sized animals. 
[
99m
Tc]MDP (0.5 mL, 322 MBq/kg, n=1) was administered via a tail vein as an infusion (0.5 
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mL/min) using a syringe pump (Harvard Apparatus, Holliston, Ma, USA) and a needle 
catheter. Data was acquired in a step-and-shoot mode with the bed also stepping to include 
the complete rat within the field of view. An energy window was used for 
99m
Tc with a peak 
at 140 keV. The SPECT acquisitions were reconstructed using InVivoScope 1.37 software 
(Bioscan) with a voxel size of 0.8 mm, using the ordered subsets expectation maximization 
iterative reconstruction algorithm with four subsets and six iterations. During reconstruction, 
high noise suppression was selected to produce smoother and more artifact-free images. The 
DICOM datasets were converted to ECAT7 format and analyzed as per the small animal PET 
protocol. The total counts within this volume were then converted to activity using a 
predetermined calibration factor. The CT acquisition was carried out in a SkyScan 1178 
(SkyScan, Belgium) and was reconstructed at standard resolution.  
 
2.9. Statistical analysis 
Continuous variables were expressed as the mean ± SD. Normality was assessed using the 
D'Agostino-Pearson normality test. Groups were compared using the Student t test or the 
Mann-Whitney U test, as appropriate. All statistical tests were 2-tailed, with a P value of less 
than 0.05 denoting significance, the symbols represent *P<0.05, **P<0.01, ***P<0.001. All 
statistical analyses were performed using GraphPad Prism (V5.02 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.com). 
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3. Results 
3.1. Radiolabeling  
The DOTA conjugated bisphosphonates were labeled with 
68
Ga, and isolated with high 
radiochemical purities of 95-98% after purification. 
 
3.2. Biodistribution 
The biodistribution data of [
68
Ga]-DOTA-bisphosphonates, [
18F]F‾ and [99mTc]MDP studied 
in normal Wistar rats are presented in tables 1 and 2. All radiotracers investigated showed a 
high degree of association with the bone. The detailed analysis of the activity associated with 
the bones reveals a significantly (P<0.001) higher level of [
68
Ga]BPPED, [
18
F]Fˉ, and 
[
99m
Tc]MDP accumulation compared to [
68
Ga]BPAMD and [
68
Ga]BPAPD. This is also 
evident from the estimation of the total activity in the skeleton for [
68
Ga]BPAPD (38% ID), 
[
68
Ga]BPAMD (31% ID), [
68
Ga]BPPED (49% ID), [
18
F]Fˉ (44% ID), and [99mTc]MDP (41% 
ID) at the end of the scan. The tracers showed fast renal elimination and high clearance from 
the blood, which is presumably a result of their high hydrophilicity. 
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Table 1. Activity (% ID, mean±SD of n animals) at different ROI’s of Wistar rats for [68Ga]BPAMD, 
[
68
Ga]BPAPD, [
68
Ga]BPPED and [
18F]Fˉ. Data recorded at 5 min p.i. 
 
 
Table 2. Activity (% ID, mean±SD of n animals) at different ROI’s of Wistar rats for for [68Ga]BPAMD, 
[
68
Ga]BPAPD, [
68
Ga]BPPED, [
18F]Fˉ (60 min p.i.) and [99mTc]MDP (120 min p.i.).  
 
mean SD n mean SD n mean SD n mean SD n
Brain 0.10 0.04 8.00 0.07 0.01 8.00 0.05 0.01 8.00 0.05 0.05 4.00
Pancreas 0.10 0.03 8.00 0.08 0.01 8.00 0.09 0.02 8.00 0.06 0.01 4.00
Spleen 0.09 0.02 8.00 0.07 0.01 8.00 0.07 0.01 8.00 0.08 0.01 4.00
Adrenals 0.02 0.00 8.00 0.02 0.00 8.00 0.02 0.01 8.00 0.01 0.00 4.00
Kidneys 3.38 0.91 8.00 2.94 1.04 8.00 3.12 0.69 8.00 1.55 0.58 4.00
Heart 0.30 0.06 8.00 0.27 0.06 8.00 0.20 0.03 8.00 0.12 0.00 4.00
Lung 0.73 0.22 8.00 0.61 0.09 8.00 0.53 0.09 8.00 0.30 0.03 4.00
Thymus 0.16 0.04 8.00 0.12 0.02 8.00 0.15 0.04 8.00 0.17 0.02 4.00
Thyroide 0.07 0.01 8.00 0.06 0.01 8.00 0.07 0.02 8.00 0.07 0.01 4.00
Harderian glands 0.08 0.01 8.00 0.08 0.01 8.00 0.06 0.01 8.00 0.04 0.01 4.00
Liver 3.53 0.51 8.00 2.96 0.40 8.00 2.68 0.35 8.00 1.44 0.10 4.00
Femur 1.38 0.20 8.00 1.29 0.09 8.00 1.91 0.13 8.00 1.74 0.14 4.00
Testes 0.53 0.08 8.00 0.47 0.08 8.00 0.53 0.08 8.00 0.24 0.05 4.00
Intestine 2.29 0.25 8.00 1.97 0.18 8.00 2.08 0.22 8.00 1.48 0.18 4.00
Stomach 0.58 0.10 8.00 0.43 0.03 8.00 0.52 0.13 8.00 0.19 0.03 4.00
Skeleton 26.21 3.87 8.00 22.71 3.09 8.00 34.21 3.16 8.00 26.60 2.14 4.00
Urine calculated 14.91 0.94 4.00 8.98 5.90 4.00 10.40 7.53 8.00 7.87 6.78 4.00
[18F]Fluoride
5 min
[68Ga]BPAPD
5 min
[68Ga]BPAMD
5 min
[68Ga]BPPED
5 min
mean SD n mean SD n mean SD n mean SD n mean SD n
Brain 0.05 0.02 8.00 0.04 0.01 8.00 0.03 0.02 8.00 0.01 0.00 4.00 0.01 0.02 6.00
Pancreas 0.05 0.02 8.00 0.10 0.14 8.00 0.08 0.09 8.00 0.03 0.03 4.00 0.01 0.00 6.00
Spleen 0.06 0.02 8.00 0.10 0.09 8.00 0.06 0.03 8.00 0.02 0.04 4.00 0.01 0.00 6.00
Adrenals 0.02 0.01 8.00 0.01 0.01 8.00 0.01 0.00 8.00 0.00 0.00 4.00 0.00 0.00 6.00
Kidneys 0.58 0.08 8.00 0.58 0.03 8.00 0.56 0.34 8.00 0.09 0.01 4.00 0.60 0.03 6.00
Heart 0.14 0.06 8.00 0.12 0.01 8.00 0.07 0.01 8.00 0.01 0.00 4.00 0.01 0.00 6.00
Lung 0.32 0.08 8.00 0.25 0.05 8.00 0.17 0.03 8.00 0.03 0.01 4.00 0.06 0.02 6.00
Thymus 0.11 0.03 8.00 0.08 0.02 8.00 0.05 0.01 8.00 0.02 0.01 4.00 0.01 0.00 6.00
Thyroide 0.04 0.01 8.00 0.03 0.01 8.00 0.03 0.01 8.00 0.04 0.02 4.00 0.02 0.01 6.00
Harderian glands 0.08 0.03 8.00 0.06 0.02 8.00 0.05 0.01 8.00 0.01 0.00 4.00 0.01 0.01 6.00
Liver 1.95 0.45 8.00 2.00 0.37 8.00 1.10 0.23 8.00 0.09 0.02 4.00 0.26 0.03 6.00
Femur 2.09 0.15 8.00 1.68 0.16 8.00 2.58 0.33 8.00 2.71 0.09 4.00 2.36 0.17 6.00
Testes 0.33 0.10 8.00 0.33 0.09 8.00 0.17 0.02 8.00 0.05 0.00 4.00 0.03 0.00 6.00
Intestine 1.93 0.37 6.00 1.76 0.62 8.00 2.56 1.78 8.00 1.13 0.18 4.00 6.57 2.87 6.00
Stomach 1.79 2.61 8.00 0.30 0.14 8.00 2.94 5.85 8.00 0.15 0.20 4.00 1.55 1.61 6.00
Skeleton 38.31 5.01 8.00 30.90 4.14 8.00 48.90 4.82 8.00 43.70 1.93 4.00 41.22 5.61 6.00
Urine calculated 25.93 7.34 8.00 42.20 5.11 8.00 31.90 9.84 8.00 24.30 2.83 4.00 38.10 4.11 6.00
[18F]Fluoride
60 min
[99mTc]MDP
120 min
[68Ga]BPAPD
60 min
[68Ga]BPAMD
60 min
[68Ga]BPPED
60 min
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PET Scans were conducted over 60 min p.i. for the [
68
Ga]-DOTA-bisphosphonates and 
[
18F]F‾, and 120 min p.i. for [99mTc]MDP. The bone to blood ratios determined at the end of 
the scan were [
68
Ga]BPAMD 3.4; [
68
Ga]BPAPD 3.7; [
68
Ga]BPPED 9.9; [
18
F]Fˉ 103; 
[
99m
Tc]MDP 52.3. The measured urine activity was 26% ID for [
68
Ga]BPAPD, 42% ID for 
[
68
Ga]BPAMD, 49% ID for [
68
Ga]BPPED, 44% ID for [
18
F]fluoride, and 41% ID for 
[
99m
Tc]MDP at the end of the respective scans. The summed activity in the skeleton and urine 
was 64% ID for [
68
Ga]BPAPD, 73% ID for [
68
Ga]BPAMD, 81% ID for [
68
Ga]BPPED, 68% 
ID for [
18F]Fˉ, and MDP 79% ID for [99mTc]. In all cases the activity concentration in the 
other tissues and organs was very low, and there was no visible activity accumulation 
observed in the brain or liver 
Table 3. Bone to blood ratios and the combined activity associated with the urine and skeleton (% ID, 
mean±SD of n animals) for [
68
Ga]BPAMD, [
68
Ga]BPAPD, [
68
Ga]BPPED, [
18F]Fˉ (at 60 min p.i.) and 
[
99m
Tc]MDP (at 120 min p.i.). 
compound 
bone/blood sum urine + skeleton (% ID) 
mean SD n mean SD n 
[
68
Ga]BPAMD (60 min) 3.42 0.54 8 64.2 12.4 8 
[
68
Ga]BPAPD  (60 min) 3.73 0.68 8 73.1 9.3 8 
[
68
Ga]BPPED  (60 min) 9.87 1.24 8 80.9 14.7 8 
[
18F]Fˉ             (60 min) 103.0 9.00 4 68.2 4.8 4 
[
99m
Tc]MDP   (120 min) 52.3 15.6 15 79.4 9.7 6 
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Figure. 2. Comparison of [
68
Ga]BPAMD, [
68
Ga]BPAPD, [
68
Ga]BPPED [
18
F]NaF and [
99m
Tc]MDP. The graph 
on the left represents the SUV of the bone at 60 min p.i., and the right hand side graph represents the SUV of 
the blood at 60 min p.i. 
 
3.3. Small animal PET 
The in vivo PET data are summarized in figure 3. [
68
Ga]BPAMD, [
68
Ga]BPAPD and 
[
68
Ga]BPPED were accumulated fast in the skeleton, reaching a plateau after one hour. The 
distribution half-lives of the radiotracers in the circulation were between one and two min, 
which correlates to the blood circulation time in rats. The half-lives of the slow components 
were 13 min for [
68
Ga]BPAMD, 19 min for [
68
Ga]BPAPD and 12 min for [
68
Ga]BPPED. The 
measured target to background ratios were equal to the established standards in bone imaging 
set by [
18
F]F‾ and [99mTc]MDP (figure 4). Figure 5 shows the distribution kinetics of [18F]F‾, 
[
68
Ga]BPAMD, [
68
Ga]BPAPD, and [
68
Ga]BPPED in the heart, kidney, spine and blood 
(vein). The curves are similar for all compounds. Variations in the curve profiles of the 
kidney time activity curves seems to be a result of the differing responses of individual rats to 
anesthesia, and resulting differences in the urine flow between rats. 
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Figure 3. MIP (maximum intensity projection) in the thorax region for [
68
Ga]BPAMD, [
68
Ga]BPAPD and 
[
68
Ga]BPPED at 5 min, 60 min and 120 min p.i. 
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Figure 4. Accumulation of the DOTA functionalised bisphosphonates in the spine (upper) of the rats and 
clearance from the blood (lower, ROI: over the heart). 
 
Figure 5. Time activity curves of 
68
Ga]BPAMD, [
68
Ga]BPAPD, [
68
Ga]BPPED and [
18F]Fˉ in the heart, kidneys, 
spine and blood stream. 
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Figure 6. µPET ([
18F]Fˉ, MIP, 60 min p.i.), CT (MIP) and SPECT ([99mTc]MDP, MIP, 120 min p.i.) scans 
recorded of Wistar rats. 
 
3.4. Metabolite analysis 
The metabolism of [
68
Ga]BPAMD, [
68
Ga]BPAPD, and [
68
Ga]BPPED was investigated in 
arterial blood plasma over one hour. The results are presented in figure 7. All three 
compounds showed similar degrees of decomposition over time. The half-lives of the parent 
compounds in the arterial blood plasma were 14.4 min (9.3 to 31.7 min) for [
68
Ga]BPAMD, 
10.2 min (7.4 to 16.5 min) for [
68
Ga]BPAPD and 20.8 min for (18.1 to 24.4 min) 
[
68
Ga]BPPED. At 60 min p.i. only about 10% of the plasma activity belonged to the parent 
compound. This did not have any effect on the blood cell and proteins binding in the arterial 
blood, where over the observed time about 4 to 7% were bound to these blood components.  
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Figure 7. Metabolic fractions of [
68
Ga]BPAMD, [
68
Ga]BPAPD and [
68
Ga]BPPED analysed in arterial blood 
plasma at 1, 3, 5, 10, 30, 60 and 120 min p.i. 
 
4. Discussion 
The three DOTA based bisphosphonates BPAMD, BPAPD and BPPED have been 
radiolabeled with 
68
Ga to give tracers of high radiochemical purity. Each of these tracers 
showed fast and high binding to the surface of healthy bones. [
68
Ga]BPPED was the most 
promising DOTA-based derivative with bone accumulation equal to [
18
F]F‾ and 
[
99m
Tc]MDP, and significantly higher than that of [
68
Ga]BPAMD and [
68
Ga]BPAPD. The 
blood clearance and renal elimination was fast for all compounds investigated. 
Approximately 90% of the radiolabeled DOTA-bisphosphonates not associated with bone 
tissue were metabolized within one hour, and eliminated rapidly via the kidneys. These 
metabolic characteristics produced a very low background from the other organs and tissues. 
The radiolabeled compounds were not observed in the brain. 
The phosphinate conjugated bisphosphonate, [
68
Ga]BPPED (2.58% ID/g), showed a 20% to 
50% higher accumulation in bone than the two amide compounds [
68
Ga]BPAMD (2.09% 
ID/g) and [
68
Ga]BPAPD (1.68% ID/g). Furthermore, [
68
Ga]BPPED also showed faster 
clearance from the blood via the renal system. The main structural difference between 
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BPPED and the other DOTA-bisphosphonates is the presence of a phosphinate group, and it 
is likely that the different pharmacokinetics observed can be attributed to this feature. It is 
possible that the presence of the phosphinate provides an additional binding site to 
hydroxyapatite surfaces, which leads to a higher bone uptake. Furthermore, the acidic 
phosphinate could be deprotonated and, given its anionic nature, may become involved in 
68
Ga binding. Regardless of whether the phosphinate oxygen ligates the metal or not, the 
complex is expected to be more polar (if not have an additional anionic charge) than the other 
two DOTA-bisphosphonates. This greater polarity may account for the enhanced renal 
clearance of [
68
Ga]BPPED.  
There was no significant difference in the bone accumulation and blood clearance of labeled 
BPAMD and BPAPD. Given that these structures only differ in the length of the spacer 
between the bisphosphonate and DOTA moiety, it is apparent that this has no influence on 
the pharmacokinetics and bone accumulation of the tracer. 
In terms of the ligating moiety, the DOTA-bisphosphonates could be described as hybrids of 
DOTA and DO3A, both of which have been shown to be effective ligands for the 
complexation of lanthanide ions [15]. In this respect, these DOTA-bisphosphonates are 
promising candidates as 
177
Lu carriers for endoradiotherapy of bone metastases. DOTA-
bisphosphonates could potentially be used as theranostic tools for the imaging and treatment 
of bone metastases [15]. This feature enhances the relevance of DOTA-bisphosphonates and 
gives them a considerable advantage over both [
18
F]F‾ and [99mTc]MDP .  
In view of a potential application of 
177
Lu-DOTA-bisphosphonates in therapy, the most 
important parameters are fast and high binding to the skeleton, combined with a fast blood 
clearance and non-target tissues (including the kidneys). All of the studied compounds share 
these parameters, however the best bone uptake and target to background ratio was achieved 
with [
68
Ga]BPPED.  
177
Lu would be ideally suited for the treatment of bone metastases, due to its excellent 
nuclide parameters: the short β- range of max. 2 mm does not harm the radiosensitive non-
target bone marrow, the non-carrier added production route leads to very high specific 
activities, and the macrocyclic Lu-DOTA complex is characterized by a high kinetic and 
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thermodynamic stability. Labeling studies and biodistribution experiments with 
177
Lu DOTA 
based bisphosphonates in an animal tumor model will be realized soon. 
In summary, all of the studied DOTA-bisphosphonates (BPAMD, BPAPD and BPPED) 
appear to be potentially useful compounds for radiolabeling and application in the diagnosis 
and therapy of bone metastases. Further investigations should involve similar evaluations in 
tumor models, to ascertain the affinity of these DOTA-bisphosphonates for bone metastases.  
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Abstract 
Painful bone lesions, both benign and metastatic are often managed using conventional 
analgesics. However, the treatment response is not immediate, and is often associated with 
side-effects. Radionuclide therapy is used for pain palliation in bone metastases as well as 
some benign neoplasms. ´Endoradiotherapy´ has direct impact on the pain producing bone 
elements, hence, response is significant, with minimal or no side effects. 
A new potential compound for endoradiotherapy is [
177
Lu]BPAMD. It combines a highly 
affine bisphosphonate, covalently bridged with DOTA through an amide bond, with the low-
energy β- emitting therapeutic radiolanthanide 177Lu. For routine chemical application, an 
automated synthesis of this radiopharmecutical and a Kit type labeling procedure appears to 
be a basic requirement for its GMP based production. A Kit formulation combining BPAMD, 
acetate buffer and ethanol resulted in almost quantitative labeling yields. The use of ethanol 
and ascorbic acid as quenchers prevent radiolysis over 48 h. An automated synthesis unit was 
designed for the production of therapeutic doses of [
177
Lu]BPAMD up to 5 GBq. The 
procedure was successfully applied for patient treatments. 
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1. Introduction 
Management of metastatic bone pain is often a multi-disciplinary concept where nuclear 
medicine can significantly contribut by applying therapeutic β- particle emitting 
radiopharmaceuticals. However, associated side-effects and absence of imaging surrogates of 
some of these tracers-are challenging. There has been an increasing research in this area for 
producing an `ideal´ tracer, which could relieve ´pain` symptoms, with minimal toxicity, and 
provide good physical characteristics for assessing biodistribution. There are several bone 
targeting radiopharmaceuticals commercially available applying β- emitting radionuclides, 
like [
153
Sm]EDTMP, [
186
Re]HEDP and 
89
SrCl2 [1]. More recently, the α-particle emitting 
223
RaCl2 was approved in Europe and by the FDA [2].  
While EDTMP and HEDP represent non-macrocyclic phosphonate ligands, a new 
macrocyclic diphosphonate (4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-
bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid (BPAMD, Figure 1), 
showed promising results in the detection of skeletal-related events (SREs) in first human 
studies, when labeled with the generator derived PET nuclide 
68
Ga [3]. This compound can 
further be used as an endoradiotherapeutic agent (Figure 2) by a stable complexation with the 
beta emitter 
177
Lu (t1/2 = 6.7 d, Eβmax = 0.5 MeV) [4]. The physical characteristics of 
177
Lu 
(long half-life and low β-range) are very suitable for the treatment of discriminated bone 
metastases. Low ranges of the particles emitted are essential for avoiding side effects, like 
haematotoxicity as induced by irradiation of the red bone marrow. Current production routs 
of 
177
Lu by the 
176
Yb pathway exclude the waste-problematic metastable 
177m
Lu (t1/2 = 160.4 
d) and carrier additions [5]. 
176Yb(n,γ)177Yb 
𝛽
→ 177Lu   
Using [
68
Ga]BPAMD PET/CT for pre- and post-therapeutic molecular imaging when using 
[
177
Lu]BPAMD for ERT, offers a system [*Me]BPAMD which reflects truly a theranostic 
(see Figure 1 and 2) option [6].  
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Since bone pain palliation was reported for [
177
Lu]EDTMP complexes in a phase II study [7]. 
Therefore, [
177
Lu]BPAMD is considered a very promising next generation compound for 
bone targeted endoradiotherapy (ERT). However, for future clinical trials, a Kit type labeling 
synthesis and an automated labeling module needs to be developed, resulting in high 
radiochemical yields and suitable for routine preparation. To design the Kit formulation in a 
way that prevents any upcoming radiolysis in therapeutic dose ranges over a reasonable time 
scale is also a challenge.  
 
Figure 1. Structure of the macrocyclic bisphosphonate ligand BPAMD and its use as theranostic when labelled 
with 
68
Ga (PET/CT) or 
177
Lu (ERT). 
We investigated different Kit compositions varying the ligand concentration, buffer and 
scavenger amount for labeling with no carrier added (n.c.a.) 
177
LuCl3 with activities up to 5 
GBq. Labeling efficiency, [
177
Lu]BPAMD complex stability, and radiolysis of the different 
batches were compared. 
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Figure 2. 70-year old male, case of prostate cancer, with rising PSA levels underwent 
18
F-Fluoride PET/CT. 
Coronal MIP image (A) showing intense tracer uptake in multiple bones in axial and appendicular skeleton and 
axial fused PET/CT (B-D) images showing hypermetabolic metastatic lesions in scapula (B), vertebrae (C) and 
pelvis (D). Patient was treated with 5358 MBq [
177
Lu]BPAMD. Post therapy images (Ant-E, Post-F) showing 
intense localization of tracer in the entire skeleton, in concordance with the pre-therapy 
18
F-Fluoride PET/CT 
study (A). 
 
2. Materials and methods 
2.1. Chemicals 
(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-
tetraazacyclododec-1-yl) acetic acid (BPAMD) was purchased from ABX (Radeberg, 
Germany). N.c.a. 
177
LuCl3 in 0.05 M HCl was provided by ITG (Garching, Germany) in a 
volume of 500 µL containing activities between 3 to 5 GBq. Sodium acetate, sodium 
ascorbate and ascorbic acid are commercially available by Sigma-Aldrich (Germany) in 
BioXtra
®
 (≥99.0%) or ReagentPlus® (≥99.0%) grade, as well as ethanol (CHROMASOLV®), 
water (TraceSELECT
®
) and citrate.  
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2.2. Kit formulation 
The ligand BPAMD as well as sodium acetate, sodium ascorbate and ascorbic acid were 
dissolved in water with a concentration of 1 mg/mL. Six different concentrations of BPAMD 
and additives were mixed in a micro reaction vial and lyophilized (Kit #1-6, table 1). 
Additionally another vial containing 2.5 mg gentisinic acid, without any ascorbate was 
prepared (Kit #7). Prior the essential labeling process the single Kits were dissolved in water 
(1 mL per 1 GBq 
177
Lu ) with exceptions for the Kits #4 and #5, which were dissolved in 
water containing 10% EtOH. Kit #7 was prepared with the lowest amount of 40 µg BPAMD 
still suitable for an efficient 
177
Lu labeling. Instead of sodium ascorbate 2.5 mg of gentisinic 
acid, which is reported as a potent scavenger, was used [8]. 
Table 1. Compositions of different Kit formulations for [
177
Lu]BPAMD preparation in 5 mL aqueous solution. 
Kit 
BPAMD 
(µg) 
NaOAc (mg) 
NaOAsc 
(mg) 
HOAsc (mg) 
gentisinic 
acid (mg) 
EtOH (%) 
#1 100 16 100 - - - 
#2 250 16 100 - - - 
#3 100 16 500 - - - 
#4 100 16 100 - - 10 
#5 250 16 100 - - 10 
#6 100 - 400 100 - - 
#7 40 16 - - 2.5 - 
 
 
2.3. Automated synthesis module 
Single modular parts of an automated synthesis module of the company Eckert&Ziegler 
(Berlin, Germany) were combined to form a new device specially designed for the 
preparation of [
177
Lu]BPAMD. This unit is a one reactor system that works with over 
pressure. The control platform of this synthesis unit is shown in figure 3. Here shown is that 
the unit contains of one Peltier Reaction Modul (R1), nine velves (two Stopcock Manifold 
Modules and one PharmTracer Module, V1-V9), six vials (G1-G6) and one optional SPE 
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(solid phase extraction) cartridge (T1). The whole system is controlled by the “electrical 
cabinet” and the program “Modular-Lab” (EZAG, Germany). The reactor has a temperature 
area from -15 °C up to 150 °C and is cooled with an external heat exchanger. Glass vials 
(micro reaction vials) common for modular radiosynthesis were purchased from Sigma-
Aldrich (Germany). The dissolved BPAMD kit is placed in vial G1. Vial G2 is reserved for 
the 
177
LuCl3 solution, while G3 is the product vial and G4 is the waste vial. The vials G5 and 
G6 are needed for the optional purification step via SPE (solid phase extraction). Here G5 
contains pure water as a washing solution and G6 the eluent solution. The unit is constructed 
for GMP based synthesis, therefor the reactor, valves and tubes are disposable and can be 
replaced. Also this unit can be run with pure Helium or Argon instead of a pump. If the 
synthesis must not be GMP based, it is possible to run a cleaning program and reuse all the 
disposable parts. It is also possible to run a purification step after the initial labeling reaction. 
If the purification step is activated the product is trapped on a SPE  cartridge (T1), washed 
with 5 mL water in G5 and eluted into G3 with the eluent solution in G6. In this case the 
whole reaction takes place in 50 min. 
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Figure 3. Schematic overview of the module composition out of EZAG-modular compartments. The sketch is 
shown as presented in the control platform of the synthesis unit in the program: Modular-Lab. 
 
2.4. Automated radiolabeling  
Labeling of BPAMD was performed with 3-5 GBq 
177
LuCl3. For this purpose the single Kits, 
listed in table 1, were dissolved in water or water + 10 % EtOH to a final concentration of 1 
mL per 1 GBq 
177
Lu and placed in the automated synthesis module as well as the 
177
LuCl3 
containing vessel (G2). The
 177
LuCl3 solution (500 µL in 0.05 M HCl) was transferred by 
over pressure to the Peltier Reaction Modul (R1) followed by the Kit solutions from vial G1. 
The reaction mixture is heated under stirring at 100°C for 30 min. After cooling the whole 
system, the solution is transferred to the product vial (G3). The whole reaction takes place in 
36 min. Because of the evaluation of the different Kit formulations in terms of labeling 
efficiency and complex stability the purification step was always skipped. Radiochemical 
yields (RCYs) and stability were determined by thin layer chromatography (TLC) (Merck 
Silica, solvent: 0.1 M sodium citrate pH 4) at the time points 0 h, 1 h , 2 h, 4 h, 24 h, and 48 h 
after labeling.  
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2.5. Automated radiolabeling  
The stability of the best performing Kits from the above mentioned experiments were further 
tested, by mixing the product in a 1:8 ratio with human serum and were incubated at 37°C 
over a period of 48 h. Radio-TLC analysis were done at time points of 0 h, 1 h, 2 h, 4 h, 24 h, 
and 48 h similar to the radiolysis experiment. 
 
2.6. Serum stability test  
The stability of the best performing Kits from the above mentioned experiments were further 
evaluated regarding the long-term stability of [
177
Lu]BPAMD.  The reaction products were 
mixed in a 1:8 ratio with human serum and were incubated at 37°C over a period of 48 h. 
Radio-TLC analysis were done at time points of 0 h, 1 h, 2 h, 4 h, 24 h, and 48 h similar to 
the radiolysis experiment. 
 
3. Results 
The lyophilized Kits presented the content as a white powder and were easily soluble in 3-5 
mL water within a minute. Additives of 10%Vol ethanol showed to have no influence on the 
solubility and were thus added as an additional scavenger. Labeling with n.c.a. 
177
Lu was 
almost quantitative (RCY ≥ 98 %) within 30 min reaction time for the Kit formulations #2, 
#5, #6 and #7 (Table 2). The Kit formulations #1 and #4 showed a somewhat less RCY of 
97.0 % for Kit #1 and 96.9 % for Kit #4, respectively. Lowest yields of 68.5 % were obtained 
for Kit #3. The total process time for the preparation of [
177
Lu]BPAMD in batches up to 5 
GBq could be achieved in 36 min and without any need for purification. 
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Table 2. Synthesis yield and radiolytic stability as percentage of intact [
177
Lu]BPAMD complexes. 
Kit 0 h 1 h 2 h 4 h 24 h 48 h 
#1 97.0 96.0 95.0 91.0 86.0 68.0 
#2 98.3 98.3 98.3 97.7 97.7 97.7 
#3 68.5 92.1 82.2 93.5 89.7 91.7 
#4 96.9 98.6 98.5 98.0 93.5 90.2 
#5 99.2 (0.1) 99.2 99.0 99.0 98.9 (0.1) 98.8 (0.2) 
#6 99.6 (0.6) 99.0 99.0 99.0 99.4 (0.6) 99.3 (0.7) 
#7 98.8 98.5 96.4 94.3 77.5 39.0 
(S.D.) standard deviation out of a triplicate 
While Kit #1 and #7 showed a continuous degradation of the complex with a resulting value 
of 68.0% and 39.0%, Kit #3 and #4 showed a good but not sufficient stability of 91.7% and 
90.2% after 48 h. Optimum complex stability of > 98% was observed for Kit #5 and Kit #6, 
followed by the Kit composition #2 with 97.7% of intact [
177
Lu]BPAMD after 48 h, cf. table 
2. In table 3 the results from the serum stability test of the [
177
Lu]BPAMD Ki #6 are listed. 
No degradation of the [
177
Lu]BPAMD complex, prepared with Kit #6 was observed in human 
serum over a period of 48 h.  
Table 3. Serum stability of [
177
Lu]BPAMD prepared with Kit #6. Data are presented as mean percentage of 
intact complex out of a triplicate.  
Kit 0 h 1 h 2 h 4 h 24 h 48 h 
#6 99.4 (0.1) 99.2 (0.0) 99.1 (0.1) 99.2 (0.1) 99.0 (0.0) 99.0 (0.1) 
(S.D.) standard deviation 
 
4. Discussion 
The automated synthesis device was proved to be useful to perform [
177
Lu]BPAMD 
preparations up to 5 GBq. Different Kit compositions were tested in terms of RCY and 
radiolytic stability under GMP like conditions. 
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a) Amount of BPAMD: In Kit #1 and Kit #2 the amount of precursor was increased from 100 
µg to 250 µg BPAMD, whereas the concentration of the ascorbate scavenger was kept 
constant. Only marginal changes in the RCY were observed, but with slightly better results 
for Kit #2 with 250 µg BPAMD. Radiolytic stability increased significantly with higher 
amounts of ligand from 68.0 % for Kit #1 to 97.7 % for Kit #2.  
b) Amount of scavenger: Kit #3 differed from Kit #1 in the amount of ascorbate scavenger, 
while the ligand concentration was kept constant. The increased sodium ascorbate amount of 
500 mg resulted in an unsteady labeling yield based on reaction pH of > 6. Nevertheless an 
increasing stability concerning radiolysis could be observed for higher scavenger amounts 
resulting in 91.7 % intact [
177
Lu]BPAMD for Kit #3 compared to 68.0 % for Kit #1 after 48 
h. 
c) Effect of ethanol: The formulation was kept constant for the Kits #1 and #4, but instead of 
dissolving the batch in pure water a mixture of water containing 10 %Vol EtOH was used for 
Kit #4. The ethanol did not influence the solubility of the ingredients, but rather it functioned 
as an additional radical scavenger. Labeling yields were similar and indeed a higher stability 
of 90.2 % for the Kit #4 was obtained compared to the 68.0 % for Kit #1 after 48 h, 
demonstrating that ethanol additions are useful to gain Kit stabilities. Based on these results, 
Ki #5 was prepared equal to Kit #2, but dissolved in 10 %Vol EtOH as for Kit #4. The 
formulation of Kit #5 with 250 µg ligand, 100 mg sodium ascorbate and a 10 %Vol of EtOH 
showed a RCY of 99.2 % and a radiolytic stability of 98.8 % over 48 h. 
Finally Kit #6 was prepared similar to Kit #3 containing 100 µg BPAMD, i.e. with a higher 
specific activity compared to Kit #5 containing 250 µg BPAMD. Instead of sodium ascorbate 
only, a mixture of sodium ascorbate and ascorbic acid was used to adjust a reaction pH < 6, 
which results in the best RCY of 99.6 % compared to that of Kit #3. Stability could be 
maintained over 48 h (99.3 % of the intact complex), similar to that of Kit #5. 
[
177
Lu]BPAMD prepared with Kit #6 exhibited also no complex degradation in human serum 
within 24 h. An additional approach was the reduction of cold BPAMD carrier amounts. Kit 
#7 exhibited the best specific activity of 125 MBq (
177
Lu) per 1 µg (BPAMD), but showed 
also the lowest stability over time.  
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5. Conclusion 
The BPAMD Kit formulation containing a mixture of 100 µg ligand, 400 mg sodium 
ascorbate and 100 mg ascorbic acid exhibited the best synthesis yields and the best radiolytic 
stabilities over 48 h, with a specific activity of 50 MBq 
177
Lu/µg BPAMD. An automated 
synthesis module for the preparation of [
177
Lu]BPAMD in scales of up to 5 GBq has been 
successfully established. The Kit and the automated synthesis unit enable a safe and routine 
in-house production of the therapeutic tracer [
177
Lu]BPAMD for the treatment of bone 
metastases. Additionally the stability over 48 h  is an appropriate time scale to even allow the 
shipment of batches from production facilities ready-to-use to clinical departments. The 
[
177
Lu]BPAMD prepared this way selectively accumulates in disseminated bone metastases. 
Preliminary therapeutic data are promising and will be reported in detail elsewhere. 
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Abstract 
Ligands with geminal bis(phosphonic acid) appended to 1,4,7-triazacyclonone-1,4-diacetic 
acid fragment through acetamide (NOTAM
BP
) or methylenephosphinate (NO2AP
BP
) spacers 
designed for 
68
Ga were prepared. Ga(III) complexation is much faster for ligand with 
methylenephosphinate spacer than that with acetamide one, both in chemical (high reactant 
concentrations) and radiolabeling studies with no-carrier-added 
68
Ga. For both ligands, 
formation of the Ga(III) complex was slower than that with NOTA due to the strong out-of-
cage binding of bis(phosphonate) group. Radiolabelling was efficient and fast only above 60 
C and in a narrow acidity region (pH ~3). At higher temperature, hydrolysis of amide bond 
of the carboxamide-bis(phosphonate) conjugate was observed during complexation reaction 
leading to the Ga-NOTA complex. In vitro sorption studies confirmed effective binding of 
the 
68
Ga complexes to hydroxyapatite being comparable with that for common 
bis(phosphonate) drugs such as pamindronate. Selective bone uptake was confirmed in 
healthy rats by biodistribution studies ex vivo and by microPET imaging in vivo. Bone uptake 
was very high, with SUV (standardized uptake value) of 6.19±1.27 for [
68
Ga]NO2AP
BP
) at 
60 min p.i. which is superior to the uptake of 
68
Ga–DOTA-based bis(phosphonates) and 
[
18
F]NaF reported earlier (SUV of 4.63±0.38 and SUV of 4.87±0.32 for [
68
Ga]DO3AP
BP
 and 
[
18
F]NaF, respectively, at 60 min p.i.). Coincidently, accumulation in soft tissue is generally 
low (e.g. for kidneys SUV of 0.26±0.09 for [
68
Ga]NO2AP
BP
 at 60 min p.i.), revealing the 
new 
68
Ga complexes as ideal tracers for non-invasive, fast and quantitative imaging of 
calcified tissue and for metastatic lesions using PET or PET/CT. 
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1. Introduction 
Positron emission tomography (PET) is a powerful method for imaging various tissue or 
physiological states. The choice of the proper PET radionuclide is given by various criteria 
such as half-life, energy of the emitted positron, production pathway, radiopharmaceuticals 
preparation and/or means of application. Compared to the most commonly used radioisotopes 
(
11
C and 
18
F) needing on-site production on a cyclotron, various metal radionuclides can 
conveniently be prepared utilizing a generator – a device containing a parent nuclide that 
decays with a long half-life to a daughter positron-emitting radionuclide which is periodically 
eluated off, purified and used. These radionuclide generators are relatively cheap, 
permanently accessible and easy to handle. One of the most promising generator-produced 
radionuclides is 
68
Ga (t½ 67.7 min, 89 % positron emission, mean 
+
 energy 0.83 MeV) 
available from commercial 
68
Ge/
68
Ga generators (1–7). 
However, with only very limited exceptions, most of the metal radioisotopes cannot be 
applied in a “free” form. The metal radioisotope must be bound in a stable complex to avoid 
non-specific deposition of the radioisotope in tissues. Ligands used for complexation of the 
metal ions must ensure very fast and efficient complexation even in highly diluted solutions, 
sufficient kinetic inertness and thermodynamic stability of the complexes as well as specific 
accumulation of the formed species in the tissue of interest. The last requirement is 
commonly fulfilled either by creating a metal-ligand system showing specific interaction 
with target organs or by adding a biologically relevant targeting vector to the metal-ligand 
system, thereby turning the “normal” ligand into a “bifunctional” one. Bifunctionality defines 
the utilization of one of the functional groups of the ligand to covalent attachment of the 
ligand to the targeting vector while preserving the complexing potency of the remaining 
structure. 
Bone tissue is a prominent target of radionuclide diagnostics and therapeutics as bone 
metastases represent a very common complication of various types of cancer. Generally, 
bone targeting is mostly realized via attachment of a germinal bis(phosphonate) moiety to a 
molecule to be delivered to bone (8–11). Bis(phosphonates) show a high affinity to 
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hydroxyapatite (HAP). Thus, compounds containing a bis(phosphonate) moiety are 
efficiently adsorbed on the surface of bones. Consequently, such conjugates have been used 
to deliver radioisotopes to the calcified tissues (10). Recently, we and others have developed 
bis(phosphonate)-bearing ligands based on a DOTA-like macrocyclic core (DOTA = 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, Figure 1) as carriers for metal ions 
to be delivered to calcified tissue (12–17). The applications include imaging techniques (111In 
and 
68
Ga for SPECT and PET imaging, respectively) (13,15,17–19) as well as therapy (177Lu, 
90
Y) (13,16) or bone metastases pain palliation in human patients (20). The conjugates 
exhibited a very high affinity to HAP as the bis(phosphonate) moiety is not coordinated to 
the central metal ion and, thus, remains active for bone targeting (21,22). However, DOTA-
like macrocycles are not the best ligands for Ga(III) as incorporation of the ion inside the 
macrocyclic cavity leads to severe distortion of coordination octahedron around Ga(III) ion 
(23–26).  
Despite high thermodynamic stability and kinetic inertness of the Ga(III) complexes with 
DOTA-like ligands (27), complexation of no-carrier-added (n.c.a.) 
68
Ga with these ligands is 
less efficient and more sensitive to experimental conditions than that of NOTA analogs 
(NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid, Figure 1) (1). Triaza- instead of 
tetraazamacrocycles have been proved to be more suitable for Ga(III). They form complexes 
exhibiting much higher thermodynamic stability as well as kinetic inertness (28,29). The size 
of the coordination cavity imposed by the nine-member macrocyclic ring corresponds very 
well to the size of the Ga(III) ion. As Ga(III) is small ion and mostly requires octahedral 
coordination sphere, the NOTA-like ligands provide an optimal size and arrangement of 
ligand cavity to accommodate trivalent gallium (logK[Ga-DOTA] = 26.1, logK[Ga-NOTA] =29.6) 
(27,28). Thus, a number of NOTA-like ligands have been investigated as promising chelators 
for 
68
Ga (1,10). Among them (by analogy with the most commonly used ligands in the 
DOTA-like family, the DOTA-monoamides), NOTA-monoamides appear as an emerging 
class of ligands due to their easy synthesis and potential easiness of introduction of 
bifunctionality through amide formation (30–33).  
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Figure 1. Ligands discussed in this paper.  
Imaging of bone lesions is important for location, staging and treatment of several diseases, 
mainly breast and prostate cancers metastases. Bone scans have been dominated by SPECT 
imaging with 
99m
Tc-bis(phosphonate) tracers. However, SPECT resolution and sensitivity is 
inferior comparing with PET; so, PET tracers should be more convenient. The [
18
F]NaF 
tracer has been introduced for bone imaging some time ago. However, 
18
F is expensive, and 
its production requires cyclotron and skilled staff. So, cheaper alternative isotopes requiring 
only relatively simple workup, as e.g. 
68
Ga produced in long-lived generator, are desired. We 
have introduced (12–14) bis(phosphonate)-containing macrocyclic ligands, DOTA-
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monoamide DOTAM
BP
 and DOTA monophosphinate analog DO3AP
BP
 (Figure 1), which 
were successfully labelled with 
68
Ga and used as PET tracers.(18–20,34) However, labelling 
DOTAM
BP
 and DO3AP
BP
 with 
68
Ga is not optimal.(19,34) Thus, in order to improve 
properties of the bone-targeted complexes such as ease labeling and improved bone/soft 
tissue ratio as well as to get a direct comparison with our previous data on 
68
Ga-DOTAM
BP
 
and 
68
Ga-DO3AP
BP
, we decided to study analogous ligands derived from NOTA.  
Thus, this paper describes synthesis of the NOTA-like ligands with a bis(phosphonate)-
containing side arm (as the bone-targeting group) connected to the metal-binding cage 
through the acetamide or methylphosphinate pendant arms, NOTAM
BP
 and NO2AP
BP
 
(Figure 1). The ligand physicochemical characterization, labeling with 
68
Ga, in vitro binding 
to HAP, ex-vivo biodistribution of the 
68
Ga-labeled compounds and small animal in vivo PET 
imaging were evaluated. In order to simplify the text, abbreviations as NOTA, Ga-
NOTAM
BP
 or Ga-NO2AP
BP
 etc. are used for the ligands/complexes regardless of the in 
charge/protonation state, except when the distinction is necessary for comprehension. 
 
2. Results and Discussion 
2.1. Synthesis 
The ligands were synthesized according to Figure 2. A previously described procedure (35) 
for the benzyl monoprotected macrocycle 2 was modified to a one-pot synthesis and its 
overall yield was improved. Further reaction with t-butyl bromoacetate followed by catalytic 
hydrogenation resulted in doubly substituted macrocycle 4. Preparations of compound 4, 
commonly used for synthesis of 1,4,7-triazacyclononane-1,4-diacetic acid (NO2A) 
derivatives, have been known for a long time (36–39); however, the present synthesis was 
slightly modified, run in much higher scale and resulted in overall yield comparable with the 
previous ones. The secondary amine of the NO2A diester 4 was used for attachment of 
geminal bis(phosphonate) moiety via the acetamide or methylphosphinate linkers. The 
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reactions were carried out with the fully esterified reagents due to their better solubility in 
organic solvents and more efficient chromatographic purification of the intermediates. The 
acetamide derivative 6 was prepared by alkylation of 4 with the appropriate chloroacetamide 
5. The phosphinate derivative 8 was prepared by Mannich-type reaction using 
paraformaldehyde and the per(ethyl) bis(phosphono)-phosphinate 7. Cleavage of the ester 
protecting groups was performed in two steps. First, t-butyl groups were cleaved by action of 
trifluoroacetic acid and, then, ethyl groups were removed by transesterification with 
trimethylbromosilane followed by silyl group removal with methanol. The final purification 
on cation exchange resin yielded NOTAM
BP
 and NO2AP
BP
 in zwitterionic form. 
 
Figure 2. Syntheses of ligands: (i) 1. Me2NCH(OMe)2, dioxan, reflux, 3 h; 2. BrCH2Ph, THF, r.t., overnight; 3. 
KOH, H2O/EtOH, reflux, 3 d; 75 %. (ii) BrCH2CO2
t
Bu, K2CO3, acetonitrile, r.t., 3 d; 91 %. (iii) H2, Pd/C, 
EtOH, 50 C, 12 h; 84 %. (iv) ClCH2C(O)NH–CH(PO3Et2)2 (5), K2CO3, acetonitrile, 50 C, 3 d; 83 %. (v) 1. 
CF3CO2H/CHCl3 1:1, r.t., 12 h; 2. BrSiMe3, acetonitrile, r.t., 12 h; 80 % (NOTAM
BP
), 41 % (NO2AP
BP
). (vi) 
(7), (CH2O)n, acetonitrile, 35 C, 3 d; 72 %. 
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2.2. Ga
3+
 complexation 
Coordination ability of the title ligands toward Ga(III) was studied due to their intended 
applications for 
68
Ga PET imaging. In addition, Fe(III) complexes were prepared as this ion 
shows similar properties (the same charge and similar ionic radius) as Ga(III) and, thus, can 
be considered as a surrogate differing just in spectral and magnetic properties. 
Dissolving the ligand in a solution containing the equimolar amount of the metal ions leads 
to significant decrease in pH (pH drops to 1.4–2.0). Addition of strong hydroxide and 
increase of pH (pH > 2) leads to immediate formation of precipitates. The precipitates are 
dissolved upon further increase in pH (pH > 4). Most likely, such behavior could be ascribed 
to a mechanism of complex formation involving several intermediates as it has been 
suggested for similar macrocyclic ligands (14,28,29). The initial mixing of the reagents leads 
to immediate coordination of the metal ion to the bis(phosphonate) oxygen atoms and release 
of protons. It is known that bis(phosphonate) group is able to interact with trivalent metal 
ions even at very low pH (40,41) and, at pH < 2, the ligands bind the metal ion in a 
protonated form (with protons bound on macrocyclic amines as well as on the phosphonate 
groups) forming out-of-cage complexes. Such species have overall positive charge and are 
soluble in water. Increase of pH causes further deprotonation of the bis(phosphonate) group 
and formation of charge-neutral complexes with low solubility in water. Such solid out-of-
cage intermediates are expected to be 3-D coordination polymers having metal ions bridged 
by phosphonate group(s), typical for phosphonate and bis(phosphonate) complexes (40,41). 
Further pH increase results in dissolution of the precipitates and is associated with the ring 
amine deprotonation and formation of final in-cage macrocyclic complexes where the metal 
ion is coordinated with three ring nitrogen atoms and three oxygen atoms of carboxylate or 
acetamide/phosphinate pendants (29,42,43). A similar mechanism involving phosphonate-
coordinated out-of-cage intermediate has been previously postulated for complexation of 
lanthanide(III) ions with analogous DOTA-like bis(phosphonate)-bearing ligands as 
DO3AP
BP
 (12,14). Formation of the in-cage complexes was directly confirmed by 
71
Ga 
NMR measurements. The Ga-NO2AP
BP
 complex shows a rather broad signal at 158 ppm 
(½ ~1300 Hz, Figure S1). The quadrupole moment of the 
71
Ga nucleus leads to a signal 
broadening if Ga(III) ion is placed in a non-symmetrical coordination environment. The non-
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symmetrical charge distribution leads to an extremely broad signal of Ga-NOTAM
BP
 
complex centered at ~170 ppm (½ = ~9700 Hz, Figure S1); 
71
Ga NMR chemical shift of 
166 ppm has been observed for other NOTA-monoamide gallium(III) complex (31).  
The time course of gallium(III) complexation with the ligand NO2AP
BP
was studied in details 
by 
71
Ga and 
31
P{
1
H} NMR. Coordination spheres of the out-of-cage intermediates are 
completely non-symmetrical and, thus, are “invisible” in the 71Ga NMR spectra. Thus, 
formation of the in-cage complex was quantified using an external capillary standard. These 
experiments were performed with Ga:L 1:1 molar ratio, at pH 2 and 3 (1 M sodium 
chloroacetate buffer), pH 4 and 5 (1 M sodium acetate buffer). In the presence of the weakly 
coordinating buffers, the above mentioned precipitation of intermediates was not observed. 
The results are summarized in Table 1 and Figures 3 and S2. The complexation rates follow 
the order pH 2 < pH 3 ~ pH 5 < pH 4. As stated above, the complexation can be described as 
a two-step process. The intermediate out-of-cage complex is formed instantly and the metal 
ion is coordinated only through oxygen atoms of the bis(phosphonate) group and the pendant 
arms (carboxylate and phosphinate), whereas the macrocyclic amines are protonated. In the 
rate-determining step, the ring nitrogen atoms lost proton(s) and the metal ion simultaneously 
moves into the macrocycle cavity; it is, generally, a base-catalyzed process. The mechanism 
explains the increase in the complexation rate between pH 2 and 3. The complexation at pH 5 
might be partially decelerated by presence of acetate anions from the buffer, however at 
milimolar concentrations used in these experiments, partially protonated bis(phosphonate) 
anion (41) is much better ligand than acetate and it is known that phosphonate coordination 
ability is considerably increased with consecutive deprotonation of the group. Thus, the 
slower complexation at pH 5 is probably caused by more extensive deprotonation of the 
bis(phosphonate) moiety at higher pH leading to its stronger interaction with the Ga(III) ion 
and stabilization of the out-of-cage complex, or by formation of Ga(III) hydroxido 
complexes.  
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Figure 3. Time course of complexation of Ga(III) with NO2AP
BP
 at different pH (40 C, molar ratio L : Ga = 
1 : 1, cGa = 0.13 M); dead time for t0 = 5 min. 
Table 1. Half-time (t1/2) of the Ga-NO2AP
BP
 complex formation (40 C, molar ratio L : Ga = 1 : 1, cGa = 0.13 
M).  
Ligand pH t1/2 [min] 95 % complexation [min] 
NO2AP
BP
 
5 10 50 
4 <5 20 
3 12 60 
2 65 360 
NOTA
a
 
3 <2  
1 270  
a
25 °C, ref. [28]. 
In the case of NOTAM
BP
, the broadening of the 
71
Ga NMR signal and overlapping of 
31
P{
1
H} NMR signals of the product and reaction intermediates disabled precise 
quantification under the same conditions as those used for the NO2AP
BP
 complexation. 
However, even after heating at 40 C for several hours, broad 31P{1H} NMR signals were 
observed showing that only an out-of-cage complex was formed which was stable under 
these conditions. If the solution was heated at 95 C (Figures 4 and S3), several signals could 
be distinguished after several minutes and the spectra indicate that the in-cage complex is 
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fully formed after ~30 min under this conditions. Further heating led only to a decrease of the 
Ga-NOTAM
BP
 complex signal and increase of that of the aminomethylene-bis(phosphonate) 
indicating that the Ga-NOTAM
BP
 complex is unstable under this conditions and decomposes 
to the Ga-NOTA complex (see also below). Some decomposition (i.e. the formation of 
[Ga(NOTA)]) was observed in the 
71
Ga NMR spectrum even after 10 min of the reaction 
(Figure S3).  
 
Figure 4. 
31
P{
1
H} NMR spectrum of the reaction mixture after 30 min of reaction of Ga(III) with NOTAM
BP
 at 
pH 3 and 90 C (cGa = 0.13 M, slight molar excess of the ligand; dead time (t0) approx. 5 min). 
The results point to an important role of the spacer connecting the bis(phosphonate) group 
and the macrocycle. Under all conditions tested, NO2AP
BP
 showed significantly faster 
gallium(III) complexation than NOTAM
BP
. Albeit phosphinates are known to be better 
complexation groups than carboxamides, the pronounced difference in the reaction rate is 
surprising; the hard and charged phosphinate group as good coordinating group for Ga(III) 
ion is probably able to assist the ion transfer from the out-of-cage species into the in-cage 
complex much better. In addition, basicity of the amine group in the >N–CH2–P(R)O2H 
moiety is significantly lowered (28,44) and, so, deprotonation of the amine group adjacent to 
the phosphinate is facilitated.  
For both ligands, the complexation rates are significantly lower than those reported for 
NOTA or its phosphinic acid analogues (28,29,45–47). So, presence of a too strongly 
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complexing hard group such as the bis(phosphonate) one in the proximity of macrocycle 
could be considered as a rate-decreasing factor in Ga
3+
 complexation reaction. In addition, it 
has been recently published that presence of three bis(phosphonate) groups in the side chains 
of a tris(methylenephosphinic acid) NOTA analog completely prevents entering the Ga(III) 
ion into the macrocyclic cavity and Ga(III) is coordinated only by the phosphonate groups in 
the out-of-cage fashion.(48) Consequently, a number of bis(phosphonate) groups should be 
balanced to have good bone targeting and, in the same time, efficient in-cage complexation. 
 
2.3. Hydrolysis of the amide bond in the Ga-NOTAM
BP
 complex 
Single-crystals were formed in time course of Ga(III) complexation with NOTAM
BP
. 
According to the X-ray diffraction, these were not crystals of Ga-NOTAM
BP
 but those of the 
known Ga-NOTA complex (41). It is result of the amide bond hydrolysis in the Ga-
NOTAM
BP
 complex (see also Figure 5). Upon complexation, Ga(III) is coordinated through 
amide oxygen or nitrogen atoms (31). This coordination decreases the electron density on the 
amide carbon atom and makes it more vulnerable for the solvent nucleophilic attack (it is the 
same effect as expressed during hydrolysis of peptide bond catalyzed by metalloenzymes). 
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Figure 5. Hydrolysis of amide bond in the Ga-NOTAM
BP
 complex expressed as increasing abundance of the 
Ga-NOTA complex in 
71
Ga NMR (A) and decreasing abundance of the Ga-NOTAM
BP
 complex in 
31
P{
1
H} 
NMR (B) (90 C, cGaL = 0.13 M). Figures do not have the same y-axis absolute scale: precipitation of the Ga-
NOTA complex, confirmed by X-ray diffraction, caused decline of the 
71
Ga NMR signal intensity by the end of 
the reaction and maximum in the 
31
P{
1
H} NMR data refers to a time when the first integration was possible, i.e. 
after 0.5–2.5 h depending on pH. 
As the reaction is important in view of utilization of the 
68
Ga-labelled ligands in nuclear 
medicine (see below), the hydrolysis was studied in more detail. It was monitored through an 
increasing intensity of the sharp Ga-NOTA signal in 
71
Ga NMR (δGa = 170 ppm; ½ = 390 
Hz) and, in parallel, through increasing intensity of the aminomethyl-bis(phosphonate) signal 
in 
31
P{
1
H} NMR (δ = 8.9 ppm, pH 3), Figure S3. The results show that the hydrolysis is 
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faster with increasing pH (Figure 5). It indicates a hydroxide-mediated reaction and could be 
explained as nucleophilic attack of the hydroxide anion on the amide carbon atom of highly 
polarized carbonyl moiety due to coordination to small trivalent metal ion; thus, the reaction 
can proceed even in slightly acidic solutions. However, the hydrolysis proceeds with much 
slower rate than the formation of the in-cage complex as only very minor decomposition was 
observed during 10 min at 90 C (Figure S3, see also above) under these “chemical” 
conditions (in this context, “chemical” conditions means milimolar or higher concentrations 
of the reactants unlike “radiochemical” conditions where the concentrations are many orders 
of magnitude lower). Thus, the hydrolysis was also checked during the labeling of 
NOTAM
BP
 with 
68
Ga and the 
68
Ga-NOTA complex was also identified via radio-HPLC (see 
below).  
It should be noticed that analogous hydrolysis might have been present during studies of 
Ga(III) complexes with simple NOTA-monoamides where a very broad 
71
Ga NMR signal of 
the complexes with a small sharp singlet at 170 ppm (probably attributable to the Ga-NOTA 
complex) was observed (31).  
 
2.4. Adsorption of iron(III) complexes on hydroxyapatite 
To estimate bone targeting efficiency, the most commonly used method is to determine the 
binding ability of the molecules on hydroxoapatite (HAP) surface. For bis(phosphonate)-
containing DOTA derivatives, the long-lived 
160
Tb metal isotope has been used as a surrogate 
for lanthanide(III) ions (21). As 
68
Ga is a short-lived radioisotope, another method was 
sought. Trivalent iron has properties (charge, size, hardness etc.) similar to those of trivalent 
gallium and both ions form analogous complexes; thus, Fe(III) was chosen as a surrogate. 
UV-Vis spectroscopy was used to quantify the sorption ability as the Fe(III) complexes 
exhibit intensive ligand-to-metal charge transfer (LMCT) band in UV region (Figure S4). 
The iron(III) complexes of DOTAM
BP
 and DO3AP
BP
 were also prepared and studied for 
comparison with analogous complexes of DOTA-like ligands already used as 
68
Ga 
radiopharmaceuticals (19,20). The adsorption process is usually described by the Langmuir 
adsorption isotherm  
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)(1m cK
cK
X
X


  
where K is the analyte (complex) affinity constant for the surface (in dm
3
 mol
–1
), Xm is the 
maximum sorption capacity of the complex (in mol m
–2
), c is complex concentration (in mol 
dm
–3
) in the solution and X is the specific adsorbed amount of the complex (in mol m
–2
). 
Aqueous suspension of HAP was used as a model of bone tissue. The results are shown in 
Figure S5 and the absorption parameters are summarized in Table 2. 
Table 2. Adsorption parameters of the Fe(III) complexes on hydroxyapatite surface (pH 7.5, 25 C, 
equilibration time 3 d). 
Constant 
Complex 
Fe-NOTAM
BP
 Fe-NO2AP
BP
 Fe-DOTAM
BP
 Fe-DO3AP
BP
 
K / 10
3
 (dm
3
 mol
–1
) 31.3 ± 6.1 20.0 ± 3.2 43.7 ± 12.2 207.6 ± 45.3 
Xm / 10
–6
 (mol m
–2
) 1.007 ± 0.035 1.271 ± 0.052 0.768 ± 0.019 1.015 ± 0.017 
 
All complexes studied show efficient binding on the HAP surface. Maximum sorption 
capacities are in the range that corresponds to the formation of monomolecular layer (12). 
For the complexes of NOTA analogues, maximum sorption capacities are higher than those 
for the DOTA complexes. This could be explained by the compact shape of the Fe(III) 
complexes with NOTA derivatives, where all pendant arms are coordinated (49,50). Larger 
size of the cyclen ring and presence of two uncoordinated pendant arm in the complexes with 
DOTA-like ligands (51) result in a larger surface area occupied by one molecule of the 
DOTA complexes. Higher affinity constants found for the complexes with DOTA derivatives 
indicate, that the uncoordinated pendant arms might be involved in the interaction with the 
HAP surface; the higher affinity constant for the Fe(III)-DO3AP
BP
 complex can be probably 
explained by the highest overall charge of among the complexes. Generally, both affinity 
constants as well as sorption capacities are comparable to those previously reported for 
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lanthanide(III) complexes with the same DOTA analogs, where all pendant arms are bound 
to the central metal ion (e.g. K = 250·10
–3
 dm
3
 mol
–1
 and Xm = 0.65·10
6
 mol m
–2
 for the 
160
Tb-DO3AP
BP
 complex) (21) as well as to those for simple bis(phosphonates), e.g. for 
pamidronate (K = 44·10
–3
 dm
3
 mol
–1
 and Xm = 1.82·10
6
 mol m
–2
) (21). It indirectly confirms 
similar accessibility of the distant bis(phosphonate) moiety for bone targeting in all the 
complexes.  
 
2.5. Radiolabeling with no-carrier-added 
68
Ga 
If ligands are considered as potential radiopharmaceuticals, the efficiency of metal 
radionuclide incorporation is one of their most important properties and, thus, the title 
ligands were tested in labeling with n.c.a 
68
Ga. The ligand-to-
68
Ga(III) molar ratio was 
approximated in the order of 10
4
 in all experiments (1 MBq 
68
Ga corresponds to ~0.01 pmol 
of Ga(III)). The complexation was followed (see an example of the TLC plate in ESI, Figure 
S6) at various temperatures and solution acidities, and the results are summarized in Figures 
6 and 7. 
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Figure 6. Time course of incorporation of no-carrier-added 
68
Ga(III) by NOTA and DOTA (A, pH 4.0) and the 
title ligands (B, pH 4.2) at various temperatures. Results for NOTAM
BP
 can be influenced by the amide bond 
hydrolysis (for details, see text).  
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Figure 7. Time course of incorporation of no-carrier-added 
68
Ga(III) by NOTA and DOTA (A) and the title 
ligands (B) at 95 C and various pH. Results for NOTAMBP can be influenced by the amide bond hydrolysis 
(for details, see text). 
The data show similar trends as those obtained in the NMR experiments (above). For both 
ligands, fast complexation requires weakly acidic conditions, i.e. pH 3–4. No complexation 
was observed at pH 1.3 and 6.9 at any temperature. The experiments also confirmed the 
strong dependence of the complexation rate on the temperature. At pH = 4.2 and at room 
temperature, no complexation was observed with both ligands. In the case of NO2AP
BP
, 
heating to 60 C is required to reach full complexation in 10 min; at 95 C 68Ga(III) was 
quantitatively bound in only 5 min. Temperatures of <60 C were insufficient for the 
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radiolabeling with NOTAM
BP
 and reasonable complexation efficiency was reached only at 
temperature of 95 C. However, radio-TLC cannot be used for evaluation of hydrolysis of 
amide bond in the 
68
Ga-NOTAM
BP
 system (as observed in the NMR experiments, above) as 
all complexes have the same mobility. To check the decomposition, labelling of NOTAM
BP
 
was carried under conditions used in sample preparation for in-vivo experiments (pH 4, 90 
C, 15 min) and the reaction mixture was evaluated by HPLC on amine-containing sorbent 
(Figure S7). Partial decomposition (~20 %) was observed and it probably influenced the 
sorption and in-vivo data (see below). NO2AP
BP
 showed much faster complexation of n.c.a. 
68
Ga(III) than NOTAM
BP
 under all tested conditions (Figures 6 and 7). This efficient 
complexation is more pronounced if compared with 
68
Ga(III) labeling of DO3AP
BP
 where 
radiochemical yield under more forced conditions was, at the best, approx. 60 %.(34) It has 
also been shown (under the same conditions) that presence of one or two methylphosphonate 
arms in NOTA analogs (NO2AP and NO1A2P; for formulae, see Figure 1) accelerates the 
labeling reaction in comparison with the labeling with NOTA (33). Thus, presence of 
methylenephosphonic/inic acid pendant arms seems to increase the complexation rate. 
Radiolabeling of the title ligands with n.c.a. 
68
Ga is less efficient than that of NOTA; 
however, NO2AP
BP
 incorporates 
68
Ga similarly to the unsubstituted DOTA (Figures 6 and 
7). Both title ligands are more efficient chelators than DOTAM
BP
 (it needs 20–25 min at 95 
C for 95 % labeling and the best pH is ~5; the same other labelling conditions as for the title 
ligands) (19). The 
68
Ga-DOTAM
BP
 complex have been already applied in vivo (19,20) and, 
compared to it, the 
68
Ga-complexes of the title ligands appear better suited for straight 
forward labelling adequate to utilization in vivo (see below).  
 
2.6. Adsorption of 
68
Ga-labeled complexes to hydroxoapatite 
Binding of complexes labeled with 
68
Ga to HAP surface was measured at room temperature 
(Figure 8). The [
68
Ga]NO2AP
BP
 complex (93.84.4 %) is bound much better compared to 
[
68
Ga]NOTAM
BP
 complex (38.1±2.6 %), while binding of the [
68
Ga]NOTA complex 
(1.5±0.3 %) is negligible under the same conditions. These results are not fully paraleling 
those of iron(III) complexes obtained under “chemical” equilibrium conditions where no 
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significant differences were observed. The [
68
Ga]NOTAM
BP
 might be partially decomposed 
during complexation decreasing the absorption on HAP. However, the difference is 
significant and another reason should be present. Because of the short half-life of 
68
Ga, a 
short contact time of the complexes with HAP had to be used and full equilibrium could not 
be reached, unlike during measurements with the Fe(III) complexes (above). Thus, the 
difference between the experiments might be attributed to the faster absorption kinetics of 
[
68
Ga]NO2AP
BP
 complex if compared with [
68
Ga]NOTAM
BP
 complex; it was observed that 
the [
160
Tb]DO3AP
BP
 complex adsorbs on HAP surface very quickly (22). These results are 
more relevant for in vivo conditions. Compounds with slow adsorption kinetics are not 
suitable for future in vivo studies. It is necessary to obtain high binding to the targeted tissue 
for imaging agents in a short timescale, otherwise long measurement time and high activities 
are required to develop adequate PET images. However, this experiment showed (Figure 1) 
no significant difference in HAP adsorption between the [
68
Ga]NO2AP
BP
, [
68
Ga]DO3AP
BP
 
and the [
68
Ga]EDTMP tracers (EDTMP = ethylenediamine-N,N,N,N-
tetrakis(methylenephosphonic acid), Figure 1). [
68
Ga]NO2AP
BP
 had a binding of 93.8±4.4 % 
on HAP after 10 min, which is one of the highest rates among 
68
Ga-labelled macrocyclic 
bis(phosphonates) (Figure 9). The data in this experiment are well correlating with those of 
the bone accumulation in vivo (in ex vivo organ distribution, see below).  
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Figure 8. Binding of 
68
Ga-labeled complexes to hydroxoapatite in isotonic saline (room temperature, 10 min). 
Data for [
68
Ga]DOTAM
BP
 (19) and [
68
Ga]EDTMP (53) were taken from literature (for EDTMP formula, see 
Figure 1). Results for NOTAM
BP
 can be influenced by the amide bond hydrolysis (for details, see text). 
 
2.7. In vivo biodistribution studies 
Uptake of the tracers in organism was followed by both PET and organ dissection. The 
dissection data (Table 3) clearly shows high uptake of [
68
Ga]NO2AP
BP
 in bone (femur 4.37 
%, 60 min p.i.) and very low uptake in non-target organs like soft tissues. Similar results 
were observed with of [
68
Ga]DOTA-based bis(phosphonates) in already published data 
(19,34). The bone uptake of [
68
Ga]NO2AP
BP
 on bones (SUV of 6.191.27 %ID/g in femur) 
is clearly superior if compared with the established SPECT, 
99m
Tc-MDP (MDP = methylene-
bis(phosphonic acid), Figure 1), or PET, [
18
F]NaF, bone tracers and also higher than that of 
the DOTA-based tracer (Figure 9). Lower uptake of [
68
Ga]NOTAM
BP
 is in line with the in 
vitro results and can be caused by partial decomposition during labeling (above).  
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Table 3. Ex vivo biodistribution of [
68
Ga]NOTAM
BP
 and [
68
Ga]NO3AP
BP
 complexes in healthy male Wistar 
rats (60 min p.i.). Data are presented as an average from five animals ( S.D.); uptake as % I.D. per gram of 
tissue (% ID/g).  
Organ 
Complex 
[
68
Ga]NOTAM
BP
 [
68
Ga]NOTAM
BP
 
Lung 0.12  0.03 0.04  0.03 
Liver 0.05  0.01 0.02  0.01 
Spleen 0.04  0.01 0.02  0.01 
Kidney 0.45  0.04 0.18  0.07 
Muscle 0.03  0.01 0.01  0.00 
Heart 0.04  0.01 0.01  0.01 
Blood 0.09  0.04 0.02  0.00 
Intestine 0.07  0.03 0.03  0.03 
Testes 0.04  0.01 0.01  0.00 
Femur 1.12  0.36 4.37  0.92 
 
The bone uptake of [
68
Ga]NO2AP
BP
 is significantly better (Figure 10) than bone uptake of 
[
68
Ga]DOTAM
BP
, the tracer already successfully used in patients, as well as that of its 
equivalent DOTA-based tracer, [
68
Ga]DO3AP
BP
.(19,34) Differences between the ex-vivo 
biodistributions and µPET images (below) might be given by a different age of the animal 
(see Experimental).  
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Figure 9. Biodistribution data for different bone-binding 
68
Ga radiotracers and [
18
F]NaF in healthy male Wistar 
rats (n = 5) after 60 min. p.i. *Data for [
68
Ga]DOTAM
BP
, [
68
Ga]DO3AP
BP
, [
18
F]NaF and [
99m
Tc]MDP (for MDP 
formula, see Figure 1) were taken from literature (19,34). Results for NOTAM
BP
 can be influenced by the amide 
bond hydrolysis (for details, see text). 
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Figure 10. Radioactivity accumulation on femur for [
68
Ga]NOTAM
BP
, [
68
Ga]DOTAM
BP
, [
68
Ga]NO2AP
BP
 and 
[
68
Ga]DO3AP
BP
 (60 min p.i.). *Data for [
68
Ga]DOTAM
BP
 and [
68
Ga]DO3AP
BP
 were taken from literature 
(19,34). Results for NOTAM
BP
 can be influenced by the amide bond hydrolysis (for details, see text). 
To illustrate usefulness of the [
68
Ga]NO2AP
BP
 as PET tracer, its biodistribution as followed 
by µPET with two animals. Uptake on bone was observed within few minutes and the 
labeled compound were cleared out of the blood during 60–120 min via the kidneys and 
bladder. The µPET images (Figure 11) show a fast clearance of the compound out from the 
blood. After 5–10 min, only 10–15 % of the injected radiotracer is found in the bloodstream, 
while a very fast accumulation in the skeleton was observed. Bone images of good quality 
can be developed at early time points. In Figures 11 and S8, the skeleton is clearly 
highlighted after only 15 min p.i. In the second animal (Figure 11), the kidneys show a high 
uptake as the main clearance organ of the [
68
Ga]NO2AP
BP
 as expressed by SUV values in 
Figures S9 and S10.  
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Figure 11. µPET image of the 2
nd
 healthy male Wistar rat at different times after injection of 31 MBq 
[
68
Ga]NO2AP
BP
. 
After a fast initial accumulation (up to 50 min. p.i.), the labeled compound is predominantly 
cleared to the bladder and washed out of the animal via the urine. [
68
Ga]NO2AP
BP
 showed a 
similar kinetics in both animals with only small differences which could be explained by 
variation between the animals weight and age. At 60 min p.i., the SUV in the spine was 1.8 
for animal no. 1 (536 g, 32 MBq)) and 1.6 for animal no. 2 (346 g, 31 MBq). Uptake of the 
68
Ga-bis(phosphonate) in bone joints was almost 50 % higher (animal no. 1, SUV in the joint 
of the scapula and the humerus was 3.1). 
 
3. Conclusions 
The new bis(phosphonate)-containing derivatives of NOTA were prepared by scaleable 
synthesis. They show efficient complexation of trivalent gallium and the phosphinate 
derivative was shown to bind the metal ion better than the acetamide derivative under any 
conditions used. The complexation rates of these new ligands were lower than those of 
NOTA or its phosphinic acid analogues due to presence of phosphonate groups forming 
rather stable out-of-cage complex which is able to compete with formation of the in-cage 
complex. The amide group in the in-cage complex is not fully hydrolytically stable due to a 
strong polarizing effect of the small Ga
3+
 ion after its coordination; thus, 
68
Ga-NOTAM
BP
 
cannot be used in practice. These results indicate that complexes of NOTA-amides can be 
hydrolytically unstable, unlike complexes of DOTA-amides where analogous hydrolysis has 
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not been observed. It should be taken into account while designing new ligands for Ga(III) 
and other highly charged metal ions. Thus, if NOTA skeleton with tri acetate pendants is 
required, NOTAGA derivatives might be good solution avoiding the hydrolysis problem. The 
hydrolysis takes place only at high temperature and is rather slow; however, it can occur even 
during labelling with n.c.a. 
68
Ga. Radiolabeling with 
68
Ga was fast at temperatures above 60 
C for the phosphinate and at 90 C for the acetamide ligand. Biodistribution and µPET 
studies in healthy male rats showed very quick uptake of the 
68
Ga-labeled probes on bones 
and fast elimination of the non-targeted probes through the kidneys. The pharmacokinetics of 
the new labeled macrocyclic ligands is similar to that of the labeled DOTA-bis(phosphonate) 
conjugates as well as that of commonly used 
99m
Tc-bis(phosphonate) radiopharmaceuticals or 
[
18
F]NaF but results in a significant higher accumulation of [
68
Ga]NO2AP
BP
 on bone. 
[
68
Ga]NO2AP
BP
 showed a superior adsorption kinetics compared to that of other 
68
Ga-
labeled macrocyclic bis(phosphonates) and a similar affinity HAP as [
68
Ga]EDTMP; 
however, [
68
Ga]EDTMP was reported as an inefficient radiotracer based on its low kinetic 
and thermodynamic in vivo stability (51). Additionally, the new ligands performed in an 
almost quantitative labeling (RCY more than 98 %) within 10 to 15 min with NO2AP
BP
 
being labeled more effectively, while the DOTA-based bis(phosphonates) showed a RCY 
between 70 % and 85 % and purification steps are necessary before applications. For the 
routine synthesis in nuclear medicine practice, easy labeling processes and high RCY are 
essential. These properties and the convenient availability of 
68
Ga from commercial 
generators render mainly NO2AP
BP
 as one of the best leading compounds for development of 
bone-targeted PET probes.  
These new 
68
Ga-based radiotracers bring improvement of a current state-of-art for bone 
imaging due to much better resolution and sensitivity of PET if compared with SPECT and 
much lower price of the generator-produced 
68
Ga radioisotope if compared with cyclotron-
produced 
18
F. Despite that no 
68
Ge/
68
Ga generator has been approved, easy operation of the 
generator and its continuously lowering prizes make the 
68
Ga-PET based bone scans possibly 
the most easily implementing PET modality in less developed countries without expensive 
cyclotrons and skilled staff. Experiments focused on better understanding of biological fate 
and, finally, directed to a human application of the new probe are under way.  
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4. Experimental 
4.1. General methods 
Reagents 5 and 7, and ligands DOTAM
BP
 and DO3AP
BP
 were synthesized according to 
published procedures (12,14). The 1,4,7-triazacyclononane (tacn) as free base was purchased 
from CheMatech (France). The other reactants and solvents were commercially available 
analytical grade chemicals. Acetonitrile was dried by distillation from P2O5. The NMR 
spectra were recorded using Varian UNITY Inova (400 MHz), Varian VNMRS (300 MHz) 
or Bruker Avance (600 MHz) spectrometers. The 
1
H and 
13
C (at 300 or 600 and 75 or 151 
MHz, respectively) NMR shifts were referenced to internal TMS or t-BuOH signal, the 
31
P 
(121 MHz) and 
71
Ga (129 MHz) NMR shifts were externally referenced relative to 85 % aq. 
H3PO4 and 0.1 M aq. Ga(NO3)3, respectively. Homo- and heteronuclear 2D-NMR spectra 
were used for final characterization of the title ligands. Mass spectra were recorded on 
Bruker Esquire 3000 spectrometer with ESI as ion source and ion trap as a detector in 
positive or negative modes. UV-Vis spectra were recorded using Biochrom Lightwave 2 
spectrometer. Elemental analyses were performed using an HARAEUS Varian EL III 
system. TLC analyses of the ligand and intermediates during their synthesis were carried out 
with silica on aluminium foil (Merck). Radio-TLC analysis was developed with a Canberra 
Packard Instant Imager.  Radioactivity of samples was measured with an Aktivimeter Isomed 
2010, MED (Nuklear-Medizintechnik Dresden GmbH). For small animal PET studies, a 
Siemens microPET Focus 120 was used and the data were reconstructed with the Pmod 
software (PMOD Technologies Ltd). Radioactivity in tissue samples was determined by 
using a Wallac WIZARD2 automatic gamma counter (Perkin Elmer, Germany).  
 
4.2. Synthesis of 1-benzyl-1,4,7-triazacyclononane (2) 
1,4,7-triazacyclononane (5.0 g, 39.9 mmol) was dissolved in the mixture of 1,4-dioxane (50 
ml) and Me2NCH(OMe)2 (5.52 g, 47.9 mmol). The mixture was refluxed for 3 h, volatiles 
were evaporated and the residue was re-dissolved in THF (40 ml). Solution of benzylbromide 
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(8.6 g, 47.9 mmol) in THF (40 ml) was added slowly under vigorous stirring and a yellow 
precipitate was formed. Then more THF (30 ml) was added and the mixture was stirred 
overnight. The yellow powder was filtered off and dissolved in a mixture of water (25 ml), 
EtOH (50 ml) and KOH (12.5 g). The mixture was refluxed for 3 d. Volatiles were 
evaporated under reduced pressure, the residue was dissolved in water (20 ml) and extracted 
with chloroform (3×40 ml). The organic fractions containing the product were combined, 
dried with Na2SO4 and solvent was evaporated. The residue was dissolved in aq. HCl (6 M, 
20 ml) and the solution was evaporated to dryness. The crude hydrochloride was dissolved in 
water (10 ml) and it was crystallized by addition of Et2O (100 ml). The product was filtered 
off and dried under vacuum to yield white crystals of 2·2HCl·H2O (8.5 g, 75 %). NMR 
(D2O): 
1
H  = 3.07 (CH2–NBn, 4H, t, 
3
JHH 6.0 Hz); 3.25 (CH2–CH2NBn, 4H, t, 
3
JHH 6.0 Hz; 
3.65 (NH–CH2CH2–NH, 4H, s); 3.95 (N–CH2–Car, 2H, s); 7.47 (aryl H, 5H, bm); 
13
C{
1
H}  
= 44.8 (CH2–CH2NBn, s); 46.1 (NH–CH2CH2–NH, s); 50.2 (CH2–NBn, s); 61.6 (N–CH2–C, 
s); 130.9, 131.4, 132.8, 137.8 (aryl C, 4s). MS(+): 219.9 [M+H]+. Elemental analysis: found 
(calcd. for C13H21N3·2HCl·H2O) C 51.1 (50.3); H 8.4 (8.1); N 13.4 (13.5).  
 
4.3. Synthesis of bis(t-butyl) 7-benzyl-1,4,7-triazacyclononane-1,4-diacetate (3) 
Protected macrocycle 2 (3.0 g, 9.7 mmol) was dissolved in the mixture of dry acetonitrile 
(100 ml) and K2CO3 (5.17 g, 38.8 mmol). Solution of t-butyl bromoacetate (3.96 g, 20.4 
mmol) in dry acetonitrile (150 ml) was slowly added. The reaction mixture was stirred at 
room temperature for 3 d, then filtered and evaporated. Product was purified by column 
chromatography (silica gel, EtOH : 25 % aq. ammonia 20:1). The fractions containing 
product were combined and evaporated to yield of product 3 (4.2 g, 91 %) in the form of 
yellowish viscous oil. NMR (CDCl3): 
1
H  = 1.40 (C(CH3)3, 18H, s); 2.73, 3.10, 3.50, 3.70 
(N–CH2CH2–N, 6H + 2H + 2H +2H; 4bm); 3.28 (N–CH2–CO2, 4H, s); 4.49 (N–CH2–Car, 
2H, s); 7.34 + 7.66 (aryl H, 3H + 2H, 2m); 13C{1H}  = 30.3 (C(CH3)3, s); 51.9 + 53.7 + 
55.1 (ring C, 3s); 60.3 (N–CH2–CO2, s); 61.6 (N–CH2–C, s); 83.9 (C(CH3)3, s); 131.3, 
131.7, 133.0 (aryl C, 3s); 172.8 (CO2, 2C, s). MS(+): 448.1 [M+H]
+
.  
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4.4. Bis(t-butyl) 1,4,7-triazacyclononane-1,4-diacetate (4) 
Compound 3 (2.1 g, 4.7 mmol) was dissolved in dry ethanol (175 ml). Pd/C catalyst (400 
mg) was added and the reaction mixture was stirred overnight at 50 °C under hydrogen 
atmosphere (atmospheric pressure). Suspension was filtered and filtrate evaporated to 
dryness. The crude product was purified by column chromatography (silica gel, EtOH : 25 % 
aq. ammonia 10:1 to elute impurities and 3:2 to eluate the product). The product-containing 
fractions were combined, evaporated and the residue was co-distilled three times with 
ethanol to remove traces of ammonia to yield colorless viscous oil that solidified after 
cooling to room temperature (1.41 g, 84 %). NMR (CDCl3): 
1
H  = 1.41 (C(CH3)3, 18H, s); 
2.81 (N(ac)–CH2CH2–N(ac), 4H, s); 3.08 (N(ac)–CH2CH2–NH, 4H, bm); 3.23 (N(ac)–
CH2CH2–NH, 4H, bm); 3.39 (N–CH2–CO2, 4H, s); 
13
C{
1
H}  = 20.1 (C(CH3)3, s); 44.5 
(N(ac)–CH2CH2–NH, s); 49.0 (N(ac)–CH2CH2–NH, s); 51.7 (N(ac)–CH2CH2–N(ac), s) 56.7 
(N–CH2–CO2, s); 81.9 (C(CH3)3, s); 170.7 (CO2, s). MS(+): 358.0 [M+H]
+
. 
 
4.5. NOTAM
BP
 in ester form (6) 
Ester 4 (1.30 g, 3.6 mmol) was dissolved in the mixture of dry acetonitrile (75 ml) and 
annealed K2CO3 (2.60 g). Then, solution of chloroacetamide 5 (2.07 g, 5.4 mmol) in 
acetonitrile (75 ml) was added. The reaction mixture was stirred at 50 C for 3 d. Solids were 
filtered off, filtrate was evaporated and the crude product was purified by column 
chromatography (silica gel, EtOH to elute impurities, EtOH : 25 % aq. NH3 50:1 to elute 
product). Pure product was obtained as yellowish viscous oil (2.1 g, 83 %). NMR (CDCl3): 
1
H  = 1.28 (P–OCH2CH3, 12H, t, 
3
JHH 7.2 Hz); 1.39 (C(CH3)3, 18H, s); 2.71 (N(ac)–
CH2CH2–N(ac), 4H, bm); 2.84 (N(ac)–CH2CH2–N(am), 8H, s); 3.29 (NCH2CONH, 2H, s); 3.35 
(NCH2CO2, 4H, s); 4.14 (P–OCH2CH3, 8H, m); 5.06 (NH–CH–P, 1H, td, 
2
JPH 21.2 Hz, 
3
JHH 
7.5 Hz); 8.90 (NH, 1H, d, 
3
JHH 6 Hz);
13
C{
1
H}  = 16.3 (P–OCH2CH3, s); 28.1 (C(CH3)3, s); 
43.6 (NH–CH–P, t, 1JPC 148 Hz); 55.3 (N(ac)–CH2CH2–N(ac), s); 56.3 (N(ac)–CH2CH2–N(am), 
s); 59.2 (N–CH2–CO2, s); 60.9 (N–CH2–CO2, s); 63.2 (P–OCH2CH3, d, 
2
JPC = 10.0 Hz); 80.7 
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(C(CH3)3, s); 171.7 (CO2, s); 172.2 (CO, s); 
31
P{
1
H}  (ppm) 17.2 (s); 31P  = 17.2 (d, 2JPH 
21.2 Hz); MS(+): 701.4 [M+H]
+
.  
 
4.6. NOTAM
BP
 
Ester 6 (2.1 g, 3.0 mmol) was dissolved in the mixture of CHCl3 (50 ml) and CF3CO2H (50 
ml) and stirred in dark at room temperature overnight. Volatiles were evaporated under 
vacuum and the residue was repeatedly dissolved in CH2Cl2 and evaporated. The resulting oil 
was dissolved in dry acetonitrile (100 ml) and BrSiMe3 (9.8 ml, 60.0 mmol) was added. The 
mixture was stirred in dark at room temperature overnight. Volatiles were evaporated, the 
residue was re-dissolved in acetonitrile and evaporated, and then dissolved in 50 % aq. 
MeOH and evaporated. The residue was dissolved in H2O (10 ml) and EtOH (100 ml) was 
added. Crystallization was finished standing in refrigerator overnight. Product was filtered 
off and dried under vacuum to yield white powder (1.15 g, 80 %). NMR (D2O, pD 2.9): 
1
H  
= 3.34 (N(ac)–CH2CH2–N(am), 4H, s); 3.38 (N(ac)–CH2CH2–N(am), 4H, s); 3.46 (N(ac)–CH2CH2–
N(ac), 4H, s); 3.89 (N–CH2–CO2, 4H, s); 3.94 (N–CH2–CO–NH, 2H, s); 4.51 (NH–CH–P, t, 
2
JPH 24.0 Hz); 
13
C{
1
H}  = 47.8 (NH–CH–P, t, 1JPC 125.6 Hz); 50.3 (N(ac)–CH2CH2–N(ac), s); 
50.5 (N(ac)–CH2CH2–N(am), s); 50.7 (N(ac)–CH2CH2–N(am), s); 57.5 (N–CH2–CO2, s); 57.9 (N–
CH2–CO–NH, s); 169.2 (CO–NH, s); 172.5 (CO2, s); 
31
P{
1
H}  (ppm) 12.7 (s); 31P  = 12.7 
(CH–P, d, 2JHP 24.0 Hz). MS(–): 474.8 [M–H]
–
. Elemental analysis: found (calcd. for 
C13H26N4P2O11·1.5H2O·0.4HCl) C 30.0 (30.1); H 5.3 (5.7); N 10.4 (10.8).  
 
4.7. NO2AP
BP
 in ester form (8) 
Ester 4 (1.55 g, 4.3 mmol) was dissolved in the mixture of dry acetonitrile (40 ml) and 
paraformaldehyde (156 mg, 5.2 mmol). Solution of phosphinate 7 (2.05 g, 5.2 mmol) in 
acetonitrile (30 ml) was added and the mixture was stirred at 35 C for 3 d. Volatiles were 
evaporated and the crude product was purified by column chromatography (silica gel, EtOH 
to elute impurities, EtOH : 25 % aq. ammonia 50:1 to eluate the product). The product-
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containing fractions were combined and evaporated to yield yellowish oil (2.40 g, 72 %). 
NMR (CDCl3): 
1
H
  = 1.31 (P–OCH2CH3, 15H, m); 1.46 (C(CH3)3, 18H, s); 2.00–2.80 
(PCH2, PCH, 5H, m); 2.90–3.20 (ring H, 12H, m); 3.56 (N–CH2–CO2, 4H, s); 4.18 (P–
OCH2CH3, 10H, m); 
13
C{
1
H}  = 20.5 (CH–P–O–CH2–CH3, s); 26.2 (PCH2CHP, d, 
1
JPC 
82.9 Hz); 32.3 (C(CH3)3, s); 34.1 (PCH2CHP, td, 
1
JPC 132.1 Hz, 
2
JPC 26.9 Hz); 58.8, 59.2, 
60.6 (N–CH2CH2–N, ring C, 3×s); 62.1 (N–CH2–CO2, s) 64.1 (NCH2P, d, 
1
JPC 95.1 Hz); 67.0 
(P–OCH2CH3, s); 85.1 (C(CH3)3, s); 174.9 (CO2, s) 
31
P{
1
H}  = 22.7 (PCH2CHP, 2P, d, 
3
JPP 
20.8 Hz); 49.2 (PCH2CHP, 1P, t, 
3
JPP 20.8 Hz). MS(+): 764.4 [M+H]
+
. 
 
4.8. NO2AP
BP
 
Ester 8 (2.40 g, 3.1 mmol) was dissolved in the mixture of CHCl3 (50 ml) and CF3CO2H (50 
ml) and stirred in dark at room temperature overnight. Volatiles were evaporated under 
vacuum and the residue was repeatedly dissolved in CH2Cl2 and evaporated. The resulting oil 
was dissolved in dry acetonitrile (100 ml) and BrSiMe3 (9.8 ml, 60.0 mmol) was added. The 
mixture was stirred in dark at room temperature overnight. Volatiles were evaporated and the 
residue was re-dissolved in acetonitrile and evaporated, and then dissolved in 50 % aq. 
MeOH and evaporated. The crude product was purified using strong cation exchanger 
(Dowex 50, H
+
-form). Impurities were eluted with H2O, product with 10 % aq. pyridine. 
Pyridine was then removed using strong anion exchanger (Dowex 1, OH
−
-form). Impurities 
were eluted with H2O and EtOH 1:1 mixture, product with H2O and HCl mixture 1:1. The 
product-containing fractions were combined and evaporated. The resulting solid was 
dissolved in H2O (10 ml) and EtOH (100 ml) was added to induce crystallization. 
Crystallization was finished on standing in refrigerator overnight. Product was filtered off 
and dried under vacuum to yield white powder (0.66 g, 41 %). NMR (D2O, pD 2.9): 
1
H  = 
2.26 (PCH2CHP, 2H, m); 2.46 (PCH2CHP, 1H, m); 3.42 (N(ac)–CH2CH2–N(ac), 4H, s); 3.50 
(N(ac)–CH2CH2–N(bp), 4H, s); 3.56 (N(ac)–CH2CH2–N(bp), 4H, s) 3.79 (NCH2P, 2H, bs) 3.88 
(N–CH2–CO2, 4H, s); 
13
C{
1
H}  = 28.2 (PCH2CHP2, d, 
1
JPC 93.5 Hz); 34.2 (PCH2CHP2, t, 
1
JPC 117.7 Hz); 50.6 (N(ac)–CH2CH2–N(bp), s); 51.7 (N(ac)–CH2CH2–N(ac), s); 52.5 (N(ac)–
CH2CH2–N(bp), s); 56.7 (NCH2P, d, 
1
JPC 90.6 Hz); 58.0 (N–CH2–CO2, s); 173.3 (CO2, s); 
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31
P{
1
H}  = 18.9 (PCH2CHP, 2P, d, 
3
JPP 24.6 Hz); 33.1 (PCH2CHP, 1P, t, 
3
JPP 24.6 Hz ). MS 
(–): 509.8 [M–H]─. Elemental analysis: found (calcd. for C13H28N3P3O13·0.6HCl) C 29.4 
(29.3); H 5.4 (5.4); N 7.3 (7.9). 
 
4.9. Stock solutions of Fe(III) complexes 
Ligand (100 µmol) was dissolved in the aq. FeCl3 solution (90 µmol, 0.9 ml of 0.1 M 
solution), pH was slowly adjusted to 7 with 0.5 M aq. NaOH (precipitates may appear in this 
stage) and the solution was stirred at 80 °C for 1 h. Finally, water was added to reach the 
final volume of 10.0 ml. 
 
4.10. Adsorption experiments 
Hydroxyapatite (50 mg; Fluka, catalog No. 55496, 63 m
2
 g
–1
) was suspended in 1 M Tris-HCl 
buffer (0.30 ml; pH 7.5). Then, stock solution of the Fe(III) complex (10 mM, 0.06 to 0.60 
ml) was added and the samples were diluted with water to get final volume of 3.0 ml. The 
samples were stirred at 25 C for 3 d. After filtration, concentration of the complex in the 
supernatant was quantified by UV-Vis spectroscopy. The experimental data obtained at 250, 
275 and 300 nm were treated by least-square fitting (Micromath Scientist software package) 
according to the Langmuir adsorption isotherm. 
 
4.11. 
31
P{
1
H} and 
71
Ga NMR complexation studies 
Solid NOTAM
BP
 (25 mg, 51 µmol) was dissolved in 338 µL of 1 M aq. sodium chloroacetate 
buffer (experiments at pH 2 and pH 3) or 1 M aq. sodium acetate buffer (experiments at pH 4 
and 5) and equivalent amount of Ga(III) (62 µL of 0.812 M solution) was added. For 
NO2AP
BP
, the amounts were: 25 mg of the solid ligand, 343 µL of buffer and 57 µL of 0.812 
M Ga(III) solutions, respectively. Samples were shaken and quickly transferred into a 
standard 5-mm NMR cuvette and measured immediately (overall dead time was ~5 min) or 
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left in an oil bath at the appropriate temperature for the given amount of time. Then, they 
were quickly cooled down to room temperature, NMR spectrum was measured at 25 C and 
heating was resumed again if necessary. Quantification was done against 
31
P or 
71
Ga NMR 
standard in the insert tube. The times given in the text are those which the samples had spent 
at the given temperature.  
 
4.12. Radiolabeling studies 
Gallium-68 (150 to 350 MBq) was obtained from a 
68
Ge/
68
Ga generator system 
(Eckert&Ziegler AG, Berlin). For in vivo experiments, 
68
Ga labeling was performed in aq. 
HEPES buffer solution (pH = 4, 0.125 M, 400 μL) by adding the 68Ga solution (400 μL) 
obtained by post-processing of the generator eluate via the cation exchange method (52); 
final pH of the solution was pH = 3.75. Then, the ligand (17 nmol, as stock solution with a 
concentration of 1 mg/ml) was added and the solution was shaken in a heating block for 10 
min at 95 C. After cooling, the pH was adjusted to pH = 7 by adding small amounts of 1 M 
aq. NaOH solution. Radiochemical yields of the 
68
Ga-complexes of the title ligands were 95–
99 %. For labeling studies under various pH conditions, the labeling was carried out in 
deionized water (pure for pH = 2) or by adding smaller amounts of the buffer solution (i.e. 
decreasing buffer capacity of the final solution) to get the appropriate final pH. The 
radiochemical yields were determined by silica TLC (Merck) using a solvent mixture 
consisting of 2 parts of A (conc. aq. HCl: acetone: water, 100 µL : 1 ml : 1 ml) and 1 part of 
B (pure acetylacetone). Activity was measured on a Canberra Packard Instant Imager. Free 
68
Ga migrates as an acetylacetonate complex with the solvent front. In-cage complexes stay 
on the base line. (
68
Ga-phosphonates: Rf = 0.0–0.1, 
68
Ga-acac: Rf = 0.8–0.9; for details, see 
ESI). The radiochemical yields were also determined by radio-HPLC (Merck-Hitachi-
LaChrom, Gabi-Raytest) using a LiChrosphere C18 (CS-Chromatographie, Germany) 
column. The reaction solution (10 µL) was added to a 50 µL of Deferoxamine (DFO) 
solution (0.1 mg/ml) in 0.1 M NaAc buffer (pH=4.0). 
68
Ga labelled bis(phosphonates) 
showed a weak retention, while [
68
Ga]DFO showed a Rt of 10 min (Figures S11–S13). The 
[
68
Ga]NOTA and [
68
Ga]DOTA complexes were synthesized with the method described 
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above by using 10 µg of each chelator. The [
68
Ga]DO3AP
BP
 was labeled with 
68
Ga with a 
different method. DO3AP
BP
 was dissolved in deioinized water with a concentration of 1 
mg/ml. This solution (17 µL, i.e. 17 µg DO3AP
BP
) was added to a 0.25 M ammonium acetate 
buffer (500 µL, pH = 5). The post-processed 
68
Ga solution (400 µL) was added and the 
mixture was shaken in a heating block for 20 min. Labeling at lower pHs was carried out by 
using less concentrated buffer solutions. Labeling at pH = 1–2 was done by using deionized 
water as the reaction solvent. 
 
4.13. Evaluation of hydrolysis during radiolabeling 
Radiolabeling was done as described above (95 C, pH 4.5, 15 min) and the solution was 
analysed by HPLC with Merck-Hitachi Lachrom equipment, Raytest Gabi radiodetector and 
Nucleosil 100-5 NH2 phase in 125×4.6-mm column. Elution: 0–30 min 100 % 0.1 M aq. 
NaH2PO4 (pH 4.5), 31–60 min 100 % 0.1 M aq. Na-citrate (pH 4.5) and 60–65 min 100 % 0.1 
M aq. NaH2PO4 (pH 4.5).  
 
4.14. Binding studies of 
68
Ga-ligand complexes on hydroxyapatite 
HAP (20 mg, Sigma-Aldrich, reagent grade powder) was incubated in isotonic saline (1 ml) 
for 24 h. The test was performed by the addition of 50 µL of the 
68
Ga-bis(phosphonates) 
solution (prepared as given above) to the HAP suspension. After vortexing for 10 s, the 
suspension was incubated for 10 min at room temperature. The samples were centrifuged and 
the supernatant was removed. The HAP fraction was washed with isotonic saline (0.5 ml). 
The 
68
Ga radioactivity in the combined liquids and that of the HAP fraction were measured 
in a curiemeter (Aktivimeter Isomed 2010, MED Nuklear-Medizintechnik Dresden GmbH). 
68
Ga-complex binding to HAP was determined as percent of 
68
Ga absorbed to HAP (53).  
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4.15. Animals, feeding, husbandry, and animal preparation 
The experiments were conducted according to institutional guidelines and the German animal 
welfare regulations. The experimental procedure used conforms to the European Convention 
for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes 
(ETS No. 123) and to the Deutsches Tierschutzgesetz. Male Wistar rats (Charles River 
Laboratories International, Inc) weighing 130 ± 15 g (mean ± SD, n = 10) for ex vivo organ 
distribution, 536 g and 346 g for µPET-imaging (n = 2) were anesthetized with isoflurane. 
Animals were put in the supine position and placed under a infra-red lamp to maintain body 
temperature.  
 
4.16. Biodistribution studies 
Biodistribution studies were performed in male Wistar rats (120–140 g). Each study group 
contained 5 rats. The rats were injected intravenously, each with 
68
Ga-labeled compound in 
saline (0.5 ml); for [
68
Ga]NO3AP
BP
 13.5±5.8 MBq, BW 142±3 g; for [
68
Ga]NOTAM
BP
, 
10.5±1.9 MBq, BW 128±7 g. Animals were sacrificed at 60 min after injection. Organs and 
tissues of interest were excised rapidly, weighted, and the radioactivity was determined using 
a Wallac WIZARD2 automatic gamma counter (Perkin Elmer, Germany). The activity of the 
tissue samples was decay- and background-corrected.  
 
4.17. Small animal µPET 
In vivo small animal µPET imaging of male Wistar rats (350–550 g) was carried out under 
general anesthesia of the rats that was induced with inhalation of 10 % and maintained with 
inhalation 6.5 % isoflurane in 30 % oxygen/air. Rats were positioned  supine to the scanner 
(Siemens microPET Focus 120). In the µPET experiments, [
68
Ga]NO2AP
BP
 (32 MBq for the 
1
st
 animal, 536 g and 31 MBq for the 2
nd
 animal, 346 g in isotonic saline (0.5 ml) was 
administered intravenously using a needle catheter into the tail vein. No correction for partial 
volume effects was applied. The image volume data were converted to Siemens ECAT7 
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format for further processing. The image files were then processed using the Pmod software 
(PMOD Technologies Ltd).  
 
4.18. Statistical analysis.  
All data were expressed as mean ± SD. Groups were compared using the t-test. All statistical 
tests were two tailed, with a P-value of less than 0.05 representative for significance, except 
the comparison of [
68
Ga]NO2AP
BP
and [
68
Ga]EDTMP in the HAP-binding experiment, which 
showed a P-value of P = 0.052. No differences were observed for [
68
Ga]NO2AP
BP
 and 
[
68
Ga]DO3AP
BP
 in the HAP-binding experiment (P = 0.7); for the values, see SI (Table S1).  
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Abstract 
Introduction: Bisphosphonates have a high affinity to calcified tissues and are commonly 
used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with 
macrocyclic chelators open new possibilities in bone targeted radionuclide imaging and 
therapy. Endoradiotheraphy with 
177
Lu-labelled macrocyclic bisphosphonates could have 
great potential subsequent to PET examinations utilized with 
68
Ga-labelled analogous in the 
treatment of painful skeletal metastases. 
Methods: Two new DOTA α-OH-bisphosphonates DOTAMPAM and DOTAMZOL were 
successfully synthesized, based on the established pharmaceuticals pamidronate and 
zoledronate, respectively. The ligands were labelled with the PET-nuclide 
68
Ga, purified and 
compared in in vitro and in vivo studies against [
18F]NaF and a known DOTA α-H-
bisphosphonate conjugate (BPAPD) in healthy Wistar rats. 
Results: The new ligands reached a RCY of 80 to 90% in 15 min with post processed 
68
Ga. 
After resin purification the purity of all studied bisphosphonates was higher than 98%. The 
tracers showed low uptake in soft tissue, a fast renal clearance and a high accumulation in 
bone. The best compound was [
68
Ga]DOTAM
ZOL
 (SUVFemur = 5.4±0.6) followed by 
[
18
F]NaF (SUVFemur = 4.8±0.2), [
68
Ga]DOTAM
PAM
 (SUVFemur = 4.5±0.2) and [
68
Ga]BPAPD 
(SUVFemur = 3.2±0.3). Best blood to bone ratios were obtained for [
18
F]NaF (97.4) and 
[
68
Ga]DOTAM
ZOL
 (11.5). 
Conclusion: The 
68
Ga-labelled DOTA-bisphosphonate compounds showed a promising 
uptake profile and a similar distribution kinetics. Bone accumulation was highest for 
[
68
Ga]DOTAM
ZOL
, which makes this compound an interesting bone targeting tracer for 
further studies with 
177
Lu. 
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1. Introduction 
Radionuclide bone scintigraphy usually applied to localize skeletal lesions from various 
cancer origins. The findings of the scintigraphy reflect the status of metabolic activity of the 
bone tissue as a result of tumour invasion. Positron emission tomography (PET) has a high 
diagnostic sensitivity and specificity for the detection of skeletal metastases [1], when used 
with the cyclotron produced [
18
F]NaF [2]. The positron emitter 
68
Ga has several advantages, 
which makes it an interesting object in the development of radiopharmaceuticals. First of all 
it is the cyclotron independent availability based on the 
68
Ge/
68
Ga generator system. 
Secondly it is the principle of the bifunctional chelating agent to design radiometal based 
pharmaceuticals. Substitution of β+ by β- or α-particle emitters in principle leads to a 
theranostic concept, wherein diagnosis and therapy is combined in one compound. Since 
bisphosphonates show a high affinity to bone, a number of new DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) based bone targeting bisphosphonate 
molecules were described in the literature [3], including conjugates of alendronic acid [4] (4-
aminobutyl-1-hydroxy-1,1-bis[phosphonic acid]) and other α-H-bisphosphonates [5]. Within 
this class of compounds, first promising human applications were reported for 
[
68
Ga]BPAMD. PET studies demonstrating equal quality to [
18
F]NaF and particularly a 
higher SUVmax in seleceted bone lesions [6]. 
 
Chart 1. Structure of discussed ligands. 
The evolution of modern osteoporosis drugs went from α-H bisphosphonates to α-OH and N-
heteroaromatic bisphosphonates [7]. Actually the synthesis of DOTA conjugated α-OH-
bisphosphonates is more difficult compared to DOTA conjugated α-H-bisphosphonates. The 
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benefit of DOTA-α-OH-bisphosphonates against DOTA-α-H-bisphosphonates is 
hypothetical and might be based on the higher affinity of α-OH bisphosphonates to calcified 
surfaces compared to the α-H bisphosphonates [7]. Consequently we synthesized a 
pamidronate (3-aminopropyl-1-hydroxy-1,1-bis[phosphonic acid]) and a zoledronate (([1-
hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid) derivatives as DOTA 
conjugates, labelled both with 
68
Ga and compared them in in vivo small animal PET and in ex 
vivo organ distribution studies in healthy Wistar rats to the known DOTA-α-H-
bisphosphonate of similar structure (BPAPD) and to [
18
F]NaF (for structures see Chart 1). 
 
2. Results 
2.1. Synthesis  
Synthesis of BPAPD is published in the literature [8] as well as the synthesis of pamidronate 
[9]. Compound (4) was prepared by a standard method for the synhtesis of hydroxyl-
bisphosphonates from carboxylic acids [10]. The cleavage of the amide to from the primary 
amine was achieved in the same step, based on the strong acidic condition after hydrolysis of 
the phosphorus trichloride. The imidazole derivative (3) was obtained from ω-N-
acetylhistamine (1) after alkylation with benzyl bromoacetate and hydrogenation. Only the 
1,4-(H-2 and H-5) imidazole (2) was formed during this reaction. A convenient method to 
discriminate between the 1,4- and the 1,5-alkylation product is described in the literature by 
the different coupling constants of the aromatic imidazole ring protons [11]. (2) showed a 
coupling constant of J2,5 = 1.3 Hz, which is characteristic for the 1,4-product (range from 1.1-
1.5 Hz). The final conjugation of the hydroxy-bisphosphonates (DOTAM
PAM
 and 
DOTAM
ZOL
) were performed via a route described by Ogawa et al [4]. Products were first 
purified by preparative HPLC workup, and the amounts of DOTA impurities remaining were 
removed by solid phase extraction (SPE) using a weak anion exchanger resin. 
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Scheme 1. Synthesis of DOTAM
ZOL
: (i) benzyl bromoacetate, DMF, Cs2CO3, 0
o
C, 12 h. (ii) H2, Pd/C, MeOH, 
RT, 24 h. (iii) 1. PCl3 ,H3PO3, MeSO3H, 75
o
C, 12 h, 2. H2O, 105
o
C, 24 h. (iv) DOTA-NHS-ester, Na2CO3, 
40
o
C, 24 h. 
 
2.2. Radiolabelling with n.c.a. 
68
Ga and quality control 
Labelling with n.c.a. 
68
Ga was performed in sodium acetate buffer under heating on a thermo 
shaker for 15 minutes. Radiochemical yields (RCY) of the 
68
Ga-DOTA-BP complexes were 
obtained between 80 and 90%. After SPE using again a weak anion exchanger, the labelled 
compounds were present in 2 mL phosphate buffered saline (PBS) with a radiochemical 
purity over 98%, ready for injection. Yields and purities were checked by radio-TLC and 
HPLC (Figure 1). Aliquots of the purified and the reaction solutions were quenched with 
desferoxamine (DFO). Remaining uncomplexed 
68
Ga converted into the stable complex 
[
68
Ga]DFO, which then could be discriminated effectively on RP-HPLC from the 
68
Ga-
DOTA-BPs. 
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Figure 1. Quality control of [
68
Ga]DOTAM
ZOL
 by means of cross checked radio-HPLC and radio-TLC, as a 
representative of 
68
Ga-labelled bisphosphonates. A: After 15 min reaction time. B: After SPE purification. 
A(HPLC): Rt([
68
Ga]DOTAM
ZOL
) =  0.6 min. (88%), Rt([
68
Ga]DFO) =  4.1 min. (12%). B(HPLC): 
Rt([
68
Ga]DOTAM
ZOL
) =  0.6 min. (98%). A(TLC): Rf([
68
Ga]DOTAM
ZOL
) = 0.1 (85%), Rf([
68
Ga]citrate) = 0.9 
(15%). B(TLC): Rf([
68
Ga]DOTAM
ZOL
) = 0.1 (99%). Control (TLC): Rf([
68
Ga]citrate) = 0.9 (99%). 
 
2.3. Adsorption experiments on apatite  
Simple binding experiments on hydroxy apatite (HAP) proved the high affinity of the 
68
Ga-
labelled compounds to calcified surfaces like bone tissue. The hydroxy bisphosphonates 
[
68
Ga]DOTAM
PAM
 (91.2±2.7) and [
68
Ga]DOTAM
ZOL
 (92.7±1.3) showed an identical 
adsorption in this experiment (Figure 2). Thus binding of the pamidronate and zoledronate 
conjugates was superior compared to the α-H-bisphosphonate [68Ga]BPAPD (83.0±0.8). 
[
68
Ga]DOTA as a control showed almost no binding. 
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Figure 2. Adsorption efficacies of the three 
68
Ga-labelled DOTA-BPs on 20 mg HAP after 10 min incubation 
time, compared to [
68
Ga]DOTA. 
 
2.4. Ex vivo biodistribution 
The results of the ex vivo organ distribution in healthy Wistar rats of [
68
Ga]DOTAM
PAM
, 
[
68
Ga]DOTAM
ZOL
, [
68
Ga]BPAPD and [
18
F]NaF are presented in Tables 1 and 2, respectively. 
All 
68
Ga-labelled compounds showed high accumulation in bone and low uptake in soft 
tissue. Compared to the bisphosphonates [
18
F]NaF showed an slight faster renal clearance 
and an overall lower concentration of activity in other organs, besides the bone. The bone to 
blood ratio determined from biodistribution were 3.7 for [
68
Ga]BPAPD, 7.6 for 
[
68
Ga]DOTAM
PAM
, 11.5 for [
68
Ga]DOTAM
ZOL
 and 97.4 for [
18
F]NaF. 
 
  3. Manuscripts and Supplementary Results 
142 
 
Table 1. Ex vivo biodistribution of [
68
Ga]DOTAM
PAM
, [
68
Ga]DOTAM
ZOL
, [
68
Ga]BPAPD and [
18
F]NaF in 
healthy Wistar rats after 60 min. p. i.  
organ [
68
Ga]DOTAM
PAM 
[
68
Ga]DOTAM
ZOL
 [
68
Ga]BPAPD
a 
[
18
F]NaF
a 
Lung 0.53 (0.16)
*
 0.45 (0.11)
*
 0.43 (0.08) 0.05 (0.01) 
Liver 0.43 (0.04)
*‡
 0.28 (0.03)
*‡
 0.37 (0.11) 0.03 (0.01) 
Spleen 0.31 (0.04)
*‡
 0.17 (0.02)
*‡
 0.23 (0.08) 0.13 (0.20) 
Kidneys 0.48 (0.06)
*
 0.53 (0.04)
*
 0.56 (0.08) 0.11 (0.01) 
Muscle 0.09 (0.02)
†
 0.08 (0.02)
†
 0.17 (0.02) 0.06 (0.05) 
Heart 0.23 (0.02)
*†‡
 0.14 (0.04)
*†‡
 0.32 (0.09) 0.02 (0.01) 
Blood 0.60 (0.03)
*†
 0.47 (0.19)
*†
 0.86 (0.21) 0.05 (0.01) 
Intestine 0.28 (0.12)
*
 0.14 (0.08)
*
 0.26 (0.05) 0.02 (0.01) 
Femur 4.53 (0.17)
†‡
 5.40 (0.62)
†‡
 3.21 (0.29) 4.87 (0.32) 
Data are expressed in SUV. Each value represents the mean (S.D.) for five animals. 
a
Data taken from lit. [12]. 
*
P<0.05 vs. [
18
F]NaF
 
†
P<0.05 vs. [
68
Ga]BPAPD 
‡
P<0.05 [
68
Ga]DOTAM
PAM
 vs. [
68
Ga]DOTAM
ZOL 
Table 2. Bone to blood ratios and calculated total activity in the skeleton in healthy Wistar rats, after 60 min. 
p. i. of [
68
Ga]DOTAM
PAM
, [
68
Ga]DOTAM
ZOL
, [
68
Ga]BPAPD and [
18
F]NaF. 
compound %ID in skeleton (S.D.) bone to blood ratio (S.D.) 
[
68
Ga]DOTAM
PAM
 48.4 (4.7) 7.6 (0.6) 
[
68
Ga]DOTAM
ZOL
 42.7 (5.2) 11.5 (5.9) 
[
68
Ga]BPAPD
a
 38.3 (5.0) 3.7 (1.2) 
[
18
F]NaF
a
 43.7 (1.9) 97.4 (26) 
Each value represents the mean for five animals. 
a
Data taken from lit. [12]. 
After 60 minutes the estimated activity in the skeleton was in the range of 40 to 50% of the 
injected dose (ID) for [
68
Ga]BPAPD (38.8% ID), [
68
Ga]DOTAM
PAM
 (48.4% ID) and 
[
68
Ga]DOTAM
ZOL 
(42.7% ID), which is comparable to that of [
18
F]NaF (43.7% ID), cf. 
table 2. 
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2.5. In vivo biodistribution 
Uptake kinetics and images from in vivo µPET studies are presented in Figure 2. 
[
68
Ga]BPAPD, [
68
Ga]DOTAM
PAM
 and [
68
Ga]DOTAM
ZOL
 showed a rapid bone 
accumulation, reaching a plateau level at 45 minutes and a fast blood elimination. The 
terminal elimination half-life of [
68
Ga]DOTAM
ZOL
 is significantly lower compared to 
[
68
Ga]BPAPD and [
68
Ga]DOTAM
PAM
, cf. table 3. Distribution kinetics as time activity 
curves, Figure 2 and Figure 3, are very similar for all 
68
Ga-tracers. Variation in the kidney 
profile is a result of differing response of the rats to anesthesia and diverging kidney activity. 
After 60 minutes all 
68
Ga-labelled bisphosphonates gave clearly visible bone scans of good 
quality[
18
F]NaF PET showed in small animals a slight better quality, which is based on the 
better spatial resolution of the lower β+-energy of 18F compared to 68Ga. In human PET 
applications these volume effects are negligible. 
Table 3. Pharamcological parameters calculated by a two-compartment model of [
68
Ga]DOTAM
PAM
, 
[
68
Ga]DOTAM
ZOL
 and [
68
Ga]BPAPD obtained from µPET experiments in healthy Wistar rats. 
Elimination half-lives [
68
Ga]BPAPD
 [
68
Ga]DOTAM
PAM 
[
68
Ga]DOTAM
ZOL
 
t1/2(α) 5 min 4.5 min 5 min 
t1/2(β) 4 h 4.5 h 
2.3 h 
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Figure 2. MIP (maximum intensity projection) in the thorax region of Wistar rats after 60 min p.i. and time 
activity curves (TAC) of [
68
Ga]BPAPD and [
18
F]NaF. 
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Figure 3. MIP (maximum intensity projection) in the thorax region of Wistar rats after 60 min p.i. and time 
activity curves (TAC) of [
68
Ga]DOTAM
PAM
 and [
68
Ga]DOTAM
ZOL
. 
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3. Discussion 
The synthetic route for the DOTA-α-OH-bisphosphonate derivatives is distinctly different 
from that of the compound BPAPD. As a consequence, The α-H-bisphosphonate is definitely 
in a more easy way to synthesize. Purities and yields are quite higher. The coupling of the 
primary amine of the pamidronate or imidazole moiety in water via the N-
hydroxysuccinimide ester of DOTA results in lower yields and the formation of problematic 
side products from ester hydrolysis, which have to be removed. Ogawa et al. [4] separated 
the [
90
Y]DOTA-alendronate derivative from [
90
Y]DOTA after labelling by semipreparative 
HPLC. A combination of semipreparative HPLC and SPE showed the best purification 
results after the amide formation. Other groups reported the synthesis of protected 
alendronate, where the hydroxy bisphosphonate part is esterified by ethyl groups and a 
tert.butyldimethylsilyl ether [13], leading to a new route for the developing of chelator α-OH- 
bisphosphonate conjugates [14]. Nevertheless, this reaction seemed to be limited for 
compounds like alendronate. We were not able to prepare other derivatives with different 
alkyl or aromatic residues on the geminal hydroxy bisphosphonate, by this synthetic 
pathway. The rearranged phosphonic acid derivative was the main product [15,16]. 
Complex formation with n.c.a. 
68
Ga was comparable for BPAPD, DOTAM
PAM
 or 
DOTAM
ZOL
 in terms of labelling yields and kinetics. Yields between 80 and 90% were 
routinely achieved after 15 min. The same strategy to remove DOTA impurities during the 
synthesis of the precursors showed to be convenient to purify the radio-labelled tracers from 
uncomplexed 
68
Ga. The 
68
Ga-DOTA-BP is trapped via its bisphosphonate moiety on a weak 
anion exchanger and separated from labelling buffer as well as from free 
68
Ga. This method 
is efficient, fast and easy and afterwards the product is present in PBS, suitable for injection 
after sterile filtration. Adding a small aliquot from the product containing solution to DFO 
results in an easy HPLC method suitable for working on common C18 columns. The 
[
68
Ga]DFO complex differs in retention time to the
68
Ga-DOTA-BPs. Together with the TLC 
and the SPE cartridge a useful package of quality control and purification methods could be 
developed for DOTA conjugated bisphosphonates labelled with 
68
Ga.  
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Data from in vitro adsorption study indicate a higher affinity towards apatite for the two 
DOTA-α-OH-BPs compared to the DOTA-α-H-BP. This could be further proofed in ex vivo 
and in vivo experiments. The DOTA pamidronate conjugate [
68
Ga]DOTAM
PAM
 
(SUVFemur = 4.5±0.2) showed a higher accumulation in bone compared to the DOTA 
bisphosphonate conjugate [
68
Ga]BPAPD (SUVFemur = 3.2±0.3). This proves the expectation 
that bisphosphonates containing an α-OH group have an enhanced affinity to calcified 
surfaces, as currently discussed in the literature. This leads to an almost doubled bone to 
blood ratio of 7.6 for [
68
Ga]DOTAM
PAM
 to that of 3.7 for [
68
Ga]BPAPD. According to 
previous studies nitrogen-containing hydroxy bisphosphonates, especially N-heteroaromatic 
compounds, have an even more enhanced accumulation on bone. Indeed the N-
heteroaromatic [
68
Ga]DOTAM
ZOL
 showed the best bone uptake (SUVFemur = 5.4±0.6) and the 
best bone to blood ratio of 11.5 of all bisphosphonates tested.  
The overall skeleton accumulation is very similar for all tracers and it is comparable to that 
of [
18
F]NaF, which is in the range of 40 to 50%ID. In rats all DOTA based bisphosphonates 
showed PET images of good quality, which proof their potential as useful skeletal imaging 
agents. Bisphosphonates are known to have a long biological half-life in bone. Since DOTA 
compounds are easy to label with β-- or α-particle emitters like 177Lu or 212Bi, the tracers 
discussed in this paper seemed to be excellently suitable for bone targeted radionuclide 
therapy. Labelling studies, complex stabilities and animal experiments with therapy nuclides 
will be reported elsewhere. 
In conclusion, simple 
68
Ga-labelled bisphosphonates like BPAPD are easier to synthesize, 
but show less affinity to bone compared to hydroxy bisphosphonates like [
68
Ga]DOTAM
ZOL
. 
The DOTA conjugated bisphosphonates attained high RCY (80-90%) with 
68
Ga after 15 min. 
A fast and easy purification and quality control method could be established. Data from in 
vivo µPET and ex vivo biodistribution showed fast blood clearance, low uptake in soft tissue 
and a high accumulation in the skeleton with [
68
Ga]DOTAM
ZOL
 as the best leading 
compound.  
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4. Experimental 
4.1. General methods. 
Chemicals and solvents were commercially available in analytical, HPLC or 
TraceSELECT® grade and were purchased by Sigma-Aldrich or Merck KGaA. DOTA-NHS 
ester (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-
hydroxysuccinimidyl ester)) was synthesized according to a procedure described in the 
literature [17] or purchased from Chematech (Dijon, France). Proton nuclear magnetic 
resonance (
1
H-NMR) spectra were recorded on a Bruker 300, 
31
P-NMR were recorded on a 
Bruker 600. Mass spectra were recorded on Agilent Technologies 6130 Quadrupole LC/MS 
spectrometer with ESI as ion source in positive or negative modes or on a Finnigan MAT-95 
spectrometer with FD as ion source. TLC analyses were carried out with silica on aluminium 
foil (Merck). Radio-TLC analysis of labelled compounds were performed also with silica on 
aluminium foil (Merck) and a Canberra Packard Instant Imager. For HPLC and radio-HPLC 
a Waters-system 1525 with an UV- and a radio-detector (Berthold Technologies, Germany) 
was used. Radioactivity of samples were measured with an Aktivimeter Isomed 2010, MED 
(Nuklear-Medizintechnik Dresden GmbH). Radioactivity in tissue samples was determined 
by using a Wallac WIZARD2 automatic gamma counter (Perkin Elmer, Germany). N.c.a. 
68
Ga was obtained from a 
68
Ge/
68
Ga generator system (Eckert & Ziegler). [
18
F]NaF was 
purchased from DKFZ (Deutsches Krebsforschungszentrum, Heidelberg, Germany). 
 
4.2. Synthesis of DOTAM
PAM
 
Pamidronate was synthesized according to a description by Kieczykowski et al [9]. 4.85 g 
(54.3 mmol) β-alanine was dissolved in 25 mL of methanesulfonic acid. 4.45 g (54.3 mmol) 
.) phosphorous acid was added and 10 mL (115 mmol) phosphorus trichloride was added 
slowly under vigorous stirring at75
o
C. The reaction mixture was kept under argon 
atmosphere for 12 h at 75
o
C. After cooling to room temperature 50 g of crushed ice was 
added under vigorous stirring. The aqueous solution was heated for 12 h under reflux. After 
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cooling to room temperature conc. aquaous NaOH was added until the formation of a white 
precipitate was observed. The mixture was stored in a fridge for 5 h to complete precipitation 
and filtered, washed with cold water and recrystallized from boiling water. Precipitation was 
initiated by adding EtOH. The white solid (5.3 g, 69 %) was filtered, washed with EtOH and 
dried in an oven at 60
o
C. 
1
H-NMR (D2O/NaOD, 300 MHz): δ 2.30 (m, 2H), 3.34 (t, JH = 6.8 
Hz, 2H). 
31
P-NMR (D2O/NaOD, 162.05 MHz): δ 17.7 (s, 2P). ESI-MS(-): cald 234.07 obsd 
234.10 (M – H+), ESI-MS(+): cald 235.07 obsd 258.0 (M + Na+). 
DOTAM
BP
 was synthesized according to a description by Ogawa et al [4]. 25 mg (0.11 
mmol) pamidronate was dissolved in 1 mL 0.1 M Na2CO3 in water. 38 mg (0.05 mmol) 
DOTA-NHS-ester was dissolved in 0.5 mL deionized water and added to the pamidronate 
solution. The reaction solution was kept at 40
o
C on a thermo shaker for 24 h. The pH was 
checked periodically and small amounts of aqueous Na2CO3 were used to keep the pH 
between 8 and 9. The crude mixture was purified initially by preparative HPLC 
(Phenomenex Synergy Hydro-RP 80, 10µ, 250 x 30 mm, H2O + 0.1% TFA). In the second 
step the crude product was purified further to remove DOTA impurities by solid phase 
extraction (SPE). An aqueous solution of the compound was passed over a silica NH2-phase 
(Merck LiChroprep NH2). After washing with water/methanol/water the product was eluted 
with H2O +2 % TFA. After lyophilisation 4.5 mg (14.5%) of a white solid was obtained. 
1
H-
NMR (D2O/NaOD, 300 MHz): δ 2.0-2.3 (b, 8H, cyclen-CH2), 2.0-2.33 (b, 2H,-CH2-), 2.9-3.5 
(b, 8H, cyclen-CH2), 2.9-3.5 (b, 2H,-CH2-), 3.74 (bs, 8H, -CH2-CO). 
31
P-NMR (D2O/NaOD, 
162.05 MHz): δ 18.3 (s, 2P). ESI-MS(+): cald 621.18 obsd 1243.3 (2M + H+), 622.1 (M + 
H
+
), 311.6 (M + 2H
+
). 
 
4.3. Synthesis of DOTAM
ZOL
 
1-(benzyl acetate) 4-(ethyl acetamide)-imidazole (2). 1 g (6.53 mmol) ω-N-acetylhistamine 
(1) was dissolved in 50 mL dry DMF. 4.4 g (13 mmol) ceasium carbonate was added. The 
solution was stirred  under Argon atmosphere and ice cooling. 2.2 g (13 mmol) benzyl 
bromoacetate was dissolved in 50 mL dry DMF and added slowly to the imidazole solution. 
The mixture was allowed to warm to room temperature and stirred for 12 h. Charcoal was 
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added and the solids were filtered off. After removing the solvents under reduced pressure, 
the crude red residue was recrystallized from ethyl acetate to obtain 1.14 g (58%) pale yellow 
crystals. 
1
H-NMR (CDCl3, 300 MHz): δ 1.97 (s, 3H, CH3-CO), 2.76 (t, JH = 6.3 Hz, 2H, 
CH2-CH2), 3.53 (q, JH = 6.0 Hz, 2H, CH2-CH2), 4.70 (s, 2H, N-CH2-CO), 5.22 (s, 2H, Bn-
CH2-CO), 6.53 (bs, 1H, NH), 6.75 (d, JH = 1.3 Hz, imidazole-H), 7.39 (m, 5H, benzyl), 7.44 
(d, JH = 1.3 Hz, 1H, imidazole-H). ). FD-MS(+): cald 301.14 obsd 302,3 (M + H
+
), 603,2 
(2M + H
+
). 
1-(1-hydroxy-ethane-1,1-bis(phosphonic acid)) 4-(ethyl amine)-imidazole (4). 300 mg (1 
mmol) of (2) was dissolved in 20 mL of dry MeOH. Pd/C (10%w) was added and stirred 
under hydrogen atmosphere (5 bar) for 12 h. After removing the solvents the hydrogenated 
product (3) was weighted to determine yield (208 mg, 98%). The acid (3) was used without 
further purification in the next step. 1 mL methanesulfonic acid and 164 mg (2 eq.) 
phosphorous acid was added. The mixture was stirred at 75
o
C and 300 mg (2.2 eq.) 
phosphorus trichloride was added slowly under argon atmosphere. After 12 h the reaction 
mixture was cooled down to room temperature and 2 mL of iced water was added. The 
aqueous solution was heated for 24 h under reflux. Charcoal was added and the solution was 
filtered. After cooling to room temperature conc. aquaous NaOH was added until the 
formation of a white precipitate was observed. The mixture was stored in a fridge overnight 
to complete precipitation and filtered, washed with cold water and recrystallized from boiling 
water to obtain 88.6 mg (28%) of a white solid. 
1
H-NMR (D2O/NaOD, 300 MHz): δ 2.46 (m, 
2H, CH2-CH2), 2.66 (m, 2H, CH2-CH2), 4.28 (m, 2H, N-CH2-phosponate), 6.89 (s, 1H, 
imidazole-H), 7.54 (s, 1H, imidazole-H). 
31
P-NMR (D2O/NaOD, 162.05 MHz): δ 14.4. ESI-
MS(+): cald 315.04 obsd 316.05 (M + H
+
), 338.04 (M + Na
+
). 
DOTAM
ZOL
 (5). To 15.75 mg (0.05 mmol) (4) in 1 mL water, triethylamine (TEA) was 
added drop wise until all solids were dissolved. 38 mg (0.05 mmol) DOTA-NHS-ester was 
dissolved in 0.5 mL water and added to the bisphosphonate solution [4]. The reaction 
solution was kept at 50
o
C on a thermo shaker for 24 h. The pH was checked periodically and 
small amounts of aqueous TEA were used to keep the pH between 8 and 9. The crude 
mixture was purified initially by preparative HPLC (Phenomenex Synergy Hydro-RP 80, 
10µ, 250 x 30 mm, solvent: H2O + 0.1% TFA). In the second step the crude product was 
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purified further to remove DOTA impurities by solid phase extraction (SPE). An aqueous 
solution of the compound was passed over a silica NH2-phase (Merck LiChroprep NH2). 
After washing with water/methanol/water the product was eluted with H2O + 2% TFA. After 
lyophilisation 5.6 mg (15.7%) of a white solid was obtained. 
1
H-NMR (D2O/NaOD, 300 
MHz): δ 2.42 (m, 2H, CH2-CH2), 2.61 (m, 2H, CH2-CH2), 2.9-3.5 (b, 16H, cyclen-CH2), 3.75 
(bs, 8H, -CH2-CO), 4.55 (m, 2H, N-CH2-phosponate), 7.28 (s, 1H, imidazole-H), 8.54 (s, 1H, 
imidazole-H). 
31
P-NMR (D2O/NaOD, 162.05 MHz): δ 14.3. ESI-MS(+): cald 701,2 obsd 
702.5 (M + H
+
), 351.1 (M + 2H
+
). 
 
4.4. Radiolabelling with n.c.a. 
68
Ga and quality control 
N.c.a. 
68
Ga was obtained in 400 µL acetone/HCl from a 
68
Ge/
68
Ga generator system by 
cationic post processing [18]. The labelling itself was performed by adding 500 µL sodium 
acetate buffer (0.5 M, pH = 4) and 25 nmol ligand to the 
68
Ga containing solution. The 
mixture was heated at 98
o
C under moderate shaking on a thermo shaker for 15 min. 
Subsequently the solution was diluted to 5 mL with water and passed over a weak anion 
exchanger cartridge (25 mg, Merck LiChroprep NH2). After washing with 1 mL water the 
purified product was eluted with 2 mL PBS. Radiochemical yields and purities were 
determined by radio-TLC (Merck silica, solvent: acetone/acetylacetone/HCl, 10/10/1) and 
radio-HPLC (Merck Chromolite RP-18e 100 x 4.6 mm, gradient: H2O to acetonitrile). To 
discriminate between free 
68
Ga and 
68
Ga-bisphosphonates a small aliquot of the product 
solution was incubated for 1 min with a 0.25 M DFO (Desferoxamine) solution. DFO 
complexes unlabelled 
68
Ga instantly and shows a longer retention time on RP-18 HPLC (see 
Figure 1). 
 
4.5. Adsorption experiments on apatite 
Hydroxy apatite (HAP) (20 mg, Sigma-Aldrich, reagent grade powder) was incubated in 
isotonic saline (1 mL) for 24 h. 50 µL of the 
68
Ga-labelled bisphosphonate solution to the 
HAP suspension. After vortexing for 10 s, the suspension was incubated for 10 min at room 
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temperature under moderate shaking on a thermo shaker. The supernatant was removed by 
centrifugation. The HAP fraction was washed with saline (0.5 mL) and the 
68
Ga radioactivity 
in the combined liquids and that of the HAP fraction were measured. 
68
Ga-complex binding 
to HAP was determined as percentage of 
68
Ga absorbed to HAP [19]. 
 
4.6. Animal studies 
Male Wistar rats were purchased from Charles River Laboratories Inc weighting 140-220 g. 
The animal experiments were carried out in consensus to institutional guidelines, the German 
welfare regulations and the European Convention for the Protection of Vertebrate Animals 
for Experimental and other Scientific Purposes. 
µPET: Small animal µPET imaging was performed under general anesthesia with isoflurane 
inhalation. The rats were positioned supine in a Siemens Focus 120 µPET and 15 to 18 MBq 
of the radio tracers were administrated in 0.5 mL isotonic saline intravenously (i.v.) via the 
tail vein. Images were reconstructed to OSEM 2D and files were processed using Pmod 
software (TAC) and Amine software (MIP). 
Biodistribution: For each compound five animals were injected with 8 to 10 MBq of the 
radio tracers in 0.5 mL PBS/isotonic saline via the tail vein. The rats were sacrificed at 60 
min p.i. and organs of interest were excised, weighed and the radioactivity was measured 
decay corrected on a gamma counter. The amount of organ accumulation is expressed in 
SUV (standard uptake value) by the equitation: SUV = (activity per g tissue)/(injected 
activity) x body weight. Activity in the skeleton was calculated as percentage of injected 
dose (%ID) by the following equitation: %ID(skeleton) = femur(%ID/g) x skeleton weight 
(g). The skeleton weight of the rats were calculated using: skeleton weight = 9.66 + 0.0355 x 
body weight [12]. 
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4.7. Statistical analysis 
All data were expressed as mean ± SD. Groups were compared using the t-test. All statistical 
tests were two tailed, with a P-value of less than 0.05 representative for significance. 
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Abstract 
Introduction: Radio-labelled bisphosphonates are commonly used in the diagnosis and 
therapy of bone metastases. In many cases, blood clearance is fast and only 30 to 50 % of the 
injected activity is retained in the skeleton, while most of the activity is excreted, 
predominantly via the kidneys and the bladder. In the context of endoradiotherapeutic 
applications, this would reduce the radioactivity accumulated at the target side. A longer 
blood circulation may enhance accumulation of bisphosphonate compounds in the bone 
metastases. A portable Albumin binder was reported to delay the excretion of polar imaging 
agents. Therefore a chemically modified macrocyclic bisphosphonate derivative with an 
additional binding entity to human albumin was synthesized and evaluated in relation to the 
modification of the pharmacokinetics of the bisphosphonate. 
Methods: The theranostic bisphosphonate BPAMD ((4-{[bis-(phosphonomethyl)) 
carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid) 
was compared to the novel albumin binding bisphosphonate DOTAGA(428-D-Lys)M
BP
 of 
similar structure. Both tracers were labelled with the generator derived PET nuclide 
68
Ga(III) 
and evaluated in binding studies to artificial bone material as well as to human serum 
albumin (HSA). The compounds were further compared in in vivo µPET and ex vivo organ 
distribution studies in healthy Wistar rats over a time period of 3 h p.i..  
Results: Radio-labelling with no carrier added (n.c.a.) 
68
Ga(III) resulted in initial yields of  
>80% and in radiochemical purities  >98% after solid phase extraction purification. Binding 
studies revealed a consistent affinity to hydroxyl apatite (HA) of both the albumin binding 
bisphosphonate (81.3 ± 2.2 %) and the original compound (81.6 ± 0.5 %). 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 showed a distinguished binding of 88.1 ± 5.9 % to HSA 
compared to 28.8 ± 1.1 % for [
68
Ga]BPAMD, respectively. In vivo µPET and ex vivo organ 
distribution studies resulted in significant longer blood concentration levels (SUVblood = 2.59 
± 0.72 and 0.06 ± 0.01, respectively). Skeletal accumulation of the modified compound 
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resulted in a SUVfemur = 4.16 ± 0.62 compared to the original compound of a SUVfemur = 4.20 
± 0.20 after 3 h p.i.. Ratios between the high metabolic femur epiphyseal plate to the ordinary 
bone showed to be more favourable for [
68
Ga]DOTAGA(428-D-Lys)M
BP
 with a ratio of 2.9 
compared to 1.9 for [
68
Ga]BPAMD respectively.  
Conclusion: The chemical modification of BPAMD towards an albumin binding 
bisphosphonate (DOTAGA(428-D-Lys)M
BP
 ) resulted in a novel compound, which 
conserves the activity of both functional groups within one and the same molecule. Blood 
retention was significantly longer for the DOTA bisphosphonate bridged to an albumin 
binding moiety. The better bioavailability of DOTAGA(428-D-Lys)M
BP
 resulted in better 
ratios between high and low metabolic bone sections. Further studies with longer living PET 
nuclides like 
44
Sc(III) or 
64
Cu(II) as well as dosimetric studies with the therapeutic nuclide 
177
Lu(III) have to be determined in future to conclude the therapeutic potential of this new 
class of tracers for the treatment of bone metastases.  
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1. Introduction 
The bone is frequently affected by metastatic invasion of tumour cells in consequence of 
various cancer diseases. This complication is accompanied by several symptoms like severe 
pain, spinal cord compression and hyper calcemia. Tumour cell invasion in the skeleton 
cause a activation of the osteoclasts and osteoblasts, which liberate signal molecules, 
resulting in a feedback mechanism, which is called the viscous circle [1]. Common treatment 
includes chemotherapy, analgesic medication, hormone respectively bisphosphonate 
treatment and external radiation therapy.  
Another application are bone-seeking radiopharmaceuticals, which showed good results in 
the last decades in the palliative care. The early approved β-emitters [32P]PO4
3-
 and 
89
SrCl2 
are now replaced by compounds of carrying radionuclides emitting lower β-energy particles 
like [
153
Sm]EDTMP and [
177
Lu]EDTMP, which cause less side effects to the radio sensitive 
bone marrow. The recently  approved α-particle emitting 223RaCl2 showed, beside pain relief, 
an overall longer survival rate of 3 month in prostate cancer patients afflicted by bone 
metastases [2]. There are several more, rather experimental compounds and nuclides like 
[
186
Re]HEDP or [
117m
Sn]DTPA described in the literature, as well as macrocyclic DOTA-
bisphosphonate conjugates like [
90
Y]DOTA-HBP [2,3]. One of these new compounds is 
BPAMD (Chart 1). In contrast to the open chain chelating agents like HEDP and ETMP the 
macrocyclic tetraaza-compound is able to complex the positron emitting PET nuclide 
68Ga(III) as well as the therapeutic low energy β-emitter 177Lu(III) [4]. BPAMD showed a 
high and stable bone association with a fast pharmacokinetic, when labelled with 
68
Ga(III) or 
with 
177
Lu(III) [5]. First 
68
Ga-PET scans in cancer patients [6] and in a rat tumour model [7] 
proofed the high potential of this tracer as a useful theranostic agent for the detection and 
treatment of skeletal metastases [8].  
Bisphosphonates are known to have a fast blood clearance and almost half of the injected 
dose is excreted via the kidneys [9]. In previous studies this effect could be confirmed also 
for the radiolabelled derivatives, i.e.  a fast body elimination of [
68
Ga]BPAMD and 
[
177
Lu]BPAMD. An injected dose of 30-40 % remained exclusively on the bone, while most 
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of the activity was washed out of the body via the urinary system[5,10] and is therefore no 
longer available for a binding on the target tissue. Nuclear magnetic resonance imaging 
(MRI) contrast agents like Gd-DTPA (Magnevist) or Gd-DOTA (Dotarem) show a similar 
fast blood clearance and these compounds are excreted in a short timescale with low 
retention in the body. Dumelin et al. conjugated MRI and fluorescence agents with an 
albumin binding entity. The albumin binding moiety induced a relative strong binding (Kd =  
3.3 µM) of a Gd-DTPA derivative to human serum proteins. Within this study the blood half-
life of [
177
Lu]DTPA was shifted from t1/2,α = 8.3 min to t1/2,α = 22.3 min for the [
177
Lu]DTPA-
albuminbinding-derivative [11]. Furthermore, it is reported that [
67/68
Ga]DOTA-folate 
conjugates have an unfavourable tumour to kidney ratio, based on the expression of the 
Folate receptor in the kidneys as well as in the targeted folate receptor positive tumour tissue 
[12]. Müller et al. further developed the concept of an albumin binding DOTA-folate 
conjugate as an 
177
Lu-endoradiotherapy (ERT) agent with an enhanced tumour to kidney 
ratio [13].  The same strategy was successful to develop a new 
18
F-labelled folate conjugate, 
where kidney uptake was reduced to a quarter compared to previously published folate 
receptor targeting compounds [14]. The longer blood circulation time of these new tracers 
resulted in distinct higher accumulation in the target tissue.  
 
Chart 1. Structure of ligands discussed in this paper. 
Since radio labelled bone tracers have a fast washout out of the body, longer blood retention 
times could first minimize unintended urinary exertion and second, consequently enhance the 
uptake of the compound on the targeted bone tissue. In addition a better metastases to healthy 
  3. Manuscripts and Supplementary Results 
162 
 
bone ratio might be achieved. Furthermore longer blood retention of a radio labelled 
bisphosphonate may have the same therapeutic effect when a reduced dose is administered, 
compared to a radio-labelled bisphosphonate, where almost half of the injected dose is 
excreted within few minutes. For that reason we synthesized the Albumin binding DOTA-
bisphosphonate conjugate (Chart 1) DOTAGA(428-D-Lys)M
BP
 aiming at a longer blood 
circulating character. The compound was labelled with 
68
Ga(III) and compared to 
[
68
Ga]BPAMD in in vitro essays and in in vivo small animal PET and ex vivo biodistribution 
studies. 
 
2. Results 
2.1. Synthesis 
The compounds tert.Butyl-DO2A (1) and α-bromoglutaric acid-1-tertbutyl ester-5-benzyl 
ester (2), which were used to form the seven dentate bifunctional chelator moiety (3) in the 
first reaction step were synthesized according to published procedures[15,16]. Mono 
alkylation of the macrocycle (1) was done under excess conditions of the nucleophile to 
prevent the formation of the di-alkylated side product. Insertion of the bisphosphonate 
targeting vector (4) was performed in the same way as described in the BPAMD synthesis 
route published [17] to form a protected bisphosphonate-DOTAGA derivative (5). Standard 
deprotection of the glutaric pendant arm under hydrogenation conditions enables the addition 
of the albumin binder 428-D-Lys mediated by HATU in two steps (6 and 7) by liquid-phase 
peptide synthesis. An excess of trimethylsilyl bromide, which is an effective an mild 
dealkylation reagent for the cleavage of phosphor esters, was used to form the bone affine 
bisphosphonate pharmacophore. Finally deprotection of the tert.Butyl ester yields the 
compound DOTAGA(428-D-Lys)M
BP
 (8).  
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Scheme 1. Synthesis of DOTAGA(428-D-Lys)M
BP
: (i) Dichloromethane, RT, 48 h. (ii) K2CO3, acetonitrile, 
40
o
C, 24 h. (iii) 1. H2, Pd/C, MeOH 2. DIPEA, HATU, DCM, RT, 12 h. (iv) 1. H2, Pd/C, MeOH 2. DIPEA, 
HATU, NMP, RT, 12 h. (v) 1. TFA/DCM, RT, 5 h 2. TMS-Br, DMF, RT, 12 h 3. H2O, RT, 24 h. 
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2.2. Radiolabelling with n.c.a. 
68
Ga and quality control 
Radiochemical yields (RCY) for [
68
Ga]DOTAGA(428-D-Lys)M
BP
, with post processed 
n.c.a. 
68
Ga(III) in sodium acetate buffer, were 80 to 90 % after 15 min at 98°C. After 
cartridge purification the tracer showed a radiochemical purity (RCP) > 98 % as determined 
by radio-HPLC (fig.1). 
 
Figure 1. RP-HPLC radiochromatograms of unbound 
68
Ga (A) and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 after SPE 
purification (B).  
 
2.3. Adsorption experiments on Apatite 
The two 
68
Ga-labelled bisphosphonate derivatives showed an almost identical binding profile 
to hydroxy apatite (HA) after 10 min incubation time, while [
68
Ga]DOTA as a control 
showed no relevant adsorption on HA. The results are presented in table 1.  
Table 1. Adsorption efficiency of 
68
Ga-labelled macrocycles on 20 mg HA after 10 min. incubation. 
 [
68
Ga]BPAMD
 
DOTAGA(428-D-Lys)M
BP
 [
68
Ga]DOTA 
% of activity on HA ± SD 81.6 ± 0.5 81.3 ± 2.2 0.8 ± 1.1 
Standard deviation (SD) 
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2.4. Protein binding 
Human serum protein binding, determined by ultrafiltration of the two 
68
Ga-labelled DOTA-
conjugated bisphosphonates, indicated a significant (P < 0.005) higher binding for 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 compared to [
68
Ga]BPAMD, which is shown in figure 2. 
Binding of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 to human serum proteins was 88.1 ± 5.9 %, 
while [
68
Ga]BPAMD showed a binding of 28.8 ± 1.1 %. Compared to that the retention of 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 and [
68
Ga]BPAMD on the ultrafilter in isotonic saline as a 
control was 33.3 ± 2.6 % and 15.0 ± 1.7 %, respectively. 
 
Figure 2. Results of the protein binding experiments for [
68
Ga]DOTAGA(428-D-Lys)M
BP
 (□) and 
[
68Ga]BPAMD (■) determined by ultrafiltration out of a triplicate. Low retention on the filter was observed for 
both compounds in isotonic saline, in contrast to human serum samples were retention was significant higher 
for [
68
Ga]DOTAGA(428-D-Lys)M
BP
 compared to [
68
Ga]BPAMD. 
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2.5. Ex vivo organ distribution 
The organ distribution of the 
68
Ga-labelled compounds in selected tissues at 1 h and 3 h p.i. 
in healthy male Wistar rats are presented in table 2. [
68
Ga]BPAMD showed a fast blood 
clearance (SUVblood = 0.34 ± 0.05) and a high degree of bone accumulation (SUVfemur = 3.36 
± 0.81) within 1 h, which is consistent to the µPET results, see below, and matching the 
literature data [10]. [
68
Ga]DOTAGA(428-D-Lys)M
BP
 showed an overall higher retention in 
the organism. Radioactivity in soft tissue is higher after 1 h p.i., which could be explained by 
a significant (P < 0.001) higher blood level of the albumin-binder bisphosphonate conjugate 
(SUVblood = 3.38 ± 0.31) compared to [
68
Ga]BPAMD (SUVblood = 0.34 ± 0.05). The 
accumulation on the femur of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 and [
68
Ga]BPAMD was 2.75 
± 0.46 and 3.36 ± 0.81, respectively, indicating a similar (P = 0.2) accumulation on bone 
within 1 h. [
68
Ga]BPAMD activity in blood and in soft tissue organs decrease after 3 h 
compared to 1 h p.i.. SUV of the blood pool was significantly lower with a value of 0.06 ± 
0.01 (P < 0.001) , while femur accumulation showed a value of 4.20 ± 0.20, which is similar 
to that of 1 h (P = 0.09). Biodistribution of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 after 3 h p.i. 
showed only minor changes in soft tissue compared to the 1 h values. Significant changes in 
the uptake profile were observed for blood (P ≤ 0.05) and femur (P < 0.005), with SUVblood = 
2.59 ± 0.72 and SUVfemur = 4.16 ± 0.62, respectively. No significant differences in femur 
accumulation of  [
68
Ga]DOTAGA(428-D-Lys)M
BP
 and [
68
Ga]BPAMD (P = 0.9) could be 
observed after 3 h p.i., while the different SUVs in the blood indicating significance (P < 
0.002). 
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Table 2. Ex vivo organ distribution of [
68
Ga]BPAMD and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 60 min and 180 
min p.i. 
organ 
[
68
Ga]BPAMD [
68
Ga]DOTAGA(428-D-Lys)M
BP
 
1 h 3 h 1 h 3 h 
lung 0.20 ± 0.11 0.16 ± 0.07 1.66 ± 0.12 1.31± 0.19 
liver 0.10 ± 0.02 0.06 ± 0.01 0.68 ± 0.18 0.77 ± 0.36 
spleen 0.08 ± 0.01 0.04 ± 0.01 0.50 ± 0.05 0.48 ± 0.12 
kidneys 0.25 ± 0.04 0.34 ± 0.06 1.06 ± 0.10 0.99 ± 0.21 
muscle 0.07 ± 0.02 0.03 ± 0.01 0.63 ± 0.20 0.42 ± 0.06 
heart 0.12 ± 0.02 0.04 ± 0.00 1.34 ± 0.36 0.84 ± 0.09 
intestine 0.08 ± 0.02 0.08 ± 0.08 0.55 ± 0.13 0.46 ± 0.15 
testes 0.07 ± 0.01 0.03 ± 0.00 0.50 ± 0.11 0.65 ± 0.13 
blood 0.34 ± 0.05 0.06 ± 0.01 3.38 ± 0.31 2.59 ± 0.72 
femur 3.36 ± 0.81 4.20 ± 0.20 2.75 ± 0.46 4.16 ± 0.62 
Data presented in mean SUV ± SD of five animals. 
Table 3 shows the calculated total retention of [
68
Ga]BPAMD and [
68
Ga]DOTAGA(428-D-
Lys)M
BP
 at 1 h and 3 h p.i. in the blood and the skeleton, respectively. After 1 h 36.3 ± 8.8 
%ID of  [
68
Ga]BPAMD  and 24.8 ± 3.8 %ID of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 were 
observed in the skeleton. While the total skeleton activity after 3 h showed no changes for 
[
68
Ga]BPAMD (33.7 ± 3.4 %ID) the bone accumulation of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 
(32.1 ± 4.0 %ID) increased this over time. The blood level of [
68
Ga]BPAMD dropped from 
2.3 ± 0.3 %ID (1 h) to 0.5 ± 0.1 %ID (3 h). A blood retention  of 22.9 ± 2.1 %ID after 1 h 
was observed for [
68
Ga]DOTAGA(428-D-Lys)M
BP
. After 3 h 17.2 ± 5.0 %ID of 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 still remained in the blood pool. 
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Table 3. Bone and blood accumulation of [
68
Ga]BPAMD and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 1 h and 3 h p.i. 
 [
68
Ga]BPAMD [
68
Ga]DOTAGA(428-D-Lys)M
BP
 
 1 h 3 h 1 h 3 h 
skeleton 36.3 ± 8.8 33.7 ± 3.4 24.8 ± 3.8 32.1 ± 4.0 
blood 2.3 ± 0.3 0.5 ± 0.1  22.9 ± 2.1 17.2 ± 5.0 
Data presented in mean % of injected dose ± SD of five animals. 
 
 
Figure 3. Comparison of the ex vivo organ distribution of [
68Ga]BPAMD (■) and [68Ga]DOTAGA(428-D-
Lys)M
BP
 (□) 1 h and 3 h p.i. 
 
2.6. In vivo µPET 
In vivo µPET scans were conducted over 120 min p.i. for [
68
Ga]BPAMD and 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 in one and the same animal. Images obtained after 120 min 
p.i. are consistent to the data obtained from ex vivo biodistribution experiments. The skeleton 
is clearly visible in the [
68
Ga]BPAMD PET scan with a low observed background activity. 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 showed bone uptake as well, but with a distinct higher 
background activity (Figure 4 and 5). The higher background activity is based on the lower 
blood clearance of the albumin binding bisphosphonate, which is consistent to the results 
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from ex vivo biodistribution. Organs of high perfusion like the heart and the abdominal aorta 
as well as the branching to the common iliac arteries are visible. No significant uptake in 
liver was observed for both compounds. The 
68
Ga-labelled albumin binding bisphosphonate 
as well as [
68
Ga]BPAMD were both excreted via the kidneys to the bladder. Particularly high 
accumulation of the radio tracers were found in the joint regions (figure 5), where bone 
metabolism is enhanced. 
 
Figure 4. MIP of [
68
Ga]BPAMD (A) and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 (B) after 120 min p.i. in healthy 
Wistar rats with the focus on the thorax region. 
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Figure 5. MIP of [
68
Ga]BPAMD (A) and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 (B) after 120 min p.i. in healthy 
Wistar rats with the focus on the pelvis region and the articulation between the femur and the tibia. 
Time activity curves (TAC) of the in vivo µPET data are presented in figures 6 and 7. 
[
68
Ga]BPAMD showed a fast uptake kinetics in the spine, reaching a plateau level between 
35 and 40 min p.i.. No significant changes in the SUV profile of the spine could be observed 
for the remaining scan time. The half-life in the blood of [
68
Ga]BPAMD was t1/2,α = 6.5 min. 
After 120 min only marginal changes in the uptake profile were monitored, indicating that 
the body distribution and excretion reaching its kinetic completion. In contrast, no kinetic 
endpoint could be determined for the TAC of [
68
Ga]DOTAGA(428-D-Lys)M
BP
, within 120 
min scan time. The uptake profile of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 on the spine showed a 
delay in time. No plateau level was reached after 120 min, rather the accumulation followed 
a linear progression. Blood retention was obviously improved for [
68
Ga]DOTAGA(428-D-
Lys)M
BP
 with a half-life of  t1/2,α = 36.7 min. 
TAC of [
68
Ga]BPAMD in the joint region between the femur and the tibia (figure 8) showed 
the profile of an exponential saturation function as well as in the spine region, but reaches 
after 120 min a higher plateau level (SUVjoint = 4.4; SUVspine = 2.3). The ratio in SUV 
between the joint of the femur and the tibia to the spine was 1.9, which reveals an almost 
doubled uptake of the radiotracer. TAC of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 in the joint 
region and in the spine (figure 6 and 7) showed a lower SUV compared to [
68
Ga]BPAMD. 
After 120 min the SUVs in the joint and the spine was 3.2 and 1.1, respectively. The graphs 
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in figure 6 and 7 indicate no kinetic equilibrium and after 120 min a SUV ratio of 2.9 
between the femur and the tibia articulation and the spine was determined, which is an almost 
threefold higher uptake of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 at the high metabolic bone 
region.  
 
Figure 6. Time activity curves (TAC) determined over 120 min p.i. in selected tissues of [
68
Ga]BPAMD and 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 administered in one and the same animal. 
 
Figure 7. Time activity curves (TAC) determined over 120 min p.i. in the spine and the blood of [
68
Ga]BPAMD 
and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 administered in one and the same animal. 
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Figure 8. Time activity curves (TAC) determined over 120 min in the joint region between the femur and the 
tibia of [
68
Ga]BPAMD and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 administered in one and the same animal.  
 
3. Discussion 
We studied the consequences of a chemical modification of the well evaluated 
radiopharmaceutical BPAMD, with the main purpose to retard the excretion rate of the 
DOTA-bisphosphonate. The modification includes the BPAMD scaffold by using an 
asymmetric substitution of DO2A, whereby a DOTAGA like BPAMD-derivative was 
formed. Contrary to BPAMD it is able to modify the pendant glutaric acid arm of 
DOTAGA(428-D-Lys)M
BP
 with the albumin binding moiety without losing one of the 
complexation donors to an additional amide bond. Since a potential therapy application with 
177
Lu, which is the long term goal, was kept in mind the conservation of seven donors had to 
be ensured. The new compound DOTAGA(428-D-Lys)M
BP
 could be synthesized in good 
yields. 
To proof the concept, we decided to label the ligand with the PET nuclide 
68
Ga and to 
quantitatively compare the pharmacokinetics of  [
68
Ga]DOTAGA(428-D-Lys)M
BP
 with the 
well evaluated tracer [
68
Ga]BPAMD in in vivo µPET, ex vivo organ distribution and in in 
vitro essays. DOTAGA(428-D-Lys)M
BP
 can be labelled  with n.c.a. 
68
Ga(III) in high RCY 
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between 80 and 90 %, within a reaction time of 15 min. The compound was successful 
purified via a C18 solid phase extraction cartridge, providing a RCP > 98%. Furthermore the 
new ligand showed distinctly retention on C18 HPLC columns, which is contrary to 
[
68
Ga]BPAMD where C18 phases are useless, indicating a very increased lipohilicity for 
DOTAGA(428-D-Lys)M
BP
. The aromatic benzyl group also lead to a better UV-adsorption, 
enhancing the HPLC analytics of the compound. 
No differences in the binding affinity was observed in terms of HA adsorption between 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 (81.3 ± 2.2 %) and [
68
Ga]BPAMD (81.6 ± 0.5 %) , which 
indicates that the modification of the original BPAMD had no relevant influence on the 
binding to the biological target. However, the albumin binder conjugate proofed to enhance 
the binding of the bisphosphonate on human serum proteins, revealed by an ultrafiltration 
essay. Both results indeed successfully prove that the chemical modification of BPAMD 
resulted in a compound, which exhibits the functionality of the bisphosphonate and the 
albumin binder moiety.  
Results from in vivo and ex vivo experiments in healthy rat showed a distinguished longer 
blood circulation time of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 compared to [
68
Ga]BPAMD. 
After 3 h p.i. still 22.9 ± 2.1 % of the injected dose of [
68
Ga]DOTAGA(428-D-Lys)M
BP
 were 
found in the blood compared to 0.5 ± 0.1 %ID of [
68
Ga]BPAMD. The blood half-life was 
enhanced up to t1/2,α = 36.7 min compared to t1/2,α = 6.5 min for [
68
Ga]BPAMD, deduced 
from µPET examinations. The data clearly showed the strong effect on the pharmacokinetics 
by the chemical modification of BPAMD. Uptake on healthy bone was lower for the albumin 
binder conjugate after the first hour p.i.. However, similar levels of bone accumulation (P = 
0.9) were found in the ex vivo organ distribution already after 3 h. The affinity to the serum 
protein decelerated not only the body clearance, but also the skeletal accumulation. The 
articulations are a region of enhanced bone turnover and the tested tracers showed an 
increased uptake in these focuses. The uptake ratio between the high metabolic joint region 
and the ordinary bone might be a hint about how the tracers eventually perform, when 
evaluated in a metastatic model or patients in expressing disseminated bone metastases. On 
the one hand, the total uptake in the joint and the ordinary bone is dependent on the affinity 
of the bisphosphonate to the calcified tissue and on the other hand it is dependent on the 
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bioavailability of the tracer. [
68
Ga]BPAMD showed a higher total uptake in the joints as well 
as in the ordinary bone compared to [
68
Ga]DOTAGA(428-D-Lys)M
BP
, although the affinity 
of both tracers to artificial HA is determined to be similar. But In the presence of albumin (35 
to 53 g/L in human blood), a competition between the binding to Albumin HSA and bone 
exists for [
68
Ga]DOTAGA(428-D-Lys)M
BP
 with a slight better affinity to HA tissues, 
resulting in a long term uptake mechanism but with a decreased initial accumulation.  Since 
the accumulation kinetics of [
68
Ga]BPAMD showed no relevant changes after 40 min p.i., the 
uptake ratio between the high metabolic joint region and the ordinary bone is lower (1.9) 
compared to the ratio of the chemical modified [
68
Ga]DOTAGA(428-D-Lys)M
BP
 (2.9). This 
shows that tissue compartments with an enhanced rate of turnover benefit from compounds 
of longer bioavailability. 
In conclusion, the chemical modification of BPAMD by means of a bi-substitution mode of 
the macrocyclic chelate, leads to a DOTAGA bisphosphonate of longer blood circulating 
time and delayed whole body clearance. In first µPET experiments with a 
68
Ga-labelled 
version the ratio between the high metabolic joints and the ordinary bone was better for the 
albumin binder conjugate compared to the non-modified compound. Overall bone 
accumulation became comparable already 3 h p.i.. However, the potential of DOTAGA(428-
D-Lys)M
BP
 as a therapy agent for the treatment of skeletal metastases in combination with 
therapeutic β-- emitters has to be further evaluated. The results obtained with  68Ga (t1/2 = 
1.1 h) are promising, but an overall 3 hours period is a bit short to figure out the total 
consequences of the chemical modification based on the longer kinetic profile of the new 
compound. Other PET nuclides with a longer half-life, like 
44
Sc (t1/2 = 4 h) or 
64
Cu (t1/2 = 
12.7 h) might be useful for further evaluations. Relating to a potential therapy with a 
177
Lu 
analogue PB, comprehensive dosimetric studies are necessary to determine the consequences 
of the longer blood retention.   
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4. Experimental 
4.1. General methods 
All solvents and chemicals were commercially available in analytical, HPLC or 
TraceSELECT® grade and were purchased by Sigma-Aldrich or Merck KgaA. 
68
Ga was 
obtained from a 
68
Ge/
68
Ga Obninsk generator system (Eckert & Ziegler). Proton nuclear 
magnetic resonance (
1
H-NMR) spectra were recorded on a Bruker 300, 
31
P-NMR were 
recorded on a Bruker 600. Mass spectra were recorded on Agilent Technologies 6130 
Quadrupole LC/MS spectrometer with ESI as ion source in positive or negative modes. TLC 
and radio-TLC analyses were carried out with silica on aluminium foil (Merck KgaA) and a 
Canberra Packard Instant Imager as a radiodetector. For HPLC and radio-HPLC a Waters-
system 1525 with an UV- and a radio-detector (Berthold Technologies, Germany) was used. 
Radioactivity of samples were measured with an Aktivimeter Isomed 2010, MED (Nuklear-
Medizintechnik Dresden GmbH). Radioactivity in tissue samples was determined by using a 
Wallac WIZARD2 automatic gamma counter (Perkin Elmer, Germany).  
 
4.2. Synthesis of DOTAGA(428-D-Lys)M
BP
 
1,4,7,10-tetraazacyclododecane-1,7-bis-tert.butyl diacetic acid ester (tert.butyl-DO2A) (1) 
and α-bromoglutaric acid-1-tertbutyl ester-5-benzyl ester (2) were synthesized according 
to a description published by Riss et al. [15] and Eisenwiener et al.[16]. The synthesis of 
tetraethyl chloro-acetamidomethyl-bis(phosphonate) (4) followed a procedure by Kubicek et 
al. [17]. 
Mono alkylation of (1) to compound (3): To a solution of 0.6 mg (1.69 mmol) (2) in 1 mL 
dichloromethane a solution of 1.0 g (2.5 mmol) tert.butyl-DO2A (1) in 3 mL 
dichloromethane was added slowly under vigorous stirring. The mixture was kept at room 
temperature for 48 h. After removing the volatiles under reduced pressure, the crude mixture 
was purified by column chromatography on silica (DCM:MeOH 10:1). The resulting fraction 
of monosubstituted product (3) yielded 0.85 mg (1.25 mmol, 74%) of a yellow solid. Rf 
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(silica, DCM:MeOH 10:1) = 0.6-0.7.
1
H-NMR (CDCl3, 300 MHz): δ 7.30-7.41 (m, 5H, 
benzyl-H), 5.10 (s, 2H, benzyl-CH2-O), 3.40 (t, 1H, N-CH-glut.), 3.24-3.36 (m, 4H, N-CH2-
CO), 2.68-3.04 (m, 16H, cyclen-CH2-N), 2.46-2.54 (m, 2H, CH2-CH2-CO), 1.88-2.04 (m, 
2H, CH2-CH2-CH), 1.43 (s, 27H, t-Bu). ESI-MS(+): cald 676.9 obsd 678 (M + H
+
), 339.5 (M 
+ 2H
+
). 
(5) was synthesized by dissolving 304 mg (0.45 mmol) (3) in 5 mL dry acetonitrile. 
Potassium carbonate (1.3 mmol) was added and 1.5 eq. (255 mg, 0.67 mmol) of the chloro 
compound (4) was added dropwise over a period of 1 h to the suspension. The reaction 
mixture was kept at 40°C and under stirring for 24 h. Charcoal was added and the solids were 
removed by filtration. After evaporation of the solvent, the resulting oil was purified by 
column chromatography on silica phase (CHCl3:MeOH 10:1), yielding 234 mg (0.23 mmol, 
51%) of a yellow oil. Rf (silica, CHCl3:MeOH 10:1) = 0.3-0.4.
1
H-NMR (CDCl3, 300 MHz): 
δ 7.31-7.44 (m, 5H, benzyl-H), 5.11 (s, 2H, benzyl-CH2-O), 4.09-4.42 (m, 8H, O-CH2-CH3; 
m, 1H, P-CH-P), 3.67-3.78 (q, 1H, N-CH-glut.), 3.49 (bs, 6H, N-CH2-CO), 2.01-3.02 (bm, 
20H), 1.46 (s, 27H, t-Bu), 1.35 (t, 12H, CH2-CH3). ESI-MS(+): cald 1019.5 obsd 1020 (M + 
H
+
), 510 (M + 2H
+
). 
Reaction of (5) to (6): 234 mg (0.23 mmol) (5) was dissolved in 10 mL methanol and 
10%w/w Pd/C was added. The mixture was kept in a pressured vessel for 24 h under 
hydrogen atmosphere (6 bar). After filtration over celite the volatiles were evaporated to 
dryness. The crude product (217.6 mg, 96%) was used in the next step without any need for 
purification. The acid of (5) was dissolved in 5 mL dry dichloromethane, followed by an 
addition of 72.3 mg (0.2 mmol) HATU ((1-[bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate)) and 65 mg (0.5 mmol) DIPEA (N,N-
diisopropylethylamine). The mixture was stirred at room temperature until any solids were 
dissolved. Subsequently 63.85 mg (0.19 mmol) H-D-Lys(Z)-OMe (Merck KgaA, Germany) 
was added in small portions and the solution was kept stirring overnight. The reaction 
mixture was diluted up to 25 mL with dichloromethane and extracted three times with an 
equivolume of 0.1 M Na2CO3, 0.1M NaH2PO4 and finally with water. The organic fraction 
was evaporated to dryness and the crude product was purified by column chromatography on 
silica (CHCl3:MeOH 10:1). The fractions containing the product were combined and after 
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removing the solvents 180.6 mg (0,15 mmol, 65%) of a yellow oil was obtained. Rf (silica, 
CHCl3:MeOH 10:1) = 0.2-0.3.
1
H-NMR (CDCl3, 300 MHz): δ 7.32-7.40 (m, 5H, benzyl-H), 
5.10 (s, 2H, benzyl-CH2-O), 4.41-4.51 (m, 1H, P-CH-P) 4.07-4.33 (m, 8H, O-CH2-CH3), 
3.73 (bs, 6H, N-CH2-CO), 1.64-3-69 (bm, 30H, N-CH-glut, cyclen-H, glut-H, lys-H), 1.47 (s, 
27H, t-Bu), 1.36 (t, 12H, CH2-CH3). ESI-MS(+): cald 1206.34 obsd 603,8 (M + 2H
+
).  
Reaction of (6) to (7): 180.6 mg (0.15 mmol) of (6) dissolved in methanol was kept under 
hydrogen atmosphere with 10%w/w Pd/C for 12 h. After removing the solids and the solvent 
the resulting colourless oil (151.4 mg, 95%) was used without further purification. 48.7 mg 
(0.17 mmol) 4-(p-iodophenyl)butyric acid (Sigma-Aldrich) was dissolved in 2 mL N-methyl-
2-pyrrolidone (NMP) together with 63.9 mg (0.17 mmol) HATU and 54.26 mg (0.45 mmol) 
DIPEA. The mixture was incubated at room temperature for 15 min, until it was added to a 2 
mL NMP solution containing the amine from (6). The reaction mixture was stirred overnight 
and the solvent was removed in vacuum. The crude residue was dissolved in 20 mL 
dichloromethane and extracted three times with an equivolume of 0.1 M Na2CO3, 0.1 M 
NaH2PO4 and finally with water. After column chromatography on silica (CHCl3:MeOH 
20:1) a pale foam of 147.8 mg (0.11 mmol, 73%) was obtained. Rf (silica, CHCl3:MeOH 
20:1) = 0.3-0.4. ESI-MS(+): cald 1343.57 obsd 672.8 (M + 2H
+
).  
The final product DOTAGA(428-D-Lys)M
BP
 (8) was obtained by successive dealkylation of 
(7). 147.8 mg (0.11 mmol) (7) was dissolved in a mixture of DCM/TFA 2:3 and stirred for 12 
h. After evaporation of the volatiles the remaining TFA was removed by repeated co-
evaporation with MeOH. Subsequently, the colourless solid was dissolved in 2 mL DMF and 
20 eq. (340 mg) of trimethylsilyl bromide (TMS-Br) was added under argon atmosphere. The 
reaction mixture was kept at room temperature and by exclusion of light for 12 h, until the 
volatiles were removed under reduced pressure. Hydrolysis of the TMS-ester was realized by 
dissolving the crude red oil in methanol. After 12 h the mixture was evaporated to dryness, 
yielding 101.2 mg (85%) of the crude product which was further purified by semi preparative 
reversed phase HPLC (Hydrosphere C-18, 5µ, 250 x 10 mm, YMC, Japan) by using a solvent 
gradient (3 mL/min) of 100% water to 80% acetonitrile. Fractions containing the product 
were determined by ESI-MS(˗) and were combined. After lyophilisation 80 mg (69%) of a 
white solid was obtained. 
1
H-NMR (D2O/NaOD, 300 MHz): δ 7.63 (d, 2H, benzyl-H, JH=8.2 
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Hz), 7.02 (d, 2H, benzyl-H, JH=8.2 Hz), 3.33 (bs, 6H, N-CH2-CO), 3.19 (t, 2H, alkyl-H), 2.60 
(t, 2H, alkyl-H) 1.2-2.6 (bm, 32H, cyclen-H, alkyl-H). 
31
P-NMR (D2O/NaOD, 162.05 MHz): 
δ 14.87 ESI-MS(˗): cald 1049.24 obsd 524 (M ˗ 2H+). 
 
4.3. Radiolabelling with n.c.a. 
68
Ga and quality control 
50 µg (48 nmol) of DOTAGA(428-D-Lys)M
BP
 was dissolved in 500 µL of a 0.5M sodium 
acetate buffer at pH = 4 and added to n.c.a. 
68
Ga (300-600 MBq), which was obtained in 400 
µL acetone/HCl from a 
68
Ge/
68
Ga generator system by cationic post processing [18]. The 
solution was kept under moderate shaking on a thermo shaker for 15 min at 98°C. 
Subsequently the solution was diluted up to 2 mL with deionized water and passed over a 
SPE cartridge (Strata X, Phenomenex). The solid phase was first washed with 3 mL of water 
followed by the elution of the purified product with 1 mL of an ethanol/water mixture. 
Aliquot samples were taken for radio HPLC (Hydrosphere C-18, 5µ, 250 x 10 mm, YMC, 
Japan, solvent A: H2O B: ACN, 5 mL/min gradient flow) and TLC (silica, solvent: 0.1 M 
citrate buffer pH = 4) analysis. 
[
68
Ga]BPAMD was prepared by dissolving 20 µg (33 nmol) of BPAMD in 500 µL 0.5M 
sodium acetate buffer at pH = 4. 400 µL n.c.a. 
68
Ga solution was added and the reaction kept 
on a thermo shaker for 15 min at 98°C. The solution was diluted with water up to 5 mL and 
passed over a SPE cartridge (Isolute NH2, Biotage). The cartridge was washed with 1 mL 
water followed by the elution of the purified [
68
Ga]BPAMD with 2 mL phosphate buffered 
saline (PBS). Aliquot samples were taken for radio-HPLC (MultoKrom 100 C18, 5µ, 250 x 4 
mm, CS-Chromatographie, Germany, solvent A: 10 mM tetrabutylammonium citrate pH = 
4.5 B: ACN, 1 mL/min gradient) and TLC (silica, solvent: acetone/acetylacetone/HCl, 
10:10:1). 
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4.4. Adsorption experiments on apatite 
20 mg of hydroxy apatite (HA) powder (Sigma-Aldrich, Germany) was incubated for 24 h in 
1 mL isotonic saline. 50 µL of the 
68
Ga-labelled bisphosphonate solution (prepared as 
described above) was added and vortexed for 15 seconds. After 10 minutes the HA was 
centrifuged at 10 x g and the supernatant was removed. 0.5 mL isotonic saline was added to 
the Ha fraction, vortexed for 15 seconds and centrifuged again. The supernatant was removed 
and combined with the first solution. Radioactivity was determined in the combined 
supernatants and the 
68
Ga-complex binding to HA was calculated as percent of 
68
Ga absorbed 
to HA [4]. 
 
4.5. Protein binding assay 
Binding to serum proteins of [
68
Ga]BPAMD and [
68
Ga]DOTAGA(428-D-Lys)M
BP
 was 
determined by ultrafiltration. 50 µL of each radio tracer was added to 200 µL human serum 
samples (Sigma-Aldrich, Germany), vortexed and incubated for 1 min. The sample was 
transferred to a centrifugal device (Nanosep®, 30K, Pall Corporation, USA) containing a 
filtration membrane which separates proteins from small molecules. As a control the radio 
tracers were incubated in isotonic saline. The ultrafiltration device was centrifuged for 45 
minutes, until 50 µL of isotonic saline was added to wash the filter by an additional 15 
minute centrifugation step. Radioactivity was counted in the filter and the filtrate solution 
and calculated as a fraction of the total activity, which was set to 100% [13]. 
 
4.6. Animal studies 
The experimental procedure used conforms to the European Convention for the Protection of 
Vertebrate Animals used for Experimental and other Scientific Purposes (ETS No. 123), and 
to the Deutsches Tierschutzgesetz (German animal welfare regulations). Male Wistar rats 
(154 ± 24 g, N = 10, 1 h; 215 ± 18 g, N = 12, 3 h) were purchased from Charles River 
Laboratories International, Inc. For dynamic in vivo µPET studies, the animal was 
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anesthetized with isoflurane and placed in supine position in the PET scanner (Siemens 
microPET, Focus 120). An infrared lamp was used to maintain body temperature. 19.8 MBq 
[
68
Ga]BPAMD (107 MBq per Kg body weight) and 17.0 MBq [
68
Ga]DOTAGA(428-D-
Lys)M
BP
 (92 MBq per Kg body weight) in 0.5 mL isotonic saline were administered 
intravenously using a needle catheter into the tail vein. The focus of the µPET scanner was 
adjusted to the thorax region. Each compound was tested in one and the same animal in a 
time distance of two days. In an additional experiment the focus of the µPET scanner was 
adjusted to the pelvis region to examine the tracer accumulation in the articulation between 
the femur and the tibia. The experiment was done in the same animal with in a timescale of 
two days. 16.3 MBq [
68
Ga]BPAMD  (80 MBq per Kg body weight) and 16.1 MBq 
[
68
Ga]DOTAGA(428-D-Lys)M
BP
 (79 MBq per Kg body weight) in 0.5 mL isotonic saline 
were administered intravenously. All images were reconstructed to OSEM2D and processed 
using Pmod (PMOD Technologies Ltd.) software. 
Ex vivo organ distribution was carried out in five animals (160-210 g) per time point and 
compound. A mean dose of 10 ± 2 MBq of the 
68
Ga-labelled bisphosphonates in 0.5 mL 
isotonic saline were injected intravenously in the tail vein. Animals were sacrificed at 1 h and 
3 h after injection. The organs of interest were excised, weighted and the radioactivity in the 
samples were measured decay- and background-corrected on an automated gamma counter. 
Data were normalized to the body weight (BW) and expressed in SUV, determined by the 
formula: (activity per g tissue)/(injected activity) × BW. The activity in the skeleton was 
calculated by using the activity concentration in the femur and the total skeleton weight 
(calculated as: skeleton weight (g) = 9.66 + 0.0355 × BW (g)) [10]. Blood density was set to 
1.05 mg/mL. The blood volume (BV) of the Wistar rats were calculated using the formula: 
BV (mL) = 0.06 × BW (g) + 0.77 to determine total blood activities of the radio tracers [19]. 
 
4.7. Statistical analysis 
All data were expressed as mean ± SD. Groups were compared using the t-test. All statistical 
tests were two tailed, with a P-value of less than 0.05 representative for significance. 
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Abstract 
General: Metastatic bone lesion is a common syndrome of many cancer diseases in an 
advanced state. The major symptom is severe pain, spinal cord compression and pathological 
fracture, associated with an obvious morbidity. Common treatments including systemic 
application of bisphosphonate drugs aim on pain reduction and on improving the quality of 
life of the patient. Particularly patients with multiple metastatic lesions benefit from bone-
targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in 
routine clinical praxis are, for example, [
89
Sr]SrCl2 and [
153
Sm]EDTMP. No carrier added 
(n.c.a.) 
177
Lu is remarkably suitable for an application in this scope. 
Methods: Five DOTA and DO2A based bisphosphonates, including including monomeric 
and dimeric structures and one NO2A derivative, were synthesized and labelled with n.c.a. 
177
Lu. Radio-TLC and HPLC methods for quality control were successful established. Their 
stability and binding to hydroxyapatite were measured in vitro. Ex vivo biodistribution 
experiments and dynamic in vivo SPECT/CT measurements were performed in healthy rat 
for 1 hour time points. Data on %ID/g or SUV for femur, blood and soft tissue organs were 
analysed and compared with [
177
Lu]citrate. 
Results: Radiolabeling yields for 
177
Lu-DOTA and NO2A monomeric bisphosphonate 
complexes was >98% within 15 minutes. The dimeric macrocyclic bisphophosphonates 
showed a decelerated labelling kinetic reaching a plateau after 30 min of a RCY = 60 to 
90 %. All 
177
Lu-bisphosphonate complexes showed exclusively accumulation in the skeleton. 
Blood clearance and renal elimination were fast (t1/2α,blood = 5-10 min) After 60 min SUV data 
in the femur ranged from 3.34 to 5.67. The bone/blood ratios were between 3.6 and 135.6, 
correspondingly. 
177
Lu-bisphosphonate dimers showed a slightly higher bone accumulation 
(SUVfemur = 4.48 ± 0.38 for [
177
Lu]DO2A(P
BP
)2; SUVfemur = 5.41 ± 0.46 for 
[
177
Lu]DOTA(M
BP
)2) but a decreased blood clearanced (SUVblood = 1.25 ± 0.09 for 
[
177
Lu]DO2A(P
BP
)2; SUVblood = 1.43 ± 0.32 for [
177
Lu]DOTA(M
BP
)2), after 60 min. In 
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conclusion, 
177
Lu-complexes of macrocyclic bisphosphonates might be become therapy 
options for skeletal metastases. 
 
1. Introduction 
The treatment of cancer is one of the most important challenge of mankind. In the year 2012 
worldwide 8.2 million people died in consequence of this disease, while 32.6 million are 
living with cancer [1]. Quite often the bones are afflicted by invasive primary tumours. These 
bone metastases occur for example in 65 % to 80 % of patients with breast and prostate 
cancer [2]. The fatal consequences are various, including bone fractures, hypercalcaemia, 
spinal cord and nerve-compression and severe bone pain syndromes [2,3]. The overall 
prediction for a cure is poor and the common therapy tends, in the present, to a palliative 
care. Since skeletal metastases disturb the close metabolic balance between the activity of 
osteoblasts and osteoclasts, bone seeking radiopharmaceuticals showed promising results in 
the last decades both for diagnosis and therapy [3]. The mechanism of the therapy effect is 
the synergy of an enhanced accumulation of osteotropic agents on the metastatic lesion and 
the energy deposit by particle radiation (β-, inner conversion or α-particles). One of the 
earliest therapeutic concepts was the administration of 
89
SrCl2 as a calcium mimetic [4]. 
While 
89
Sr showed unfavourable nuclear properties in the such as β-energy and half-life 
(βmax = 1.5 MeV, t1/2 = 50.d d) [5], new radiopharmaceuticals, like [
153
Sm]Sm-EDTMP were 
utilized. More radionuclides are under consideration such as IC-transforming 
117m
Sn. 
Recently, α-emitting [223Ra]RaCl2 was introduced [3].  
The potential of lanthanide radionuclides for bone targeting was recognized early [6]. 
Skeletal 
177
Lu-images were obtained with the Anger camera already in the 60´s [7]. The γ-
photons of 113 keV (6.4%) and 208 keV (11.4%) [8] from the 
177
Lu decay are a pleasant side 
effect for the usage in Single Photon Computed Tomography (SPECT), whereas today the 
focus of 
177
Lu-compounds is mainly on the therapeutic benefit of the β--emission. 177Lu-
labelled somatostatine analogs are successfully used in the treatment of neuroendrocrine 
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tumours in the peptide receptor radionuclide therapy (PRRT) [9]. The ideal nuclide 
properties of a half-life of 6.7 d and the maximum β-energy of 0.497 MeV [8] together with 
the carrier free production route, makes 
177
Lu an interesting candidate in the treatment of 
skeletal metastases. 
In the early times of radiopharmacy it was discovered already that the addition of chelating 
agents alters the biological distribution of lanthanides from primary liver up-take to almost 
exclusively bone accumulation [7]. “Bone seeking” polycarboxy-polyphosphates like 
EDTMP (ethylenediamine tetra(methylene phosphonic acid)) showed promising first results 
[10,11]. Due to their low stability with lanthanide ions (logK = 14.4 ) [12] a high EDTMP 
concentration in the blood pool is necessary for a stable complexation in vivo, which 
consequently creates a high amount of carrier [13]. As opposed to these open chain, 
macrocyclic chelators, like DOTA (1,4,7,10-tetraazacyclododecane N,N',N",N'"-tetra-acetic 
acid) show a very strong thermodynamic and kinetic stability (logK = 25.4) with 
lanthanides[14,15]. Even equimolar metal to DOTA ratios show well complexation and in 
vivo stability results. Initial experiments with phosphonic acid derivatives (DOTP) of DOTA 
complexed with 
177
Lu showed sufficient bone accumulation and low uptake in soft tissue 
[16]. 
Theranostic concepts, which in one compound combine imaging and therapy modalities, 
come more and more into the focus also in nuclear medicine. An ideal chelator based PET 
(positron emission thomography) nuclide is the generator derived 
68
Ga. In contrary to the 
177
Lu outcomes, [
68
Ga]EDTMP and [
68
Ga]DOTP showed only disappointing results [17,18]. 
The first compound, which yielded excellent 
68
Ga-PET was the DOTA-based bisphosphonate 
BPAMD (for formula see Chart 1) [19,20]. [
68
Ga]BPAMD-PET/CT showed uptake values on 
disseminated bone metastases as high as 
18
F-fluoride, sometimes even superior [21]. 
Recently, the NOTA-derivative [
68
Ga]NO2AP
BP
 was identified to show even improved 
imaging quality [22]. The current question is, whether analogue macrocyclic bisphosphonate 
ligands can directly converted from 
68
Ga complexes to 
177
Lu analogues, i.e. retaining organ 
uptake and pharmacology profiles known from Ga(III) structures, or whether an alternative 
ligand chemistry is needed to match the coordination features of Lu(III). 
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Chart 1. Structure of ligands discussed in this paper. 
Currently, several new macrocyclic bisphosphonates are intensely discussed in the literature 
as candidates for complex formation with 
177
Lu and 
90Y and subsequent “bone seeking” 
parameters, including hydroxy bisphosphonates [23] and phosphinates (Chart 1) [24]. In this 
paper the biodistribution and bone accumulation of various macrocyclic bisphosphonates, 
including two dimeric DOTA and one NO2A (1,4,7-triazacyclononane-1,4-diacetic acid) 
compounds (Chart 1) were studied in a healthy rat model. The ligand synthesis, in particular 
the synthesis of the new dimeric bisphosphonates DO2A(P
BP
)2 and DOTA(M
BP
)2 as well as 
labelling, radio-analytics with 
177
Lu are reported. All the 
177
Lu species were investigated in 
healthy rats in in vivo small animal SPECT and ex vivo organ distribution (1 h p.i.) studies 
and SUV data were determined (n=4) of the interested organs. 
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2. Experimental 
Chemicals: Chemicals and solvents were commercially available in analytical or HPLC 
grade and were purchased from Sigma-Aldrich or Merck KGaA 
Analytics: Proton nuclear magnetic resonance (
1
H-NMR) spectra were recorded on a Bruker 
300, 
31
P-NMR were recorded on a Bruker 600. NMR shifts were referenced to internal TMS 
or externally referenced to 85 % aq. H3PO4 signal. Mass spectra were recorded on Agilent 
Technologies 6130 Quadrupole LC/MS spectrometer with ESI as ion source in positive or 
negative modes. TLC analyses of the ligand and intermediates during their synthesis were 
carried out with silica on aluminium foil (Merck). 
Radio-TLC analysis of labelled compounds were carried out with silica on aluminium foil 
(Merck) or RP18 on alumina and a Canberra Packard Instant Imager. Radio-HPLC was 
performed on a Hewlett Packard Series 1100 with a Raytest (Radeberg, Germany) Ramona 
radiodetector. Radioactivity of samples was measured with an Aktivimeter Isomed 2010, 
MED (Nuklear-Medizintechnik Dresden GmbH).  
Radionuclides: N.c.a. 
177
Lu was produced via the 
176
Yb-based neutron capture pathway 
provided by ITG (Garching, Germany) as LuCl3 in 0.05 M HCl [25]
.
 
 
2.1. Synthesis of the dimeric bisphosphonates DOTA(M
BP
)2 and DO2A(P
BP
)2 
1,4,7,10-tetraazacyclododecane-1,7-bis-tert.butyl diacetic acid ester (tert.Butyl-DO2A) [26], 
tetraethyl chloro-acetamidomethyl-bis(phosphonate) (1), 
tetraethyl{[(ethoxyhydrophosphoryl)methyl]methylene} bis(phosphonate) (4) and the 
compounds DOTAM
BP
, DO3AP
BP
, DOTAM
EBP
 and NO2AP
BP
 were synthesized according 
to the published literature [22,27,28]. 
DOTA(M
BP
)2 in ester form (2): Tert.Butyl-DO2A (200 mg, 0.5 mmol) was dissolved in 50 
mL dry acetonitrile. Potassium carbonate ( 10 eq., 5 mmol, 691 mg) was added and the 
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mixture was heated to 40
o
C. tetraethyl chloro-acetamidomethyl-bis(phosphonate) (1) (5 eq., 
2.5 mmol, 948 mg) was dissolved in 25 mL dry acetonitrile and added drop wise to the 
DO2A solution. The reaction mixture was kept at 40
o
C for 24 h under stirring and Argon 
atmosphere. Activated charcoal was added, the solution was filtered and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography 
(silica phase using a solvent mixture of NH4OH:MeOH:EA (1:4:15). Rf = 0.2-0.4) resulting 
in a yellow oil (308.5 mg, 57%). 
1
H-NMR (CDCl3, 300 MHz): δ 1.37 (m, 24H, CH2-CH3), 
1.46 (s, 18H, t-Bu), 2.6-3.0 (bs, 8H, cyclen- CH2-N), 3.1-3.5 (bs, 8H, cyclen- CH2-N), 3.5 (s, 
8H, N-CH2-CO), 4.23 (m, 8H, CH2-CH3),
 31
P-NMR (CDCl3, 162.05 MHz): δ 7.78 (s, 2P). 
ESI-MS(+): cald 1086.49 obsd 1087.50 (M + H
+
), 1109.48 (M + Na
+
). 
DOTA(M
BP
)2 (3): The protected compound (2) (308.5 mg, 0.29 mmol) was dissolved in dry 
dichloromethane and Trimethylsilylbromide (20 eq., 6 mmol, 920 mg) was added at room 
temperature under argon atmosphere. The reaction mixture was stirred overnight and 
volatiles were removed under reduced pressure. The resulting red oil was dissolved in 
methanol and stirred for 5 h until the solvent was removed. The residue was kept under high 
vacuum to remove volatiles until no change in weight was observed. Subsequent a 2:1 
mixture of TFA/DCM was added and the mixture was stirred overnight under argon 
atmosphere. After removing the solvents under reduced pressure the crude compound was 
purified two times by recrystallization from boiling water. The precipitating white solid was 
filtered, washed with ethanol and dried in vacuum with a yield of 140 mg (64%). 
1
H-NMR 
(D2O/NaOD, 300 MHz): δ 2.84 (bs, 8H, cyclen-CH2-N), 2.92 (bs, 8H, cyclen-CH2-N), 3.37 
(bs, 4H, N-CH2-CO), 3.64 (bs, 4H, N-CH2-CO), 4.38 (t, 2H, P-CH-P, 
2
JPH=18.22 Hz). 
31
P-
NMR (H2O/NaOD, 162.05 MHz): δ 13.5. ESI-MS(–): cald 750.42 obsd 749.21 (M – H
+
), 
374.10 (M – 2H+). 
DO2A(P
BP
)2 in ester form (5): To a solution of bisphosphonate (4) (2.4 g, 6 mmol) in 70 mL 
dry toluene 601 mg tert.Butyl-DO2A (0.25 eq., 1.5 mmol) and 180 mg (1 eq., 6 mmol) 
paraformaldehyde was added. The reaction solution was stirred under reflux for 24 h. The 
solvent was removed under reduced pressure and the residue was purified by column 
chromatography (silica gel, NH4OH:MeOH:EA (1:4:15). Rf = 0.2-0.3) resulting in 625 mg 
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(35%) of a pale yellow oil. 
31
P-NMR (CDCl3, 162.05 MHz): δ 22.3 (m, 4P), 36.3 (m, 2P). 
ESI-MS(+): cald 1212.52 obsd 1213.51 (M + H
+
), 1236.53 (M + Na
+
). 
DO2A(P
BP
)2 (6): The protected bisphosphonate (5) (625 mg, 0.52 mmol) was dissolved in 50 
mL 6 M aqueous HCl and kept at a temperature of 100
o
C for 24 h. The solvent was 
evaporated under reduced pressure and the excess of HCl was removed by repetitive co-
evaporation from deionized water. The crude product was passed over a strong cation 
exchanger (Dowex 50, H
+
-form) and the aqueous solution was dried by lyophilisation. The 
white solid was further purified by recrystallization from boiling water. Precipitation was 
initiated by adding small volumes of ethanol. The white solid (337 mg, 79%) was filtered, 
washed with ethanol and dried in vacuum. 
1
H-NMR (D2O/NaOD, 300 MHz): δ 2.56 (m, 4H 
–CH2–CH), 3.1 (bs, 8H, cyclen-CH2-N), 3.3 (bs, 8H, cyclen-CH2-N), 3.4 (bs, 4H, N-CH2-P) 
3.5 (m, 2H, P-CH-P) 3.7 (bs, 4H, N-CH2-CO). 
31
P-NMR (D2O/NaOD, 162.05 MHz): δ 22.01 
(s, 4P), 43.50 (s, 2P). ESI-MS(–): cald 820.08 obsd 819.04 (M – H+), 409.00 (M – 2H+). 
 
2.2. Radiolabelling with n.c.a. 
177
Lu and quality control 
Labelling of bisphosphonates with n.c.a. 
177
Lu was performed in 0.1 M sodium acetate buffer 
at pH = 4, by adding 4 volume equivalents of buffer to a solution of 
177
LuCl3 in 0.05 M HCl. 
A 10 molar excess, based on 
177
Lu concentration, of bisphosphonate containing chelator was 
added and the solution was kept on a thermo shaker at 98ºC up to 30 minutes. [
177
Lu]citrate 
was prepared by adding 100 µL 
177
LuCl3 in 0.05 M HCl to 100 µL of 0.25 M citrate buffer. 
Radiochemical yields (RCY) were determined by radio-HPLC (Zorbax 300SB-C18, 9.4 x 
250 mm 5µ, solvent: 100 mM tetraethylammonium phosphate  pH=2.24, 1 mL/min isocratic 
flow) and were cross-checked by two radio-TLC methods (silica, solvent: 0.1 M citrate 
buffer pH 4 and RP18 on alumina, solvent: 100 mM tetraethylammonium phosphate  
pH=2.24 + 20% ACN).  
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2.3. Animal studies 
The experiments were realized corresponding to the german animal welfare regulations, 
institutional guidelines and with the permission of the local animal research committee at the 
Landesdirektion Dresden. All experimental procedures are following the guidelines of the 
European Convention for the Protection of Vertebrate Animals used for Experimental and 
other Scientific Purposes (ETS No. 123). Male Wistar rats weighing157.69 ± 17.10 g (mean ± 
SD, N = 35), were purchased from Unilever (HsdCpb:WU, Harlan Winkelmann, Borchen, 
Germany). Anaesthetization was initiated and maintained by desflurane and animals were put 
in the supine position and placed on a heating pad to maintain body temperature. A needle 
catheter was used for administration of the tracers in the tail vein. A second catheter was 
introduced into the right femoral artery for the extraction of blood samples for metabolite 
analysis, which was routinely done during SPECT/CT measurements.  
 
2.4. Ex vivo organ distribution 
The male Wistar rats received a short term anaesthetization by desfluran inhalation and a 
mean activity of 2.36 ± 0.27 MBq/kg of the 
177
Lu labelled tracers in isotonic saline were 
injected in a volume of. 0.5 mL in the tail vein, with the following specific details: 
[
177
Lu]citrate: 2.56 ± 0.07 MBq/kg, 128.58 body-weight (BW, g), n = 4 (g); [
177
Lu]BPAMD: 
2.33 ± 0.11 MBq/kg, 159.41 BW (g), n = 4 (g); [
177
Lu]BPAPD: 2.58 ± 0.24 MBq/kg, 156.38 
BW (g), n = 4 (g); [
177
Lu]BPPED: 2.27 ± 0.25 MBq/kg, 153.43 BW (g), n = 4 (g); 
[
177
Lu]NO2AP
BP
: 2.52 ± 0.25 MBq/kg, 173.82 BW (g), n = 4 (g); [
177
Lu]DOTA(M
BP
)2: 
1.80 ± 0.10 MBq/kg, 181.64 BW (g), n = 4 (g); [
177
Lu]DO2A(P
BP
)2: 2.46 ± 0.15 MBq/kg, 
150.60 BW (g), n = 4 (g). Animals were sacrificed after 60 min p.i. and organs of interest 
were excised rapidly, weighted and the 
177
Lu activity was determined with a Wallac 
WIZARD automatic gamma counter (PerkinElmer, Germany) and were decay corrected. The 
distribution data is expressed in %ID/g tissue or is normalized to the BW as SUV (standard 
uptake value), which was calculated with the formula: SUV = (activity per g tissue)/(injected 
activity) × BW. The skeleton weight was calculated using: skeleton weight = 9.66 + 0.0355 × 
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BW and the total activity associated with the skeleton was calculated by using the activity 
concentration in the femur and the total skeleton weight [29]
.
 
 
2.5. Metabolite Analysis and in vivo stability 
Arterial blood plasma samples were taken during SPECT/CT examinations after 1, 3, 5, 10, 
20, 30, 60 and 120 min. p.i. and the in vivo metabolism of [
177
Lu]BPAMD, [
177
Lu]BPAPD, 
[
177
Lu]BPPED, [
177
Lu]NO2AP
BP
, [
177
Lu]DOTA(M
BP
)2 and [
177
Lu]DO2A(P
BP
)2 was 
analyzed. Plasma was separated by centrifugation (3 min, 11000 g) followed by precipitation 
of the plasma proteins with ice-cold methanol (1.5 parts per 1 part plasma) and centrifugation 
(3 min, 11000 g). The supernatants were analyzed by radio-TLC and HPLC using the above 
mentioned methods for quality control. Additionally urine samples were treated in the same 
way prior radio-TLC and radio-HPLC analysis. 
 
2.6. SPECT/CT 
Tracer accumulation in vivo was monitored with a nanoScan
®
 SPECT (Mediso Medical 
Imaging Systems, Budapest, Hungary) scanner. CT images were obtained with a nanoScan
®
  
PET/CT (Mediso Medical Imaging, Budapest Hungary) scanner. Rats were prone and head 
first positioned. The animals were anesthetized by 5% desflurane inhalation.  
 
2.8. Statistical analysis 
The statistical analyses was performed by using GraphPad Prism (V5.02 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com). Data are expressed as 
an average ± standard deviation (S.D.). Two tailed students t-test was usually done to 
compare groups of data. 
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3. Results 
3.1. Synthesis 
The pendant arms (1) and (4) were prepared as described in literature procedures (see 
experimental part) in good yields. Alkylation of DO2A was done by a nucleophilic 
substitution (2) or by a mannich like reaction (5), followed by a two-step cleavage (3) of the 
protection groups, by using trimethylsilyl bromide as a mild and efficient de-esterification 
agent of ethyl protected bisphosphonates and trifluoroacetic acid for the t-butylesters of the 
carboxylic acid arms. 6 M aqueous HCl was used to de-protect the phosphinate compound 
(6) (Scheme 1). The final dimeric bisphosphonates DOTA(M
BP
)2 (3) and DO2A(P
BP
)2 (6) 
were obtained in moderate yields after resin and recrystallization purification. 
Scheme 1. Synthesis of DOTA(M
BP
)2 and DO2A(P
BP
)2 
 
i) K2CO3, acetonitrile, 40
o
C ii) 1. TMS-Br, DCM, RT; 2. MeOH; 3. TFA/DCM, RT. 
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i) Toluene, H2CO, reflux ii) 6 M HCl. 
 
3.2. Radiolabelling with n.c.a. 
177
Lu and quality control 
The DOTA, DO2A and NO2A conjugated bisphosphonates were successfully labelled with 
n.c.a. 
177
Lu(III). Yields and purities were controlled by radio-TLC and HPLC (Figure 1) All 
bisphosphonates showed a very fast complexation kinetic. Since DOTA derivatives show a 
very excellent complexation ability with lanthanides, a radiochemical yield (RCY) of more 
than 98% was obtained for the abovementioned compounds within 30 minutes. Even the 
NO2A based bisphosphonate NO2AP
BP
 showed an excellent labelling efficiency. 
Complexation occurred fast and quantitative (RCY > 99%). 
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Figure 1. Radio-HPLC chromatograms of [
177
Lu]BPAMD, [
177
Lu]BPAPD and [
177
Lu]NO2AP
BP
 as a 
representative for 
177
Lu-labelled bisphosphonates in comparison to 
177
Lu
3+
.  
 
3.3. Biodistribution 
The 
177
Lu-labelled bisphosphonates showed a similar organ distribution with a predominant 
accumulation in the skeleton, cf. table 1 and 2. Besides the bone an appreciable amount of 
activity was found in the kidneys, which is reasonable according to the compounds renal 
clearance. Considerable liver accumulation was only observed for [
177
Lu]citrate and 
[
177
Lu]DOTA(M
BP
)2 with SUVs of 1.04 ± 0.09 and  0.69 ± 0.36, respectively. After 60 min 
p.i. the SUV in the femur for the monomeric DOTA conjugates was 4.84 ± 0.44 for 
[
177
Lu]BPAMD, 4.05 ± 0.36 for [
177
Lu]BPAPD and 5.67 ± 0.10 for [
177
Lu]BPPED. The SUV 
for the dimeric bisphosphonate compounds was 4.48 ± 0.38 for [
177
Lu]DO2A(P
BP
)2 and 
5.41 ± 0.46 for [
177
Lu]DOTA(M
BP
)2 in the femur. [
177
Lu]NO2AP
BP
 showed a femur SUV of  
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3.34 ± 0.38 and [
177
Lu]citrate showed a SUV of 4.12 ± 0.38 after 60 min p.i., respectively. 
SUVs in blood, liver and kidney showed the strongest variations between the tested 
compounds. Highest blood levels were determined for the dimeric compound 
[
177
Lu]DOTA(M
BP
)2 with a SUV of 1.43 ± 0.32 after 60 min p.i. Lowest blood SUV of 0.04 
± 0.01 was obtained for [
177
Lu]BPAMD and [
177
Lu]BPAPD. The SUV in the liver was 
highest for [
177
Lu]citrate with a value of 1.04 ± 0.09, contrary to the bisphosphonates which 
showed a consistently low liver accumulation, with a SUV of 0.04 ± 0.01 for [
177
Lu]BPAMD 
for example. Activity accumulation in the kidneys was lowest for [
177
Lu]BPAMD and 
[
177
Lu]BPAPD with SUVs of 0.35 ± 0.06 and 0.39 ± 0.06, respectively. Highest kidney 
concentrations were found for the dimeric bisphosphonates [
177
Lu]DO2A(P
BP
)2 and 
[
177
Lu]DOTA(M
BP
)2 as well as for [
177
Lu]citrate with SUVs of 1.66 ± 0.40, 1.41 ± 0.16 and 
1.41 ± 0.11, respectively. The highest SUV determined for [
177
Lu]citrate was found in the 
harderian glands with a value of 9.62 ± 5.62, which is more than the doubled uptake value 
compared to the femur after 60 min p.i.. Contrast to that all the tested bisphosphonates 
showed obviously lower SUVs in the harderian glands with SUVs between 0.04 and 0.46. 
Table 1. Biodistribution of radioactivity after 5 min p.i. of 
177
Lu-complexes in Wistar rats.  
organ 
[
177
Lu]citrate [
177
Lu]BPAMD [
177
Lu]BPAPD [
177
Lu]BPPED [
177
Lu]NO2AP
BP
 [
177
Lu]DO2A(P
BP
)
2
 [
177
Lu]DOTA(M
BP
)
2
 
mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
blood n.d. n.d. 0.90 0.42 0.84 0.07 1.30 0.20 2.08 2.83 3.35 0.33 3.98 0.40 
brain n.d. n.d. 0.04 0.01 0.05 0.02 0.04 0.01 0.04 0.01 0.09 0.01 0.13 0.03 
pancreas n.d. n.d. 0.31 0.14 1.60 1.18 0.37 0.12 0.27 0.08 0.73 0.15 0.68 0.14 
spleen n.d. n.d. 0.37 0.35 1.27 0.94 0.39 0.05 0.23 0.03 0.60 0.13 0.78 0.10 
adrenal gland n.d. n.d. 0.40 0.13 0.55 0.17 0.70 0.41 0.60 0.42 1.23 0.19 1.07 0.19 
kidneys n.d. n.d. 4.53 4.01 3.61 1.81 3.09 0.48 3.08 1.14 2.87 0.29 3.10 0.54 
adipose tissue n.d. n.d. 0.42 0.19 1.80 0.78 0.24 0.07 0.53 0.14 1.52 0.50 0.55 0.13 
muscle n.d. n.d. 0.19 0.08 0.78 0.70 0.24 0.03 0.21 0.05 0.49 0.30 0.49 0.11 
heart n.d. n.d. 0.36 0.14 0.36 0.04 0.52 0.10 0.31 0.06 1.34 0.17 1.45 0.30 
lung n.d. n.d. 0.61 0.24 0.61 0.07 0.75 0.08 0.50 0.05 1.87 0.41 2.04 0.32 
thymus n.d. n.d. 0.29 0.11 0.30 0.06 0.38 0.08 0.22 0.04 0.76 0.09 0.93 0.14 
thyroid n.d. n.d. 0.79 0.13 0.77 0.11 0.71 0.29 0.87 0.34 1.13 0.23 1.75 0.85 
harderian gland n.d. n.d. 0.36 0.13 0.37 0.10 0.40 0.12 0.35 0.08 0.95 0.23 1.12 0.16 
liver n.d. n.d. 0.26 0.11 0.39 0.08 0.48 0.12 0.29 0.12 1.07 0.15 1.13 0.39 
testes n.d. n.d. 0.25 0.07 0.28 0.03 0.36 0.01 0.32 0.05 0.24 0.02 0.30 0.03 
femur n.d. n.d. 3.36 0.63 3.43 0.44 4.16 0.35 2.67 0.04 2.11 0.22 2.31 0.15 
Data are expressed in SUV. Each value represents the mean (S.D.) for four animal. Data not determined (n.d.). 
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Table 2. Biodistribution of radioactivity after 60 min p.i. of 
177
Lu-complexes in Wistar rats.  
organ 
[
177
Lu]citrate [
177
Lu]BPAMD [
177
Lu]BPAPD [
177
Lu]BPPED [
177
Lu]NO2AP
BP
 [
177
Lu]DO2A(P
BP
)
2
 [
177
Lu]DOTA(M
BP
)
2
 
mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
blood 0.22 0.11 0.04 0.01 0.04 0.00 0.06 0.01 0.07 0.02 1.25 0.09 1.43 0.32 
brain 0.06 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.04 0.01 0.05 0.01 
pancreas 0.50 0.05 0.04 0.02 0.04 0.02 0.03 0.01 0.06 0.01 0.31 0.05 0.30 0.07 
spleen 0.70 0.12 0.07 0.06 0.05 0.01 0.14 0.04 0.05 0.01 0.31 0.03 0.52 0.25 
adrenal gland 0.62 0.05 0.04 0.04 0.09 0.06 0.08 0.12 0.11 0.05 0.49 0.09 0.52 0.20 
kidneys 1.41 0.11 0.35 0.06 0.39 0.06 0.38 0.04 0.47 0.07 1.66 0.40 1.41 0.16 
adipose tissue 0.35 0.03 0.04 0.02 0.06 0.02 0.02 0.01 0.09 0.03 0.55 0.12 0.29 0.16 
muscle 0.35 0.02 0.02 0.01 0.03 0.02 0.02 0.00 0.02 0.01 0.15 0.01 0.24 0.06 
heart 0.87 0.10 0.02 0.01 0.03 0.00 0.04 0.01 0.04 0.01 0.54 0.10 0.63 0.12 
lung 1.13 0.13 0.07 0.01 0.06 0.00 0.08 0.02 0.07 0.01 0.89 0.12 0.89 0.13 
thymus 0.53 0.09 0.08 0.04 0.06 0.02 0.03 0.01 0.06 0.01 0.39 0.05 0.37 0.10 
thyroid 0.89 0.18 0.57 0.06 0.44 0.21 0.62 0.44 0.21 0.06 1.00 0.27 0.85 0.12 
harderian gland 9.62 5.62 0.04 0.01 0.11 0.11 0.16 0.08 0.06 0.01 0.42 0.05 0.46 0.09 
liver 1.04 0.09 0.04 0.01 0.04 0.01 0.13 0.01 0.04 0.00 0.52 0.11 0.69 0.36 
testes 0.42 0.03 0.03 0.01 0.02 0.01 0.03 0.00 0.03 0.01 0.28 0.03 0.33 0.04 
femur 4.12 0.31 4.84 0.44 4.05 0.36 5.67 0.10 3.34 0.28 4.48 0.38 5.41 0.46 
Data are expressed in SUV. Each value represents the mean (S.D.) for four animal. 
 
The bone to soft tissue ratios are presented in table 3 and 4. Ratio between bone and blood 
was 3.6 for [
177
Lu]DO2A(P
BP
)2, 3.8 for [
177
Lu]DOTA(M
BP
)2, 18.7 for [
177
Lu]citrate, 45.8 for 
[
177
Lu]NO2AP
BP
, 92.9 for [
177
Lu]BPPED, 95.1 for [
177
Lu]BPAPD and 135.6 for 
[
177
Lu]BPAMD after 60 min p.i., respectively. The best bone to muscle ratio was observed 
for [
177
Lu]BPPED (355.8) followed by [
177
Lu]BPAMD (251.7). [
177
Lu]BPPED showed as 
well the best bone to kidney ratio of 14.9 followed by 14.0 for [
177
Lu]BPAMD again. The 
best bone to liver ratio was determined for [
177
Lu]BPAMD (127.5) followed by 
[
177
Lu]BPAPD (105.4), while the lowest ratio was obtained for [
177
Lu]citrate (4.0). The total 
skeleton retention was calculated as following, starting with the lowest value of 
30.5 ± 1.1 %ID for [
177
Lu]NO2AP
BP
, 39.4 ± 2.5 %ID for [
177
Lu]BPAPD, 44.6 ± 3.2 %ID for 
[
177
Lu]DO2A(P
BP
)2, 45.7 ± 6.2 %ID for [
177
Lu]citrate, 46.7 ± 5.3 %ID for [
177
Lu]BPAMD, 
48.2 ± 4.1 %ID for [
177
Lu]DOTA(M
BP
)2 and 56.3 ± 6.7 %ID for [
177
Lu]BPPED. 
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Table 3. Ratios between bone and soft tissue after 5 min p.i. of 
177
Lu-complexes in Wistar rats.  
bone/organ [
177
Lu]citrate [
177
Lu]BPAMD [
177
Lu]BPAPD [
177
Lu]BPPED [
177
Lu]NO2AP
BP
 [
177
Lu]DO2A(P
BP
)
2
 [
177
Lu]DOTA(M
BP
)
2
 
blood n.d. 3.7 4.1 3.2 1.3 0.6 0.6 
brain n.d. 83.9 68.5 104.0 66.8 23.4 17.7 
pancreas n.d. 10.8 2.1 11.2 9.9 2.9 3.4 
spleen n.d. 9.1 2.7 10.7 11.6 3.5 3.0 
adrenal gland n.d. 8.4 6.2 5.9 4.5 1.7 2.2 
kidneys n.d. 0.7 0.9 1.3 0.9 0.7 0.7 
adipose tissue n.d. 8.0 1.9 17.3 5.0 1.4 4.2 
muscle n.d. 17.7 4.4 17.3 12.7 4.3 4.7 
heart n.d. 9.3 9.5 8.0 8.6 1.6 1.6 
lung n.d. 5.5 5.6 5.5 5.3 1.1 1.1 
thymus n.d. 11.6 11.4 10.9 12.1 2.8 2.5 
thyroid n.d. 4.2 4.4 5.9 3.1 1.9 1.3 
harderian gland n.d. 9.3 9.3 10.4 7.6 2.2 2.1 
liver n.d. 12.9 8.8 8.7 9.2 2.0 2.0 
testes n.d. 13.4 12.2 11.6 8.3 8.8 7.7 
 
 
Table 4. Ratios between bone and soft tissue after 60 min p.i. of 
177
Lu-complexes in Wistar rats.  
bone/organ [
177
Lu]citrate [
177
Lu]BPAMD [
177
Lu]BPAPD [
177
Lu]BPPED [
177
Lu]NO2AP
BP
 [
177
Lu]DO2A(P
BP
)
2
 [
177
Lu]DOTA(M
BP
)
2
 
blood 18.7 135.6 95.1 92.9 45.8 3.6 3.8 
brain 65.4 613.4 513.9 419.9 254.3 111.5 104.0 
pancreas 8.2 136.4 104.9 181.6 56.7 14.5 18.0 
spleen 5.8 68.2 85.7 41.0 66.0 14.2 10.4 
adrenal gland 6.6 109.6 45.8 72.5 31.4 9.1 10.4 
kidneys 2.9 14.0 10.3 14.9 7.1 2.7 3.8 
adipose tissue 11.8 134.5 70.7 269.7 37.2 8.2 18.4 
muscle 11.8 251.7 158.7 355.8 141.4 29.8 22.9 
heart 4.7 210.1 158.7 141.1 89.0 8.2 8.6 
lung 3.7 69.1 62.6 67.5 46.8 5.1 6.1 
thymus 7.7 58.6 70.7 212.0 59.0 11.6 14.4 
thyroid 4.7 8.5 9.2 9.1 15.6 4.5 6.3 
harderian gland 0.4 118.8 35.8 36.4 85.6 10.6 11.7 
liver 4.0 127.5 105.4 42.3 87.0 8.6 7.8 
testes 9.9 179.1 199.7 185.1 113.5 15.8 16.2 
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Figure 4. Blood concentration curves of different 
177
Lu labelled bisphosphonates. 
 
3.4. Metabolite Analysis and in vivo stability 
Radio-HPLC and TLC analysis of blood samples showed no evidence of any metabolization 
of the compounds [
177
Lu]NO2AP
BP
, [
177
Lu]BPAMD, [
177
Lu]BPAPD and [
177
Lu]BPPED 
within a period of 120 min. The above mentioned compounds were found to be intact in the 
urine and the serum probes as revealed by radio-HPLC and TLC. No traces of unknown 
177
Lu species or compounds were observed. The elimination half-lives were determined from 
blood samples and summarized in table 5. 
Table 5. Elimination half-lives of the 
177
Lu-labelled bisphosphonates calculated by a two comparatement 
model. 
 [177Lu]BPAMD [177Lu]BPAPD [177Lu]BPPED [177Lu]NO2APBP [177Lu]DO2A(PBP)2 [
177Lu]DOTA(MBP)2 
t1/2(α) 8.5 min 6.5 min 9.0 min 12.3 min 12.6 min 9.5 min 
t1/2(β) 76.2 min 93.8 min 63.0 min 93.8 min 100.5 min 120.0 min 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
0 50 100 150
%
ID
/m
L
 
time[min] 
BPAMD
BPAPD
BPPED
DO2A(PBP)2
DOTA(MBP)2
NO2APBP
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3.5. SPECT/CT 
Images obtained from SPECT showed that the therapeutic 
177
Lu-labelled bisphosphonates 
exclusively accumulated in the skeleton with a high target to background ratio, cf. figure 5. 
After 60 min no considerable fractions of 
177
Lu activity was found in other organs, which is 
consistent to the data gathered from the ex vivo organ distribution. An obviously 
concentration of activity was present in the epiphyseal gap as well as in other articulations.  
 
Figure 5. [
177
Lu]BPAMD SPECT image (left) and SPECT/CT fusion image (right) developed in a healthy 
Wistar rat 60 min p.i., as a representing example for 
177
Lu-labelled bisphosphonates.  
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4. Discussion 
The DOTA based monomeric bisphosphonates BPAMD, BPAPD, BPPED have been 
successfully radiolabeled with the therapeutic β--emitter 177Lu(III) in excellent yields over 
98 % as well as the NO2A based bisphosphonate NO2AP
BP
 and the dimeric compounds 
DOTA(M
BP
)2 and DO2A(P
BP
)2. All tracers tested showed a distinguished high accumulation 
on the bone surface, eminently in the epiphyseal plate. High uptakes were observed for the 
dimeric compound [
177
Lu]DOTA(M
BP
)2 (SUVfemur = 5.41 ± 0.41). All bisphosphonates 
underwent a renal body clearance and the blood elimination was very fast especially for the 
monomeric compounds. No brain or notable liver uptake was observed. The compounds were 
found to be intact in the urine and blood.  
The characteristic accumulation specific in the growth plate of the skeleton shows that the 
compounds uptake profile is subject to the bone turnover. For that reason the described 
compounds in this manuscript should be well suited for a targeted 
177
Lu therapy to 
osteoblastic bone metastases, in which they should preferred accumulate. An important factor 
for a therapeutic application is the target to background ratio (TBR) and a fast excretion of 
non-target bond activity. A good TBR and a fast blood and body clearance reduces the 
radiation dose of the non-targeted tissue and thus will reduce toxic side effects and enhances 
the therapeutic efficiency and tolerance.  
Although the dimeric compounds [
177
Lu]DOTA(M
BP
)2 and [
177
Lu]DO2A(P
BP
)2 showed the 
highest bone accumulation, their TBR was lowest, beside [
177
Lu]citrate. The additional 
bisphosphonate moiety might to have a stronger bone binding effect. Albeit the blood levels 
of these compounds were significantly higher after 60 min (SUVblood{[
177
Lu]DOTA(M
BP
)2} 
= 1.43 ± 0.32; SUVblood{[
177
Lu]DO2A(P
BP
)2} = 1.25 ± 0.09) compared to the monomeric 
bisphosphonates (SUVblood{[
177
Lu]BPAMD} = 0.04 ± 0.01; SUVblood{[
177
Lu]NO2AP
BP
} = 
0.07 ± 0.02). It might be the case that these higher blood concentration are the reason for the 
enhanced skeletal accumulation. Because of the fast blood and renal clearance of the 
monomeric bisphosphonates the time scale for target accumulation is shortened compared to 
the dimeric compounds. The reason for the decreased clearance of the dimeres is yet not clear 
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and it might be an effect of the higher negative charge of these compounds or may be 
influenced by serum protein binding. The data from ex vivo organ distribution of the dimeric 
bisphosphonates are also not matching with [
177
Lu]citrate. Liver uptake, blood values and the 
accumulation in the harderian glands as well as in the femur are significantly different. If a 
therapeutic approach of bone metastases benefits from the higher skeleton accumulation of 
the dimeric bisphosphonates has yet to be evaluated in future in a dosimetry study, 
considering the lower TBR and the higher blood levels. 
The lowest skeleton uptake was observed for the NO2A phosphinate linked bisphosphonate 
[
177
Lu]NO2AP
BP
 (SUVfemur{[
177
Lu]NO2AP
BP
} = 3.34 ± 0.28, 60 min p.i.). Contrary to the 
results with 
177
Lu(III) it was reported previously, that [
68
Ga]NO2AP
BP
 showed an excellent 
bone binding with a brilliant TBR [22], remarkably suitable as an PET imaging agent. 
However it is known that lanthanides require seven dentate chelators like DOTA-derivates 
and the NO2A-phosphinate offer only six. Since the bisphosphonate moiety is able to 
complex divalent metal ions like Ca
2+
 it might be the case that some parts of the phosphonate 
groups function as additional donors to the 
177
Lu-NO2AP complex. A partly loss of the 
functional bisphosphonate moiety due to stabilizing the 
177
Lu(III) complex might reduce the 
binding potential of the bisphosphonate group to the bone and thus reduces the affinity of the 
[
177
Lu]NO2AP
BP
 compound to the target tissue in contrast to the 
68
Ga(III) complex. 
Highest bone accumulation of tested tracers was observed for [
177
Lu]BPPED with a SUV of 
5.67 ± 0.10 in the femur after 60 min. with a TBR of the muscle and blood of  355.8 and 
92.3, respectively. Excellent bone accumulation (SUV = 4.84 ± 0.44) as well as superb TBRs 
were observed also for [
177
Lu]BPAMD, with TBR values of 127.5 to the liver and 135.6 to 
the blood, which was the highest for all tested compounds. [
177
Lu]BPAMD revealed a very 
fast blood clearance and renal excretion.  
Within this study BPAMD revealed its great potential as a palliative bone targeting agent to 
treat skeleton metastases with 
177
Lu(III). Contrary to other actual discussed tracers like 
EDTMP, BPAMD proved to be an efficient 
68
Ga-PET imaging agent for bone metastasis 
[21]. Neither 
177
Lu/
153
Sm-EDTMP nor 
223
RaCl2 offer this theranostic approach. Patients 
would benefit greatly from a specific [
177
Lu]BPAMD dose application, calculated from the 
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patients individual uptake profile previously determined by [
68
Ga]BPAMD PET 
examinations.  
 
5. Acknowledgment 
The authors are grateful to Jan Holub and Petr Hermann for providing the bisphosphonate 
compounds BPAMD, BPAPD, DO3AP
BP
 and NO2AP
BP
. The n.c.a. 
177
Lu was provided from 
ITG, Germany. Financial support from the THERANOSTICS Center for Molecular 
Radiotherapy and Molecular Imaging ENETS, Bad Berka (Germany) is particularly 
acknowledged. This study was supported by the grant of the Max Planck Graduate Center 
Mainz. 
 
6. References 
[1] GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence 
Worldwide 2012. World Health Organization. 
[2] K. N. Weilbaecher, T. A. Guise, L. K. McCauley, Cancer to bone: a fatal attraction, 
Nature Reviews|Cancer, 2011; 11: 411-425. 
[3] O. Sartor, P. Hoskin, Ø. S. Bruland, Targeted radio-nuclide therapy of skeletal 
metastases, Cancer Treatment Reviews, 2013; 39: 18–26. 
[4] J. Kutzner, W. Grimm, K. Hahn, Palliative radiotherapy with Strontium-89 in case 
of extended formation of skeleton metastases, Strahlentherapie, 1978; 154:317-22. 
  3. Manuscripts and Supplementary Results 
206 
 
[5] S. Zenda, Y Nakagami, M. Toshima, S. Arahira, M. Kawashima, Y. Matsumoto, H. 
Kinoshita, M. Satake, T. Akimoto, Strontium-89 (Sr-89) chloride in the treatment of 
various cancer patients with multiple bone metastases, Int J Clin Oncol, 2013. 
[6] P. W. Durbin, C. W. Asing, M. E. Johnston, The metabolism of the lanthanons in 
the rat. II. Time studies of the tissue deposition of intravenously administered 
radioisotopes. USAEC Report, 1956: ORINS-12; 171. 
[7] R. E. O'Mara, Rare earth nuclides as potential agents for skeletal imaging, J Nucl 
Med, 1968; 10: 49-51. 
[8] Lutetium-177: Handling Precautions, 2010, Perkin-Elmer Inc. 
www.perkinelmer.com 
[9] D. Campana, G. Capurso, S. Partelli, F. Nori, M. Falconi, P. Tomassetti, 
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic 
neuroendocrine tumours: factors associated with response and suggestions for 
therapeutic sequence. EJMMI, 2013; 40(8):1197-205. 
[10] J. Yuan, C. Liu, X. Liu, Y. Wang, D. Kuai, G. Zhang, J. J. Zaknun, Efficacy and 
safety of 
177
Lu-EDTMP in bone metastatic pain palliation in breast cancer and 
hormone refractory prostate cancer: a phase II study, Clin Nucl Med., 2013; 38: 88-
92. 
[11] S. Chakraborty, T. Das, P. R. Unni, H. D. Sarma, G. Samuel, S. Banerjee, M. 
Venkatesh, N. Ramamoorthy, M. R. Pillai, 
177
Lu labelled polyaminophosphonates as 
potential agents for bone pain palliation, Nucl Med Comm, 2002; 23: 67-74. 
[12] N. V. Jarvis, J. M. Wagener, G. E. Jackson, Metal-ion speciation in blood plasma as 
a tool for elucidating the in vivo behaviour of radiopharmaceuticals containing 
153
Sm and 
166
Ho, J. Chem. Soc. Dalton Trans., 1995; 1411-1415. 
3. Manuscripts and Supplementary Results 
207 
 
[13] B. J. Beyer, R. Offord, G. Künzi, Y. Aleksandrova, U. Ravn, S. Jahn, J. Barker, O. 
Tengblad, M. Lindroos, The Influence of EDTMP-Concentration on the 
Biodistribution of Radio-Lanthanides and 225-Ac in Tumor-Bearing Mice, Nucl 
Med & Biol,1997; 24: 367-372. 
[14] J. Byegård, M. Skarnemark, M. Skålberg, The stability of some metal EDTA, DTPA 
and DOTA complexes: Application as tracers in groundwater studies, J Radioanal 
& Nucl Chem, 1999; 241: 281-290. 
[15] L Smentek, Lanthanides caged by the organic chelates; structural properties, J Phys: 
Condens Matter, 2011; 23: 143202. 
[16] S. Chakrabotry, T. Das, H. D. Sarma, M. Venkatesh, S. Banerjee, Comparative 
studies of 
177
Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative 
radiotherapy of bone metastasis, Applied Radiation and Isotopes, 2008; 66: 1196–
1205. 
[17] M. Mitterhauser, S. Toegel, W. Wadsak, R. R. Lanzenberger, L. K. Mien, C. Kutner, 
T. Wanek, R. Dudczak, K. Kletter, Pre vivo, ex vivo and in vivo evaluations of 
[
68
Ga]-EDTMP, Nucl Med & Biol, 2007 ; 34: 391–397. 
[18] M. Fellner, P. Riss, NS. Loktionova, KP. Zhernosekov, O. Thews, F. Rösch, 
Comparison of different phosphorus-containing ligands complexing 
68
Ga for PET-
imaging of bone metabolism. Radiochim. Acta, 2011; 99: 43–51. 
[19] M. Fellner, B. Biesalski, N. Bausbacher, V. Kubícek, P. Hermann, F. Rösch, O. 
Thews, 
68
Ga-BPAMD: PET-imaging of bone metastases with a generator based 
positron emitter, Nucl. Med. Biol., 2012; 39: 993–999. 
[20] T. Vitha, V. Kubícek,  P. Hermann, Z. I. Kolar, H. T. Wolterbeek, W.A.P. Breeman, 
I. Lukeš,  J. A. Peters, Lanthanide(III) Complexes of Bis(phosphonate) Monoamide 
Analogues of DOTA: Bone-Seeking Agents for Imaging and Therapy, J. Med. 
Chem. 2008; 51: 677–683. 
  3. Manuscripts and Supplementary Results 
208 
 
[21] M. Fellner, R. P. Baum, V.  Kubíček, P. Hermann, I. Lukeš , V. Prasad, F. Rösch, 
PET/CT imaging of osteoblastic bone metastases with 
68
Ga-bisphosphonates: first 
human study, Eur. J. Nucl. Med. Mol. Imaging, 2010; 37: 834. 
[22] J. Holub, M. Meckel, V. Kubicek, F. Rösch, P. Hermann, Gallium(III) complexes of 
NOTA-bis(phosphonate) conjugates as radiotracers for bone imaging, CMMI, 2014, 
may 6 
[23] K. Ogawa, K. Takai, H. Kanabara, T. Kiwada, Y. Kitamura, K. Shiba, A. Odani, 
Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as 
a bone scintigraphy agent, Nucl Med & Biol, 2011; 38: 631–636. 
[24] T. Vitha, V. Kubicek, P. Hermann, Z. I. Kolar, H. Th. Wolterbeek, J. A. Peter, I. 
Lukes, Complexes of DOTA-Bisphosphonate Conjugates: Probes for Determination 
of Adsorption Capacity and Affinity Constants of Hydroxyapatite, Langmuir, 2008; 
24: 1952-1958. 
[25] N. A. Lebedev , A. F. Novgorodov, R. Misiak, J. Brockmann, F. Rösch, 
Radiochemical separation of no-carrier-added 
177
Lu as produced via the 
176Yb(n,γ)177Yb®177Lu process, Appl Radiat Isot, 2000; 53: 421-425. 
[26] P. J. Riss, C. Burchardt, F. Rösch, A methodical 
68
Ga‐labelling study of DO2A‐
(butyl‐L‐tyrosine) 2 with cation‐exchanger post-processed 68Ga: practical aspects of 
radiolabelling, CMMI, 2011; 6: 492–498. 
[27] V. Kubıcek, J. Rudovsky, J . Kotek,  P. Hermann, L. Vander Elst,  R. N. Muller, Z. 
I. Kolar, H. T. Wolterbeek, J. A. Peters, I. Lukes, A Bisphosphonate Monoamide 
Analogue of DOTA: A Potential Agent for Bone Targeting, J. Am. Chem. Soc., 
2005; 127: 16477-16485.  
[28] T. Vitha, V. Kubicek, J. Kotek, P. Hermann, L. Vander Elst, R. N. Muller, I. Lukes 
J. A. Peters, Gd(III) complex of a monophosphinate-bis(phosphonate) DOTA 
analogue with a high relaxivity; Lanthanide(III) complexes for imaging and 
radiotherapy of calcified tissues, Dalton Trans., 2009, 3204–3214. 
3. Manuscripts and Supplementary Results 
209 
 
[29] W. Sontag, Long-term Behavior of 
239
Pu, 
241
Am and 
233
U in Different Bones of 
One-year-old Rats: Macrodistribution and Macrodosimetry. Human Toxicol, 1984; 
3: 69-483. 
 
  
  3. Manuscripts and Supplementary Results 
210 
 
3.7.1. Supplementary Results I: Ex vivo organ distribution studies of the α-
particle emitting calcium mimetic 
223
RaCl2 (Xofigo®) in healthy Wistar 
rats. 
 
1. Introduction 
After the discovery of radioactivity a strange cult about radioactive rays in general and 
particular in radium emerged in these early days of nuclear sciences. The people as well as 
the scientists believed to have an ultimate form of elixir to cure any kind of diseases or other 
forms of malaises. Mineral waters and a plenty number of every days objects were added 
with radium in odd ways to prevent the bearer from any kind of healthy misfortune, until the 
toxic effects of radium isotopes circularized as first reported by physicians, who treated 
necrosis of the jaws in painters of luminous watch-dials [1]. 
Radium itself is an earth alkaline element and therefore it behaves as a calcium analog. 
Incorporated radium isotopes undergo the calcium metabolism in the human body and thus 
large fractions are accumulated in the skeleton with quite a long biological half-life [2,3]. 
The same metabolic mechanism was used with isotopes of strontium to treat skeletal 
metastases. The β-particle emitter 89Sr, when injected as 89SrCl2, accumulates in high 
metabolic osseous tumor sites to attain pain relief [4]. 
89
Sr has a relatively long physical half-
life of 50.5 days, considered to its usage as an endotherapeutic agent. The maximum energy 
of the β-particles emitted is 1.46 MeV [5]. Due to this high β-energy, the decay of 89Sr 
inflicts the radio sensitive bone marrow with a high dose fraction and yet showed no benefit 
in survival rates against external radiation [4,6]. Contrary the range of α-particles is very 
short and is accompanied with a very high energy deposit in the surrounding tissue and 
conceptually should not affect the bone marrow [4].  
The high linear energy transfer (LET) of α-particles and the short range of only few cell 
diameters inflict an intense damage of the DNA. Especially DNA double strand breaks 
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caused by α-irradiation initiate the apoptosis mechanism in cells. First results in cell and 
animal studies revealed the high potential of the targeted α-particle therapy (TAT) [7,8]. The 
only α-particle emitter approved for endo-radiotherapy is 223RaCl2 for the treatment of 
castrate resistant prostate cancer metastasized in the bone [4]. 
223
Ra has a moderate long half-
life of 11.4 days and the daughter nuclides in the decay chain convert quickly to the stable 
lead isotope 
207
Pb, cf. figure 1. 
 
Figure 1. Decay chain from 
223
Ra to the stable isotope 
207
Pb. 
First data in castrate resistant prostate cancer patients with proven skeletal metastases 
revealed a significant pain relief and a drop of PSA (prostate specific antigen) and ALP 
(alkaline phosphatase) levels [9]. The short ranged α-irradiation destroys the tumor cells 
nearby the bone surface as well as the osteotropic cells of the tumor lesion and thus decreases 
the bone turnover and reduces further skeletal related events with an overall benefit 
according to the survival rate [10]. In a randomized patient study 
223
RaCl2 offered a 
significant longer overall survival rate in metastatic prostate cancer patients of 2.8 month 
against placebo [10,11]. Unfortunately, 
223
RaCl2 showed also some problematic side effects 
related especially to the red bone marrow, which is may be caused by the ´hard´ β-emission 
of the daughter nuclides in the decay chain. Dosimetric studies estimate a dose of 16 Gy 
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absorbed by the bone endosteum and 1.5 Gy by the red bone marrow after a cycle of six 
injections of 21 MBq 
223
RaCl2 [12]. Since 
223
Ra behaves as a calcium mimetic it undergoes 
the same excretion route as Ca
2+
-ions in the human body, which is mainly the guts. 
Szintigraphic images of patients treated with 
223
Ra showed therefor mainly the intestine, cf. 
figure 2.  
 
Figure 2. Szintigraphic images of patient developed with [
99
Tc]MDP (A) and 
223
RaCl2 on day 0 (B), day 2 (C) 
and day 6 (D) p.i [4]. 
Also the liver, the colon and the intestine receive a significant dose of radiation by 
223
RaCl2, 
whereby the dose of the colon and the intestine was calculated based on the β-emission of the 
daughter nuclides from the 
223
Ra decay chain only [12]. However, the authors of this study 
assumed that the emitted α-particles are self-absorbed by the colon and intestine content and 
thus the emitted α-particles were excluded from the dose calculations of the intestine and 
colon [12]. The side effects of an α-therapy of bone metastases with 223RaCl2 are mainly the 
hematological toxicity and diarrhoe [13]. To reduce these effects a treatment with 
223
RaCl2 is 
divided into six applications of 0.05 MBq/kg contrary to the standard radioparmaceutical for 
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the palliative treatment of bone metastases [
153
Sm]EDTMP, where only one application is 
needed to obtain pain relief.   
Another concept of treating painful bone metastases are 
177
Lu(III) labelled DOTA conjugated 
bisphosphonates. Compounds like [
177
Lu]BPAMD proved in animal studies to have a high 
bone accumulation and a fast body clearance via the kidneys [14]. 
177
Lu is a therapeutic 
emitter of low energetic β--particles and commonly used in the ERT. Furthermore, BPAMD 
offers the opportunity as an imaging agent, in combination with the positron emitter 
68
Ga(III). This theranostic concept allows for a patient specific dose calculation of 
[
177
Lu]BPAMD concerning the patients individual tracer uptake profile. [
177
Lu]BPAMD 
therapy of osseous metastases is now offered in some hospitals with promising results and 
therefore the different pharmacokinetics of 
223
RaCl2 and [
177
Lu]BPAMD have to be described 
in terms of bone accumulation, excretion route and target to background ratio in a healthy 
animal model [15]. 
 
2. Materials and Methods 
223
RaCl2 (Xofigo®) was purchased from Bayer HealthCare (Germany). Male Wistar rats 
weighting 205 ± 19 g were obtained from Charles River Laboratories International, Inc. The 
animal studies were done according to the guidelines of the European Convention for the 
Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 
No. 123), and to the Deutsches Tierschutzgesetz (German animal welfare regulations). In 
mean 9.5 ± 0.6 kBq and 51.0 ± 2.7 kBq were injected in tail vein in each rat, after 1 h and 24 
h the rats were sacrificed at the and organs of interest were harvested. Radioactivity of 
samples were measured with a γ-spectrometer (MUCHA, raytest Isotopenmessgeräte GmbH, 
Germany) previously calibrated with a 
223
Ra standard. Data are calculated in SUV (standard 
uptake value) by the formula: (activity per g tissue)/(injected activity) × BW. The skeleton 
weights of the rats were calculated by the formula: skeleton weight = 9.66 + 0.0355 × BW. 
The total skeleton accumulation of 
223
RaCl2 was calculated by the activity concentration in 
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the femur and the total skeleton weight. Data of the organ distribution of the 
177
Lu-labelled 
bisphosphonates and the experimental process is described elsewhere (this manuscript: 3.6). 
 
3. Results 
Activity accumulation in the excised tissue samples are shown in table 1. The results validate 
that 
223
RaCl2 strongly retains in the bones. After 1 h p.i. a SUV in the femur of 7.04 ± 3.02 
was observed and the total activity in the skeleton was found to be 56 ± 22 %ID. Beside the 
calcified tissues significant concentrations of 
223
Ra were determined in the kidneys (SUV = 
3.01 ± 0.97) followed by the intestine (SUV = 2.87 ± 0.82), respectively. 
223
Ra accumulation 
on the femur was still present after 24 h with a SUV of 5.93 ± 0.14. Total skeleton retention 
was calculated after 24 h to be 52 ± 3 %ID. Activity concentrations in other organs were 
significantly lower after 24 h. The SUV in the kidneys and the intestine decreased to 
0.10 ± 0.03 and 0.07 ± 0.01, respectively. The lowest activity observed was in muscle and 
heart samples with SUVs of 0.01 ± 0.01. 
Table 1. Ex vivo organ distribution of 
223
RaCl2 in healthy Wistar rats at different time points. 
organ 1 h p.i. 24 h p.i. 
lung 0.53 ± 0.33 0.05 ± 0.03 
liver 0.26 ± 0.12 0.03 ± 0.03 
spleen 0.19 ± 0.10 0.02 ± 0.02 
kindeys 3.01 ± 0.97 0.10 ± 0.03 
muscle 0.10 ± 0.06 0.01 ± 0.01 
heart 0.17 ± 0.04 0.01 ± 0.01 
blood 0.29 ± 0.09 0.02 ± 0.01 
intestine 2.87 ± 0.82 0.07 ± 0.01 
testes 0.11 ± 0.04 0.04 ± 0.01 
femur 7.04 ± 3.02 5.93 ± 0.14 
Data are expressed in mean SUV ± S.D. (standard deviation) out of three animals. 
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Activity ratios between bone and soft tissues after 1 h and 24 h p.i. are presented in table 2, 
respectively. Highest target to background ratio (TBR) was observed for muscle tissue after 1 
h and 24 h, with TBR of 72 and 558. The lowest TBR of 2.3 and 2.4 was determined for the 
kidneys and the intestine after 1 h p.i. Ratios after 24 h p.i. of the TBR for the kidneys and 
the intestine increased to 58 and 82. The bone to blood ration was found to be 25 after 1 h p.i. 
and 272 after 24 h p.i.  
Table 2. Ratios between bone and soft tissue 1 h and 24 h p.i. of 223RaCl2 in healthy Wistar rats. 
bone / organ 1 h p.i. 24 h p.i. 
lung 13 ± 13 128 ± 74 
liver 28 ± 25  215 ± 215 
spleen 38 ± 37 306 ± 289 
kindeys 2 ± 2 58 ± 17 
muscle 72 ± 72 558 ± 364 
heart 41 ± 28 531 ± 524 
blood 25 ± 18 272 ± 180 
intestine 2 ± 2 82 ± 10 
testes 63 ± 51 386 ± 296 
 
 
4. Discussion 
The data obtained from ex vivo organ distribution in male healthy Wistar rats showed a 
strong retention of 
223
RaCl2 in the skeleton, the intestine and the kidneys. However, kidney 
accumulation is not reported in humans and excreted 
223
Ra activity is only found in the 
faeces. Significant 
223
Ra accumulation is reported for the spleen (12.4 %ID/g, after 60 min.) 
in mice with only a slow decrease over time contrary to the data in dogs and rats, where no 
relevant spleen uptake was observed [16]. The distribution data of 
223
Ra are consistent to the 
literature in healthy Wistar rats. After 24 h 
223
Ra was exclusively present in the skeleton. It is 
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reported that 
223
Ra inflicts the red bone marrow, with a reduction in blood levels and effects a 
strong toxicity [16,17]. However it is not clear, if this is mainly caused by the hard β-fraction 
of the daughter nuclides 
212
Pb and 
207
Tl or by secondary conversation effects, like X-ray or γ-
emissions. Discussible in this term is may be the low bone to blood ratio (24.6) during the 
first hours after injection. 
Although bisphosphonates have a high affinity to calcified tissues, the skeletal accumulation 
of [
177
Lu]BPAMD (SUVfemur = 4.8 ± 0.4) was lower than 
223
RaCl2 (SUVfemur = 7.0 ± 3.0), but 
not significant (P = 0.34), cf. figure 1. The %ID retained in the skeleton was calculated to be 
48 ± 4 for [
177
Lu]BPAMD and 56 ± 22 for 
223
RaCl2, respectively.  
 
Figure 1. Ex vivo organ distribution of 
223
RaCl2 () and [
177
Lu]BPAMD () 60 min p.i. 
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Figure 2. Ratios between bone and soft tissue of 
223
RaCl2 () and [
177
Lu]BPAMD () 60 min p.i. 
The higher body retention of 
223
RaCl2 can be explained by the resorption of 
223
Ra
2+
 in the 
intestine and kidneys similar to Ca
2+
-ions, while [
177
Lu]BPAMD showed a fast renal 
elimination to the bladder. The missing resorption pathway of bisphosphonates in the kidneys 
and the intestine result in distinctly higher target to background ratios for [
177
Lu]BPAMD, 
even though the bone uptake is slightly lower, cf. figure 2. In contrast to 
223
RaCl2, 
[
177
Lu]BPAMD showed an excellent target to background ratio even in the first minutes. The 
bone to blood ratios of [
177
Lu]BPAMD was 4 after 5 min p.i. and 136 after 60 min. p.i., 
which is more than 550% higher compared to 
223
RaCl2 after 60 min.  
Consequently, [
177
Lu]BPAMD showed a superior body distribution in terms of TBR, blood 
clearance and excretion rate and should thus be better tolerable. Whether [
177
Lu]BPAMD 
attains pain relief and an overall longer survival rate in cancer patients as reported for 
223
RaCl2 needs to be revealed in future patient studies. Indeed bone targeting compounds like 
[
153
Sm]EDTMP, 
223
RaCl2 or 
89
SrCl2 cannot offer a pre-therapeutic diagnosis strategy, where 
the patients individual uptake profile conducts to a personalized dose calculation. Only 
macrocyclic bisphosphonates like BPAMD provide this opportunity as 
177
Lu(III) and 
68
Ga(III) ligands. Furthermore, these compounds are also suitable as possible carriers for 
other α-particle emitting therapy nuclides, such as 212/213Bi(III) and 225Ac(III). A treatment of 
bone metastases with 
225
Ac(III) in combination with [
68
Ga]/[
177
Lu]BPAMD would combine 
the benefits of the α-radiation therapy known from 223RaCl2 with the superior excretion route 
0
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and target to background ratio of macrocyclic bisphosphonates. On account of this the 
complex formation and stability as well as the organ distribution in an animal model of  
225
Ac- or 
212/213
Bi-bisphosphonates should be investigated in future. 
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3.7.2. Supplementary Results II: Synthesis and metal chelate stability studies of 
DOTA bisphosphonates with the α-particle emitter 225Ac(III). 
 
1. Introduction 
Alpha particle emitting radionuclides were discussed in the radiopharmaceutical research for 
cancer treatment, since they are uniquely suited for the targeted endoradiotherapy (ERT). 
While commonly used β-particle emitters in the ERT have an energy range of  few keVs, the 
energy range of  α-particles are in scales of MeV [1]. Therefor the benefit of α-particle 
emitters is the short range of the α-particle emission paired with a high energy deposit in the 
targeted tissue. The range of the α-particles in tissue is approximately one to only a few cell 
diameters, whereby energies of 3 to 8 MeV were delivered in a linear profile. Thus a higher 
therapeutic efficiency of α-particle emitters compared to β-particle emitters is not only 
postulated, but also shown in cell and animal studies [2,3]. The main isotopes which come 
into question in the targeted α-particle therapy (TAT) are 225Ac, 211At, 212/213Bi, 212Pb, 223Th 
and 
223
Ra [1]. The TAT is only a subdomain of the ERT and it stays mostly in the pre-clinical 
phase, due to its continual unsolved problems in terms of nuclide availability, costs and 
labelling chemistry. Another problem depicts the daughter nuclides of the initial therapy 
isotope. It is rarely the case that the decay of the α-particle emitter used in the TAT ends up 
in a stable isotope in only one conversion step, rather the most TAT nuclides follow a decay 
chain, including several additional α- and β- emissions until they reach the stable end-
nuclide. It is to be assumed that after the initial α-conversion the tight macrocyclic complex 
dissociates and the daughter nuclide is released. The recoil energy as well as the re-
coordination of the electron shell of the decay product after an α-conversion is usually 
stronger than the energy release by complexation [1]. Therefor TAT nuclides with a short 
decay chain, or rather very short half-lives of the daughter nuclides are preferable. Though 
promising candidates with good relations to that criteria, like 
212/213
Bi lack in their short half-
life of only 45 and 60 min and the usage of the halogen 
211
At (t1/2 = 7.2 h) is related with a 
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difficult chemistry and in vivo stability [1]. 
225
Ac(III) has been considered as a TAT nuclide, 
due to its half-life of 10 days, suitable for radioimmuno therapy and the relatively short half-
lives of the daughter nuclides, cf figure 1 [4,5]. 
 
Figure 1. Decay chain from 
225
Ac to the stable isotope 
209
Bi. 
Actually the best way to form stable Ac(III) complexes is not well documented. The number 
of coordination sites and the radius of the macrocyclic cavity seem to be an important factor 
for stable actinide complexation and the question of the best ligand is not yet clear today, due 
to the fact that no stable Ac(III) isotopes exist, which makes investigations of the character of 
Ac(III) complexes quite difficult [1,5,6].  In the literature several macrocycles as well as 
open chain ligands, like CHX´-DTPA (N-[(R)-2-amino-3-(p-isothiocyanato-phenyl) propyl]-
trans-(S,S)-cyclohexane-1,2-diamine-N,N,N’,N”,N”-pentaacetic acid) are discussed in terms 
of  complexation efficiency and in vivo stability. DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) derivatives and HEHA (1,4,7,10,13,16-hexaazacyclohexadecane-
1,4,7,10,13,16-hexaacetic acid) seem to  be the most promising candidates [5,7].  
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Actually the α-particle emitting 223Ra is approved by the FDA and the EMA for treatment of 
painful skeletal metastases. Radium itself as an alkaline earth metal functions as a calcium 
mimetic and it naturally accumulates in the bones. It is known and verified in rat studies ( 
this manuscript: Supplementary Results I) that the main excretion route of 
223
Ra is the 
intestinal way. Since DOTA conjugated bisphosphonates showed promising results in the 
treatment of bone metastases with the β-particle emitter 177Lu, patients may benefit from a 
TAT in combination with compounds like BPAMD and DO3AP
BP
, cf chart 1. 
 
Chart 1. Structure of macrocyclic bisphosphonates for potential 
225
Ac(III) comlexation. 
Because of the better pharmacokinetics in terms of bone to soft tissue ratios and body 
excretion (this manuscript: Supplementary Results I) these macrocyclic bisphosphonates 
should be further investigated as promising candidates for an 
225
Ac(III) TAT. Therefore it is 
necessary to reveal the labeling efficiencies as well as the complex stabilities in different 
medias of these ligands with 
225
Ac(III), to outline the future prospects of this concept. 
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2. Materials and Methods 
2.1. General methods 
Solvents and chemicals were commercially available in analytical, HPLC or TraceSELECT® 
grade and were purchased from Sigma-Aldrich. Radio-TLC analyses were carried out with 
silica on aluminium foil (Merck KgaA) and a Raytest RITA (Raytest Isotopenmessgeräte 
GmbH, Germany) radiodetector. Radioactivity of samples were measured with an 
Aktivimeter Isomed 2010, MED (Nuklear-Medizintechnik Dresden GmbH). 
225
Ac(III) was 
obtained from ITM AG (Garching, Germany) as actinium nitrate in a concentration of 60 
MBq in 100 µL 6 M HNO3. 
 
2.2. Radiolabelling with 
225
Ac(III) 
The 100 µL 
225
Ac(III) stock solution was diluted with 5.9 mL TraceSELECT® grade water 
to obtain a total volume of 6 mL with a final 
225
Ac(III) concentration of 6 MBq/mL in 0.1 M 
HNO3. 15 µg of the ligand was dissolved in 500 µL of a 0.1 M sodium acetate solution ( pH 
= 7.8) and ~1 MBq (150-200 µL) of the diluted 
225
Ac(III) stock solution was added, which 
results in a final pH of 5.5-6.0. The solution was kept on a thermo shaker for 30 min at 98°C 
under moderate shaking and samples were taken regularly for TLC analysis. The TLC were 
developed in 0.1 M citrate buffer (pH 4) and radioactivity was analyzed 24 h post developing 
to wait for the decay equilibrium.  
 
2.3. Stability studies in different mediums 
100 µL of the 
225
Ac labelled DOTA bisphosphonates, like prepared above were added to 500 
µL of different mediums (0.1 M DTPA pH = 7.2, 0.1 M NaOAc pH = 5.5, human serum 
probes). The solutions were kept at room temperature and samples were taken regularly for 
TLC analysis. The TLC were developed in 0.1 M citrate buffer (pH 4) and radioactivity was 
analyzed 24 h post developing to wait for the decay equilibrium. 
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3. Results 
Complexation of 
225
Ac(III) with BPAMD and DO3AP
BP
 occurred within 30 min reaction 
time. Whereas the 8-dentate ligand DO3AP
BP
 showed not only a slight faster kinetic, but also 
a higher radiochemical yield (RCY), which was quantitative (RCY > 99%) compared to 
BPAMD, which showed a RCY ≥ 97.8 %, cf figure 2 and 3. The [225Ac]BPAMD complex 
showed in 0.1 M sodium acetate buffer at pH = 5.5 a slight decomposition over time, 
resulting in a loss of intact complexes of approximately 60 % at day 6. In contrast to 
[
225
Ac]DO3AP
BP
, which showed at the same conditions a loss of intact complexes of only 
4 % at day 6. In human serum probes (pH ~7.4) decomplexation of the 
225
Ac-labelled 
bisphosphonates occurred slowly over time and close to 72 % of [
225
Ac]BPAMD and close to 
80 % of [
225
Ac]DO3AP
BP
 was found to be intact after 7 days. Both complexes showed very 
low stabilities in the trans-chelating experiment with 0.1 M DTPA (pH = 7.2). After 5 days 
only [
225
Ac]DTPA was present.  
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Figure 2. Complexation kinetic in 0.1 M sodium acetate pH 5.5 and complex stabilities in different mediums of 
[
225
Ac]BPAMD out of a triplicate. 
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Figure 3. Complexation kinetic in 0.1 M sodium acetate pH 5.5 and complex stabilities in different mediums of 
[
225
Ac]DO3AP
BP
 out of a triplicate. 
 
4. Discussion 
A major criterion, which assessed the targeted α-particle therapy for future prospects is the 
stability of the 
225
Ac-complexes in the body. Since uncomplexed or weakly complexed 
225
Ac 
species accumulate in the liver with a high toxicity, a stable chelating of the ligand with 
225
Ac(III) is explicitly essential [8]. Just this question, related to the stability of different 
chelators, is yet to be discussed in the literature [1,6,9] and only few clinical trials with 
225
Ac-labelled compounds are published [4]. It is reported that DOTA derivatives show 
adequate labelling efficiencies and stabilities with 
225
Ac(III) [2,5], elsewhere the most 
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favorable in vivo  stability of 
225
Ac(III) complexes showed [
225
Ac]HEHA (,4,7,10,13,16-
hexaazacyclohexadecane-N,N′,N′′,N′′′,N′′′′,N′′′′′-hexaacetic acid) [6].  
Thus the 7-dentate ligand BPAMD and the 8-dentate ligand DO3AP
BP
 showed both excellent 
complexation kinetics with 
225
Ac(III), with a slight better RCY for [
225
Ac]DO3AP
BP 
(RCY > 
99%) within this study. The [
225
Ac]BPAMD complex dissociates slowly over time (60 % 
within 6 days) in 0.1 M sodium acetate (pH = 5.5) in contrast to [
225
Ac]DO3AP
BP
 were only 
marginal decomposition (4 % within 6 days) was observed. Since the kinetic inertness of 
complexes of macrocyclic ligands is usually determined in acidic medias [10,11] the results 
in the slight acidic acetate buffer (pH = 5.5) indicate that the [
225
Ac]BPAMD complex show 
a distinctly lower kinetic stability in contrast to [
225
Ac]DO3AP
BP
. It might be the case, that 
225
Ac is released by radiolysis. Even low 
225
Ac activities of few MBqs can cause strong 
oxidation processes [2]. The results should be verified in future experiments with the addition 
of scavengers, like ascorbic acid. 
Both compounds showed no inertness against transchelating with the 8-dentate and open 
chain chelator DTPA. Complex dissociation kinetics of [
225
Ac]BPAMD and 
[
225
Ac]DO3AP
BP 
in this experiment was found to be similar. The results are consistent to 
assumptions in the literature, which pronounced that more than 8 donors are necessary for a 
kinetically stable actinide complexation. Within this study the kinetic inertness of the 
225
Ac-
labeled bisphosphonates increased from the 7-dentate BPAMD to the 8-dentate DO3AP
BP
. In 
addition it is discussed in the literature that DOTA derivatives have a to small macrocyclic 
cavity for a stable ´in cage´ complexation of Ac(III), due to its larger ionic radius of ~1.14 Å 
in contrast to  ~0.9 Å for the better fitted lanthanides [6]. The results from the transchelating 
experiment with the open chain ligand DTPA might sustain these assumptions. However 
both ligands showed a low and similar dissociation rate in human serum samples with 
225
Ac. 
The pH in serum is around 7.4 and this higher pH seemed to have stabilizing effects to the 
formed complexes. The results are consistent to the literature, where it is described a similar 
stability in human serum for DOTA conjugates [5].  
Thus the stability of [
225
Ac]BPAMD and [
225
Ac]DO3AP
BP
 should better be further 
investigated in vivo in an animal model, with regards to increasing radioactivity 
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concentrations in the liver over time. It might be the case that once the compound is attached 
to the bone surface the released daughter nuclides just as released 
225
Ac are adsorbed 
instantly on the bone as well and thus the accumulation in critical organs like the liver might 
to be kept in a low concentration. Additionally new bisphosphonate conjugates to chelators 
like HEHA should be synthesized in future concerning to the better assumed in vivo stability 
of [
225
Ac]HEHA complexes.  
As a conclusion, TAT in combination with macrocyclic bisphosphonates might be a strong 
advantage in the treatment of bone metastases contrary to the therapy with 
223
RaCl2. The 
better pharmacokinetics of the radio-bisphosphonates, in terms of body clearance might be 
reduce the critical toxic sight effects of a 
223
Ra-therapy by keeping a high radiation dose to 
tumor sites. The complex stability of 
225
Ac-labelled bisphosphonates is indeed an important 
hurdle, which is to be overcome in future.  
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4 Summary, Conclusion and Future Perspective  
Since bone metastases still preserve as an untreatable infirmity worldwide with an increasing 
number of cases, the medical research is enforced to focus on novel concepts and 
developments in the recent decade. New discovered molecular biological pathways routed to 
the emerging of artificial antibodies and specific targeting agents, which aim on a 
substantially improved tumor management. Among these novel concepts, 
radiopharmaceuticals appear to have a leading position and particularly macrocyclic 
bisphosphonates are to be highlighted.  
Within this present work the novel macrocyclic bisphosphonate concept was further 
developed, not only in terms of practice by a kit-type application, but also in terms of more 
modern compounds and experimental nuclide capabilities. These new compounds were 
successfully synthesized and evaluated in an healthy animal model with the diagnostic PET-
nuclide 
68
Ga(III) and the therapy nuclide 
177
Lu(III). Furthermore, the concept was rudimental 
extended to the targeted α-particle therapy by implying the nuclide 225Ac(III). A milestone in 
the progress of the work were the first human studies in cancer patients with the most 
promising compounds [
68
Ga]NO2AP
BP
 and [
68
Ga]/
 
[
177
Lu]DOTAM
ZOL
, which finally leaded 
to an initial clinical trial in collaboration with international hospitals. The outcomes of the 
single segments of the project are discussed as follows. 
One task aimed on the development of a kit-type application of [
177
Lu]BPAMD. The 
radiopharmaceutical was evaluated by Fellner et al. in previous work and was first 
administered in prostate cancer patients suffering from bone metastases in collaboration with 
the Zentralklinik Bad Berka. The first results appeared to be promising, but an important 
hurdle had to be overcome to introduce [
177
Lu]BPAMD in routine clinical practice. A 
[
177
Lu]BPAMD-kit is a distinct need for a GMP conform production of the 
radiopharmaceutical and the kit composition was evaluated in terms of a high labelling 
efficiency and complex stability. Within this work the kit development was successfully 
completed and the kit complies all scheduled requirements in terms of radiochemical yields 
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and radiolytic stabilities. The kit will be produced in future by a collaborating company and 
opens the implementation of future clinical trials, which have set to reveal the potential of the 
[
177
Lu]BPAMD therapy. 
A further task was the development of improved targeting structures to enhance the bone 
affinity of new macrocyclic bisphosphonate derivatives. With an increased bone 
accumulation the target to background ratio should also be further augmented and hence this 
would strengthen the diagnostic and therapeutic efficiency. The improvements should be 
achieved by two different concepts.  
 
Figure. 4.1. Schematic overview of the BPAMD modification sites based on the bifunctional chelator concept 
of radiopharmaceutical. 
① The development of the NOTA derivatives resulted in a class of bisphosphonates with 
perfect tracer characteristics for 
68
Ga(III). The compound NO2AP
BP
 showed not only 
excellent labelling abilities with 
68
Ga(III), but also an outstanding target to background ratio 
combined with a high bone accumulation. The compound was easy and robust to label and no 
purification steps were necessary. The in vivo results in an animal model were such 
auspicious, that the compound was chosen for an initial study in a prostate cancer patient, 
who was suffering from bone metastases. The compound [
68
Ga]NO2AP
BP
 confirmed the 
outcomes in the patient from the animal testing and convinced with a brilliant imaging 
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quality. The NOTA based bisphosphonate [
68
Ga]NO2AP
BP
 was compared against [
18
F]NaF 
and the results of the first patient are depicted in figure 4.2. 
 
Figure 4.2. First patient study of [
68
Ga]NO2AP
BP
 in a male prostate cancer patient. Left: Whole body 
scintigraphy of [
68
Ga]NO2AP
BP
 vs. [
18
F]NaF. Right: PET, CT and PET/CT slices of the L4 vertebra of 
[
68
Ga]NO2AP
BP
 vs. [
18
F]NaF. Acquisitions were obtained after 60 min p.i. developed with 161 MBq 
[
68
Ga]NO2AP
BP
 and 252 MBq [
18
F]NaF (Prof. R. P. Baum, Zentralklinik Bad Berka, Germany). 
The novel tracer [
68
Ga]NO2AP
BP
 showed a high uptake in the metastatic lesions combined 
with a high contrast to the healthy bone. The blood clearance was quite fast and images could 
be obtained after 60 min p.i.. In the L4 vertebra a SUVmax of 75.5 was determined compared 
to a SUVmax of 50.8 in the previous [
18
F]NaF scan. Subsequent to the first promising human 
study the tracer was chosen to undergo a phase I clinical trial in collaboration with the All 
India Institute of Medical Sciences (AIIMS) in New Delhi, India. In this study the compound 
[
68
Ga]NO2AP
BP
 will be compared against the common diagnostic tracers [
18
F]NaF and 
[
99m
Tc]MDP in female breast cancer and male prostate cancer patients. The study will focus 
on the quantity of the detected bone lesions by the different tracers. Preliminary results from 
the first 12 patients are summarized in table 4.1.  
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Table 4.1. Bone lesion score of breast cancer patients. Examinations were performed by [
68
Ga]NO2AP
BP
-PET, 
[
18
F]NaF-PET and [
99m
Tc]MDP-SPECT and compared against each other, respectively (Data were obtained in 
collaboration with AIIMS, New Delhi, India). 
Nr. age 
no. of lesions 
[
68
Ga]NO2AP
BP
 
no. of lesions 
[
18
F]NaF 
no. of lesions 
[
99m
Tc]MDP 
disconcordance 
18
F vs. 
68
Ga 
disconcordance 
18
F
 
vs. 
99m
Tc 
1 55 6 10 4 4 6 
2 38 30 32 29 2 3 
3 40 22 23 12 1 11 
4 40 11 12 10 1 2 
5 65 1 1 1 0 0 
6 50 4 4 2 0 2 
7 45 1 1 1 0 0 
8 35 2 2 2 0 0 
9 36 4 5 - 1 - 
10 60 3 3 2 0 1 
11 30 4 3 3 1 0 
12 45 8 8 5 0 3 
 
The diagnostic efficiency of the novel 
68
Ga-tracer showed to have a high concordance with 
the current gold standard [
18
F]NaF and showed to be superior against [
99m
Tc]MDP. An 
example of the images from the preliminary clinical study is illustrated in figure 4.2. Since 
68
Ga is derived from a generator system, similar to 
99m
Tc, the new tracer NO2AP
BP
 offers 
now hospitals or small nuclear medical practices a convenient opportunity to perform high 
qualitative skeletal PET scans without any expansive cyclotron infrastructure. The evaluation 
of the PET tracer is actually ongoing and first results will be published soon. 
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Figure 4.3. Whole body images of a female breast cancer patient suffering from bone metastases. A: Common 
[
99m
Tc]MDP skeletszintigraphy. B: [
68
Ga]NO2AP
BP
 PET scan developed with 140 MBq. C: [
18
F]NaF PET scan. 
The images are examples out of the ongoing patient study in collaboration of the All India Institute of Medical 
Sciences, New Delhi, India by Prof. C. S. Bal. 
② The link between the bisphosphonate targeting moiety and the chelator showed to have a 
remarkable influence on the bone binding and the pharmacokinetics. Contrary to compounds 
containing an amide bond, the phosphinate conjugates have a slightly higher skeletal 
retention and faster blood elimination. A further advantage is the additional donor group, 
provided by the phosphinates. This comes into effect positively, when nuclides are used, 
which need more than 7-dentate chelators. Further tracer designs should take account of that. 
③ Excellent outcomes could be achieved with the modern bisphosphonate conjugates. On 
the one hand the synthesis of the new DOTA α-OH-bisphosphonates could be successfully 
accomplished. The pharmacophore of the highly potent osteoporosis drugs zoledronate and 
pamidronate were successfully conjugated to the DOTA macrocycle and labelled with 
68
Ga(III) and 
177
Lu(III). On the other hand these new derivatives showed a significant 
enhanced bone affinity and thus an improved target to background ratio as revealed from 
in vivo studies. The results are very promising and it might be the case that these next 
generation compounds replace the DOTA α-H-bisphosphonates, but further patient 
examinations with the hydroxyl bisphosphonates are necessary to ascertain their true 
potential in clinical practice. 
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④ One of them aimed on raising the quantities of the targeting vectors per molecule. Such 
dimerisations or multimerisations showed promising results in the past with other 
radiopharmaceutical agents, like RGDs, and it might be the case that an additional 
bisphosphonate moiety on the chelator backbone may enhance the blood excretion and 
adsorption kinetics on the bone surface. Within this project two dimeric compounds 
DOTA(M
BP
)2 and DO2A(P
BP
)2 were successfully synthesized and compared to the 
corresponding monomers BPAMD and DO3AP
BP
. In contrast to the mono-substituted 
macrocycles, the dimers were not able to complex 
68
Ga(III) effectively and thus they are not 
suitable as PET imaging agents. The reason behind the low complexation-ability might be the 
additional bisphosphonate entity. Since it is known that bisphosphonates are good ligands for 
divalent and trivalent metal ions, the two bisphosphonate moieties tend to form relatively 
strong ´out of cage´ complexes with radio metal cations and thus compete with the rigid 
complexation of the macrocyclic cavity. This effect could also be observed for the 
177
Lu(III) 
labelled dimers, but merely in a weakened form resulting in significant higher radiochemical 
yields. The better complexation-ability with the therapy nuclide 
177
Lu(III) opened the 
possibility for a comprehensive animal study by SPECT and ex vivo organdistribution. 
Within this study no significant improvements of the skeletal uptake could be observed for 
the dimers compared to the monomeric bisphosphonates. On the contrary, the blood and 
organ clearance of the 
177
Lu-labelled dimers was obviously decelerated, which resulted in 
lower target to background ratios. The reason therefor remained unclear, but it might be the 
case that the character of the 
177
Lu-bisphosphonate-dimer complexes are rather similar to 
open chain complexes than rigid macrocyclic complexes. As a consequence, 
177
Lu might be 
released in the body and thus would reduce the target to background ratio. The results from 
the in vivo experiments strengthen this assumption, since the data of the dimers take a 
position between the corresponding monomers and the [
177
Lu]citrate control. Finally, the 
concept of increasing the quantities of the targeting vectors per molecule did not result in any 
improvements, but other approaches were successful. 
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Figure 4.4. Asymmetric substituted DO2A derivatives with an albumin binding entity and a bisphosphonate 
targeting vector. The targeting structure R1 may consist of a hydroxyl bisphosphonate or a simple 
bisphosphonate. R2 represents different lipophilic substitutions with a possible weakened albumin affinity.  
The chemical modification of the well-established tracer BPAMD with an albumin-binding 
motif leaded to a bone targeting tracer with a decelerated body excretion. Since the body 
clearance is usually very fast for the bisphosphonate tracers, the most of the injected activity 
is not retained in the skeleton and excreted out of the body. The albumin binding entity 
shows a strong affinity to serum albumin and thus slowed down the excretion and bone 
accumulation kinetic. The blood pool functions as a reservoir for the tracer. As a 
consequence, the total skeletal retention was enhanced and furthermore the ratio between the 
high metabolic foci and the areas of normal bone turnover was strongly improved. It is to 
mention that this novel concept focusses more on the 
177
Lu-therapy than on the 
68
Ga-
imaging, because of the higher tracer blood levels during the first hours the imaging quality 
is greatly influenced. The tracer was initially evaluated with 
68
Ga and hence the total 
consequences of the chemical modification are yet not fully clear, first 
177
Lu examinations 
will reveal the total potential and will follow. 
Nevertheless, the improvement of the pharmacological structure based on the albumin 
binding motif can further be aimed. The conjugates may contain of an improved targeting 
vector, for example an α-OH-bisphosphonate, and a less potent albumin binding moiety, like 
it is outlined in figure 4.4. Such structures might also result in increased blood retentions, but 
a in a faster skeletal binding, which reach its kinetic endpoint earlier. Although the total 
consequences in terms of dose calculations of critical organs by the albumin binder conjugate 
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is not fully clarified, a less strong blood retention combined with an improved targeting 
moiety might be favorable.  
⑤ The usage of the bone targeting bisphosphonates in combination with the targeted α-
particle therapy may be further advancemet. The α-particle emitter 223RaCl2 was approved for 
therapy of skeletal metastases and showed good results in terms of pain relief and an overall 
longer survival rate, but it showed significant side effects, which are mainly based on the 
intestinal excretion route. Since the macrocyclic bisphosphonates are excreted via the 
kidneys, these side effects should be avoided or reduced. The first experiments with the α-
particle emitter 
225
Ac were promising, but the stable complexation of actinides is still an 
unanswered question. New compounds based on the eventually better fitted macrocycle 
HEHA may enhance the complex stability and examples of hypothetical derivatives are 
sketched in figure 4.5. It might also be the case that the 7-dentate ligand DO3AP
BP
 is suitable 
for a stable in vivo complexation of 
225
Ac, but finally these assumptions have to be disclosed 
in future. 
 
Figure 4.5. Macrocyclic bisphosphonates based on the chelator HEHA as potential high stable 
225
Ac(III) 
carriers for the targeted α-therapy. 
 
dies. The beginning trials with the PET tracer [
68
Ga]NO2AP
BP
 seem to be very promising 
and the [
177
Lu]BPAMD labelling kit will expand the application of [
177
Lu]BPAMD to other 
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users, resulting in comprehensive phase I and II clinical trials. In the long term, the advanced 
α-OH-bisphosphonate derivatives will replace the first generation compounds and thus 
makes initial patient studies and kit formulations a necessary goal in future.  
In conclusion, the potential of bisphosphonates conjugated with a macrocyclic chelate is very 
promising in nuclear medicine. The concept offers twice an option, compared to currently 
available techniques. With the generator derived PET nuclide 
68
Ga(III) a high qualitative 
skeletal examination is possible, followed by a subsequent therapy option with 
177
Lu(III). 
Since the therapy and the diagnosis can be realized with one and the same precursor 
molecule, DOTA-based bisphosphonates function as true theranostics and patients would 
benefit strongly from individual therapy dose calculations carried out by preceded 
68
G-PET 
scans. This concept might be a next step towards personalized medicine in cancer treatment. 
Maybe the results out of this work will be another small leap in the global fight against 
cancer, a disease that tantalizes mankind from the early beginning [1]. 
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